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Diarrheal diseases are a leading cause of global morbidity and mortality with an 
especially high disease burden in children under the age of 5 living in developing 
countries. Shigella species are a leading contributor to this disease burden and is also a 
significant antimicrobial resistance threat. While vaccination remains one of the most 
viable options to significantly reduce the disease burden caused by Shigella species, 
immune correlates of protection have yet to be defined for Shigella-specific immune 
responses. This dissertation aims to investigate Shigella specific protective immune 
mechanisms by: 1) characterizing the immune responses induced after oral challenge 
with Shigella flexneri 2a or Shigella sonnei, 2) identifying immune responses associated 
with protection from shigellosis after parenteral immunization, and 3) investigating 
similarities and differences in protective immune profiles associated with parenteral 
immunization with a S. flexneri 2a bioconjugate, oral exposure to S. flexneri 2a and, oral 
exposure to S. sonnei.  
Two different controlled human infection models (CHIMs) conducted in North 
American adult populations were used to accomplish the research for this dissertation. 
The first CHIM investigated immune responses pre- and post-infection with increasing 
doses of virulent S. sonnei. The second CHIM investigated immune responses associated 
with protective efficacy after parenteral immunization with a S. flexneri 2a bioconjugate 
vaccine. Subjects were immunized intramuscularly twice and challenged orally with 
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virulent S. flexneri 2a. The placebo cohort from this second CHIM was used to investigate 
immune responses pre- and post-challenge with S. flexneri 2a without prior intervention.  
Protective efficacy in vaccinated subjects strongly correlated with 
lipopolysaccharide (LPS)-specific serum IgG and IgG1 responses. The bioconjugate also 
induced LPS-specific gut-homing B cells associated with protective efficacy, indicating the 
vaccine induced immune effectors functioning at the site of intestinal infection. Subjects 
challenged with S. flexneri 2a or S. sonnei without prior intervention demonstrated 
robust mucosal responses, increases in Shigella-specific serum antibodies, as well as 
functional and memory B cell antibody responses. Pre-challenge LPS-specific memory B 
cell IgA responses were associated with a reduced risk of shigellosis post-challenge with 
both serotypes. 
An important finding from the current research was the difference in immune 
response profiles post-infection with S. sonnei or S. flexneri 2a. Prior Shigella infection 
has demonstrated protection from subsequent infection in a serotype-specific manner, 
indicating that serotype-specific immune responses post-infection may serve as immune 
correlates or surrogates of protection. In the current research, infection with S. sonnei 
induced robust mucosal responses however, little variance was observed in the systemic 
responses across disease outcome. In contrast, oral challenge with S. flexneri 2a induced 
a more balanced systemic and mucosal response. Results indicate that protection from 
each serotype could require different protective immune mechanisms. As a quadrivalent 
vaccine including S. sonnei and S. flexneri 2a would be required to significantly reduce the 
disease burden, different protective immune mechanisms could have important impacts 
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on Shigella vaccine design, as well as the epidemiological patterns of Shigella species. 
Although the two CHIMs were not appropriately powered to fully define the protective 
immune profiles, several molecular and pathogenic differences in S. sonnei could explain 
some of the observed differences. The results presented herein warrant further 
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CHAPTER 1. INTRODUCTION 
1.1. SPECIFIC AIMS  
This dissertation uses two Shigella controlled human infection models to evaluate the 
following three specific aims:  
1) To characterize the immune responses induced in humans after controlled infection 
with Shigella sonnei 53G. 
2) To characterize the immune responses in a human challenge study after parenteral 
immunization with a Shigella flexneri 2a bioconjugate vaccine, as well as after 
controlled infection with Shigella flexneri 2a 2457T. 
3) To investigate and describe protective immune profiles for Shigella infection in 
order to guide the rational design and assessment of Shigella vaccines. 
 
1.2. OVERARCHING HYPOTHESIS  
Multiple different immune profiles exist to provide protection against Shigella infection, 
depending on the route of exposure or Shigella strain, rather than a singular immune 
correlate of protection. 
 
1.3. DISSERTATION ORGANIZATION  
This dissertation is presented in six chapters. Chapter 1 focuses on providing an 
introduction of the research focus and specific aims. Chapter 2 uses current literature to 
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provide a background on diarrheal diseases and their public health significance. Chapter 
2 then moves into a detailed background on Shigella infection and pathogenesis, as well 
as immunological correlates of protection and proposed mechanisms of protection from 
Shigella infection. Chapters 3, 4 and 5 correspond to Specific Aims 1, 2 and 3 and are 
three separate manuscripts that have been, or will be, submitted to peer reviewed 
journals. The first manuscript (Chapter 3) has been accepted for publication and 
describes the immune responses in North American adults pre- and post-oral challenge 
with Shigella sonnei. The second manuscript (Chapter 4) has been submitted for 
publication and describes the immune responses in North American adults pre- and post-
parenteral immunization with Shigella flexneri 2a bioconjugate vaccine. As the primary 
outcome of the study used in Chapter 4 was to assess the efficacy of the bioconjugate 
vaccine, the study also included a population of non-vaccinated “placebo” subjects that 
were orally challenged with Shigella flexneri 2a. The third manuscript (Chapter 5) uses 
both studies described in Chapters 3 and 4 to compare and contrast the immune 
responses induced after parenteral immunization versus oral challenge. Chapter 5 also 
investigates differences in immune responses in subjects orally challenged with different 
Shigella species. Finally, Chapter 6 contains the conclusions of the current research as 




CHAPTER 2. BACKGROUND 
2.1. DIARRHEAL DISEASES AND PUBLIC HEALTH  
According to the World Health Organization (WHO), deaths due to diarrheal 
diseases are the eighth-leading cause of global mortality with approximately 1.6 million 
deaths per year.1 In addition to the high mortality estimates, diarrheal disease 
associated-morbidity is ranked as the sixth leading cause of global disability adjusted life 
years.2,3 While global morbidity and mortality estimates have decreased over the past 
decade, low to middle income countries (LMICS) with limited access to proper sanitation, 
health care, and safe water and food sources remain disproportionately affected by 
diarrheal diseases.4 LMICs in sub-Saharan Africa and Southeast Asia are particularly 
affected, with diarrheal diseases named one of the leading causes of years of lost life.5 
Disease progression and severity is often further exacerbated in these areas due to poor 
nutritional and health status of infected persons.6-10 
Children under 5 years of age living in LMICs have been identified as an especially 
vulnerable population, accounting for approximately 27% of diarrheal disease-associated 
global mortality making it the second leading cause of death in this age group .1,11-13 The 
effects of diarrheal diseases in children under 5 extends beyond the acute illness and 
mortality with their demonstrated negative impacts on child development.6-8,10,14 
Repeated, non-fatal enteric infections can lead to reduced gut permeability causing not 
only an increased susceptibility to additional enteric infections but also a reduction in 
intestinal absorption of nutrients.7,15 Reducing the ability to absorb nutrients in a 
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population where access to nutrient rich food sources may already be problematic, can 
lead to a constant state of malnutrition.7,15 Such extended periods of malnutrition during 
childhood development have been associated with reduced height-for-age Z scores, as 
well as an intelligence quotient decrement of up to 10 points.7,9,16  
Children impacted by this physical and cognitive stunting are estimated to be at a 
higher risk of both mortality due to other infectious diseases17,18 as well as adulthood 
obesity and its associated comorbidities.7 Additionally, enteric infections have been 
shown to increase the risk of developing inflammatory bowel disease (IBD),19,20 resulting 
in symptoms that may require life-long treatments. Altogether, these developmental 
deficits can result in reduced human capital as exemplified by a reduction in economic 
productivity, overall intelligence (as measured by IQ) and progression of communities.7,21 
For these reasons, WHO and the United Nations International Children’s Emergency Fund 
have prioritized the treatment and prevention of diarrheal diseases with the goal of 





2.2. SHIGELLA EPIDEMIOLOGY AND POST-INFECTIOUS SEQUALAE 
While many pathogens contribute to the diarrheal disease burden observed in 
children under 5 years old living in LIMCs, a select few pathogens have been identified as 
being responsible for 70-80% of the diarrheal disease-associated morbidity and 
mortality.11,23-26 During an investigation of the pathogen-specific attributable fractions for 
moderate to severe diarrhea (MSD) in children under 5 years of age living in several sites 
across Africa and Asia, the Global Enteric Multicenter Study (GEMS) revealed that the 
majority of MSD cases in this population were caused by rotavirus, followed by 
Cryptosporidium, Shigella and heat-stable producing enterotoxigenic Escherichia coli.24 
While the GEMS employed commonly used enteric-specific pathogen identification 
methods, such as conventional culture techniques and microscopy, these methodologies 
have varied sensitivities across different pathogens, potentially leading to inaccurate 
disease burden estimates. For these reasons, a re-analysis of the GEMS samples was 
conducted using a highly sensitive and reproducible quantitative real-time PCR assay 
which revealed Shigella species as having the highest diarrheal disease attributable 
fraction.26 Members of the genus Shigella are gram-negative, rod-shaped, non-motile, 
facultative anaerobes transmitted via the fecal-oral route that have been traditionally 
associated with bacillary dysentery. Recent evidence has also implicated Shigella species 
as being a significant cause of watery diarrhea,27 making Shigella infection responsible for 
upwards of 83.2% of diarrheal cases in children between the ages of 1-5.26,27  
While focus is often placed on the Shigella-specific disease burden associated 
with children living in LMICs, shigellosis is also considered a risk for those traveling to 
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endemic regions, including deployed military personnel.28 The importance of Shigella 
infection in military populations was further emphasized when diarrheal diseases caused 
by bacterial pathogens, including Shigella, was ranked as the leading infectious disease 
threat to deployed military troops.29 While Shigella infection can increase the risk of 
incapacitation or hospitalization due to the severe acute illness it causes, additional risks 
exist for military personnel.28,30 Acute stress, such as that experienced during 
deployment, can have detrimental effects on the gut-brain axis, potentially leading to 
alterations of the gastrointestinal barrier and eventually causing gastrointestinal barrier 
dysfunction.31-35 A pattern similar to that observed in malnourished children living in 
LMICs soon begins to emerge in these military populations as gastrointestinal barrier 
dysfunction causes a subsequent increased susceptibility to enteric infections and 
reduced absorption of nutrients.33,35  
The risk of receiving an IBD diagnosis after repeated enteric infections is also of 
concern for military populations as IBD is further complicated by its association with an 
increased risk of post-traumatic stress disorder (PTSD) upon return from deployment.36 
The cycle of stress, increased disease susceptibility and increased risk of an IBD diagnosis 
is not only limited to deployed military personnel but extends to others who may be 
traveling to Shigella endemic LMICs in support of humanitarian efforts, or to act as 
peacekeepers in areas of conflict.29,37,38 Each outlined scenario requires intense 
concentration as well as rapid response times and Shigella infection may affect either 
acute or chronic cognitive functions both during, and after infection. These negative 
cognitive outcomes in military populations draw similarities to LMIC children and the 
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strong link between physical/cognitive stunting and negative health outcomes in this 
population.18 Together, these observations provide further evidence for the relationship 
between the gut-brain axis and potential cognitive impairments associated with Shigella 
infection and emphasize the importance of further investigations to fully understand this 
relationship.31-34  
Additional Shigella-specific post-infectious sequalae have been identified as a risk 
across all populations, regardless of nutritional status or gastrointestinal barrier health. 
Reactive arthritis, an inflammatory autoimmune disorder, is identified in approximately 
6% of individuals post-infection with Shigella species.39,40 The genetics of the association 
between reactive arthritis and Shigella infection has been attributed to the presence of 
human leukocyte antigen molecule B27 (HLA-B27). HLA-B27, a gene that has also been 
associated with other inflammatory auto-immune disorders such as ankylosing 
spondylitis,41 codes for a class I major histocompatibility complex on the surface of all 
nucleated cells and is responsible for presenting antigenic peptides to CD8+ T 
lymphocytes. The presence of HLA-B27 is associated with a higher percentage of 
individuals receiving a diagnosis of reactive arthritis post-Shigella infection to 
approximately 80%.39 
Shigella-associated post-infectious sequalae are not only a concern for those 
living in, or traveling to, LMICs where Shigella species are endemic. Higher income 
countries, such as those across North America and Europe, have reported an increased 
frequency of Shigella outbreaks over the past decade. The United States Center for 
Disease Control (CDC) National Outbreak Reporting System has reported an especially 
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high number of outbreaks across Texas, Ohio, Pennsylvania and California.42 Additionally, 
the European Centre for Disease Prevention and Control has observed an increase in 
shigellosis outbreaks associated with an influx of refugees emigrating from countries 
where Shigella is endemic.43 Increased shigellosis outbreaks in healthcare and daycare 
settings have also been reported with some outbreaks continuing for months.44-47 
Sustained transmission in health/daycare settings is likely attributable to the fact that 
Shigella species are highly infectious, with as few as 100 bacteria reported to cause 
disease,48-51 subsequently allowing for rapid spread in such settings.44 
Shigella infections and outbreaks also occur when developed nations experience 
breakdowns of infrastructure, as exemplified by the 2014 water crisis in Flint Michigan. 
After a change in water sources, officials in Flint, MI failed to ensure proper 
infrastructure of piping systems supporting the new water source. Without the proper 
infrastructure in place, water sources were soon contaminated with serious health 
hazards, including heavy metals and infectious pathogens. A large outbreak of shigellosis 
was reported in surrounding MI counties with over 100 cases of Shigella infection 
reported.52,53 Furthermore, natural disasters and civil war crises causing infrastructure 
breakdowns or population upheaval also increases the risk of shigellosis outbreaks with 
multiple Shigella epidemics attributed to such instances.54 
Currently, treatment for Shigella infection involves a course of antibiotics and 
potentially oral rehydration solution. Although antibiotics are generally effective against 
shigellosis, access to antibiotics may be limited in LMICs and increasing rates of 
resistance to first line (ciprofloxacin), as well as alternative antibiotics, including other 
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fluoroquinolones, have been reported.55-59 The CDC has classified drug-resistant Shigella 
species as a serious public health threat with high potential to worsen in the coming 
years and suggests increased public health monitoring and prevention activities.60 
Additionally, the WHO has placed Shigella on a global priority list of antibiotic-resistant 
bacteria in an effort to help prioritize the development of alternative measures to treat 
or prevent shigellosis.55,56 For these reasons, in addition to Shigella-associated post-
infectious sequalae, Shigella species have garnered the attention of multiple 
international agencies and stakeholders who recommend the prioritization and 
acceleration of vaccine development to prevent shigellosis.55,61 The prioritization of 
Shigella vaccine development was further emphasized by the WHO during a recent 
workshop convened in order to investigate reduced timeline pathways to licensure and 




2.3. SHIGELLA PATHOGENESIS 
Shigella species are divided into four serogroups (S. flexneri, S. sonnei, S. 
dysenteriae and S. boydii) and, with the exception of S. sonnei, each serogroup is further 
divided into multiple serotypes (N=54, Table 2.1) based on the O-polysaccharide (OPS) 
structure of the lipopolysaccharide (LPS).62 S. boydii is relatively uncommon while S. 
dysenteriae is traditionally associated with epidemics and pandemics, leaving the S. 
flexneri and S. sonnei serogroups responsible for the majority of the global disease 
burden.24,26,54 Interestingly, infection with S. sonnei is most commonly associated with 
higher income countries as compared to LMICs; however, this paradigm does appear to 
be shifting.18,63-65 Shigella infection in humans is characterized by the ability of the 
bacteria to invade the mucosal epithelium, replicate intracellularly and spread 
intercellularly, all while evading host immune responses. Successful infection is 
accomplished with the help of virulence proteins encoded for on a circular plasmid which 
is highly conserved across all virulent Shigella species. While the LPS biosynthesis genes 
are typically coded for on the chromosome, S. sonnei is unique in that the virulence 
plasmid of this serogroup also houses the LPS biosynthesis genes. 
Table 2.1. Listing of 54 known species and serotypes within the genus Shigella. 
 
Serogroup Species Serotypes Total 
A Shigella dysenteriae 1 – 15 15 
B Shigella flexneri 1a, 1b, 1d, 2a, 2b, 3a, 3b, 4a, 4av, 4b,  5a, 5b, 6, 7a, 7b, X, Xv, Y, Yv 19 
C Shigella boydii 1 – 19 19 
D Shigella sonnei 1 1 




In order for shigellae to reach its site of infection, the large intestine, the bacteria 
must first pass through the stomach and small intestine. Highly effective acid resistance 
systems allow the bacteria to safely travel through the acidic environment within the 
stomach.66,67 Once the small intestine is reached, shigellae make use of host bile salts to 
induce the up-regulation of bacterial survival genes.68 During this time, Shigella species 
also down-regulate the expression of host antimicrobial peptides, such as LL-37 and 
human β-defensin-1, which are released at mucosal surfaces in order to act as barrier 
effectors.69 Together, these virulence factors allow the safe passage of Shigella species 
through the stomach and small intestine, and ultimately contribute to the low infectious 
dose observed with Shigella species.66,67 
Shigella species show high selectivity to the heavily glycosylated mucins located in 
the human colon, allowing them to begin creating their environmental niche once the 
site of infection has been reached.70 The first step of host cell invasion requires the 
assembly of a Type 3 Secretion System (T3SS), a process triggered at 37˚C. Assembly of 
the T3SS begins with the formation of a seven-section basal body which spans the 
bacterial inner and outer membrane, as well as the periplasm and peptidoglycan layer. 
The basal body is composed of several Mxi and Spa virulence proteins and is built with 
the help of Ipg proteins which act to stabilize the basal body and anchor it within the 
periplasmic leaflet of the outer membrane.67,71 
After completion of the basal body, formation of the secretion needle can begin. 
The needle is largely composed of MxiH, with MxiI creating a needle base spanning the 
outer membrane and periplasm.67,71 Interestingly, needle length, which is regulated by 
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Spa32, is thought to have coevolved with the OPS of each Shigella species in order to 
allow for optimal infectivity while still providing protection from innate immune 
effectors.72 Once the needle has been created at its optimal length, the final step of 
forming the needle tip can begin. The T3SS needle tip is composed of translocator 
proteins IpaB, IpaC and IpaD, each of which is essential in the early stages of host cell 
invasion. IpaB and IpaC await translocation signals in the bacterial cytoplasm, bound and 
separated by the chaperone protein IpgC. IpaD also resides in the cytoplasm, however, as 
IpaD has self-chaperoning activity, it does not make use of a chaperone protein. Once 
translocation signals are received, IpaB and IpaC interact upon their release from IpgC, 
and all three Ipa proteins are translocated to the needle tip, forming a plug to prevent 
the excretion of effector proteins prior to receiving the appropriate signals.67 With a 
completely formed T3SS, the bacteria are ready to begin host cell invasion. 
While Shigella species carry out their replicative life cycle within intestinal 
epithelial cells, they are unable to invade the lumen exposed apical side of these highly 
polarized epithelial cells as they are lined with several defenses, including a thick 
glycocalyx, competing commensal bacteria and their by-products, as well as host 
antimicrobial substances. Therefore, Shigella species must gain access to the basolateral 
side of intestinal epithelial cells and they do so by inducing their own uptake into 
specialized epithelial cells. These specialized epithelial cells, known as M cells, are 
responsible for transporting antigens from the intestinal lumen to the underlying 
lymphatic tissues called Peyer’s patches. Multiple innate and adaptive immune cells 
reside in Peyer’s patches waiting to sample antigens that are transcytosed via M cells. 
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Shigellae take advantage of M cell function and specifically target these cells in order to 
gain access to the lamina propria.  
Shigella species target areas of cholesterol accumulation on host cell membranes, 
known as lipid rafts, to begin the process of induced transcytosis. The virulence protein 
IpaB binds cholesterol with high affinity and causes the aggregation of additional lipid 
rafts which ultimately function as a docking station for the bacteria. Once docked, IpaB 
also binds host CD44 while the IpaB/IpaC/IpaD complex binds host integrin α5β1, 
subsequently inducing M cell cytoskeleton remodeling and beginning the process of 
engulfing the docked Shigella. While the binding of Ipa proteins to CD44 and α5β1 
receptors begins the process of host cell cytoskeleton remodeling, bacterial uptake is 
dependent on the ability of the Shigella to translocate six effector proteins into the host 
cell which function to further reorganize host cell cytoskeleton and complete the process 
of bacterial engulfment. Effector proteins VirA, IpgB1 and IpgB2 are responsible for 
microtubule destabilization while IpgB2 and IpaA work together to polymerize or 
depolymerize host cell actin as needed in order to close the phagocytic cup.67,71  
Once completely engulfed by the M cell, shigellae are transcytosed from the 
apical side of the epithelium to the basolateral side where they are deposited into the 
Peyer’s patches. Macrophages are typically the first cells to come into contact with 
shigellae on the basolateral side and immediately begin to phagocytize the bacteria and 
form a phagosome. Shigellae enhance this process of phagocytosis using the same 
mechanisms employed to induce its uptake via M cells. Typically, macrophages then fuse 
the phagosome with a lysosome in order to kill the engulfed bacteria. However, shigellae 
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make use of phagosome membrane lipid rafts and bacteria-derived effector proteins to 
prevent the formation of a phagolysosome. IpaC plays an essential role in disrupting the 
integrity of the phagosome phospholipid membrane, allowing shigellae to quickly 
degrade the membrane and efficiently escape from macrophage phagosome within 15 
minutes of uptake.67,71 
Upon escape from the phagosome, the strong innate inflammatory response 
observed during Shigella infection begins to unfold as the bacteria start the process of 
inducing pyroptotic macrophage cell death. Multiple effector proteins, including IpgD 
and MxiE, provide anti-apoptotic signaling in order to override host cell-induced 
apoptosis, therefore ensuring the progression through the pyroptotic inflammatory cell 
death pathway. Simultaneously, OspF, OspG and IpaH interfere with MAPK and NF-κB 
signaling in order to prevent the infected macrophage from making other host innate 
immune cells aware of the infection and subsequently working to kill the infected 
macrophage. At this stage, IpaB initiates the process of pyroptosis by directly binding to 
and activating Caspase-1. Activated Caspase-1 proteolytically cleaves pro IL-1β and pro 
IL-18 cytokines to their active proinflammatory forms which are released from the 
macrophage upon pyroptotic cell death. Additionally, the shigellae contained within the 
macrophage are released upon cell death and are now free to invade the basolateral 
surface of the intestinal epithelial cells. 
Release of IL-1β and IL-18 into the lamina propria upon macrophage cell death 
induces a strong inflammatory response as these cytokines act as chemoattractants, 
recruiting natural killer cells and neutrophils to the site of infection.67,71 Natural killer 
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cells work to further activate host immune responses through the secretion of IFN-γ and, 
while neutrophils eventually contribute to controlling Shigella infection, they exacerbate 
the inflammatory response during the initial stages of infection. The influx of neutrophils 
can damage the integrity of the epithelial cell lining as they insert themselves between 
epithelial cell tight junctions in an effort to find and kill the shigellae. While neutrophils 
are inserting themselves between the epithelial cells, shigellae are also able to pass 
through the widened spaces in the epithelial cell lining and gain access to the lamina 
propria and basolateral side of epithelial cells, without having to use M cells.67,71 
Epithelial cell invasion and subsequent escape from epithelial cell phagosomes 
occur in the same manner as described for M cell invasion and macrophage phagosome 
escape. Upon release from epithelial cell phagosomes, the bacteria do not induce cell 
death, but rather begin their process of replication and intercellular spread. Shigellae 
quickly replicate within host cells and reach a critical mass where additional space is 
needed. While shigellae do not possess structures such as flagellin, which allow bacterial 
motility, they are able to make use of host cell actin in order to move about host cells. 
Virulence protein VirG plays a vital role in the movement of shigellae by localizing to one 
pole of the bacteria and recruiting a complex of N-WASP and Arp2/3. The N-WASP-
Arp2/3 complex serves as an actin nucleator, polymerizing host cell actin and creating 
actin tails which propel the bacteria forward. VirA works at the opposite pole of the 
bacteria to degrade host cell α-tubulin, essentially clearing a pathway forward for the 
bacteria. During movement of the bacteria around the host cell, shigellae will eventually 
interact with the epithelial cell wall and begin the process of intercellular spread as they 
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continue to propel their forward motion until they are able to push through the wall of 
the current cell into an adjacent epithelial cell. At this point, the shigellae are contained 
within a new epithelial cell phagosome allowing them to begin the process anew.67,71 
During the process of bacterial replication and intercellular spread, epithelial cells 
also contribute to the intestinal inflammatory response of Shigella infection. Intracellular 
spread of the bacteria and exposure of epithelial cells to high amounts of cytosolic 
bacterial LPS induces inflammasome activation through the non-canonical pathway after 
TLR-4 recognition of LPS and subsequent activation of caspase-4. Additionally, host cell 
NOD-1 receptors recognize bacterial peptidoglycans and activate NF-κB signaling 
pathways, causing the release of chemoattractant IL-8 into the lamina propria. IL-8 works 
to recruit additional neutrophils to the site of infection in order to help manage the 
infection. Eventually, the immune system is able to control the intercellular spread of the 
bacteria but not before a tremendous amount of inflammation and damage to the 
epithelial cell lining occurs, all of which results in the bloody mucoidal stools and colonic 
ulceration often observed in Shigella infection.67,71 
While most Shigella species use the same virulence factors to cause infection in a 
similar manner, a few serotypes set themselves apart from the rest of Shigella serotypes. 
S. dysenteriae 1 has traditionally been known as the only Shigella serotype to harbor the 
Shiga toxin; one of the most potent toxins across all bacterial species.73,74 More recently 
however, the Shiga toxin has also been discovered in Shigella flexneri serotypes, 
indicating that S. dysenteriae 1 may no longer be the only serotype to make use of this 
toxin. The Shiga toxin is an αβ toxin which works to inhibit host cell protein synthesis 
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causing a breakdown of the epithelial cell lining and subsequent hemorrhaging.73,74 This 
toxin is associated with severe life-threatening disease and is one of the reasons S. 
dysenteriae is often associated with epidemics and pandemics. 
Shigella sonnei is another unique serotype for several reasons. S. sonnei encodes 
for a Type 6 Secretion System (T6SS) which is used to directly compete with and kill, not 
only other Shigella species, but also other enteric bacteria including E. coli species.75 
Interestingly, the T6SS of S. sonnei has been cited as one of the reasons that S. sonnei has 
been able to rise to dominance in higher income countries: individuals in LMIC settings 
have gained natural immunity to S. sonnei through frequent exposure to Plesiomonas 
shigelloides, a bacterium which possesses a homologous LPS structure to S. sonnei and is 
found often in low-resource settings with poor infrastructure.76 Those living in more 
developed nations do not have the opportunity to gain this cross-reactive natural 
immunity as infrastructure and sanitation measures in these countries have resulted in a 
low prevalence of P. shigelloides. Without this natural immunity in higher income 
countries, S. sonnei has been able to out-compete other Shigella serotypes with the help 
of its T6SS. Another unique attribute of S. sonnei is its adeptness in acquiring 
antimicrobial resistance genes as compared to other Shigella serotypes, allowing them 
the opportunity to persist during infection, even during treatment.64 Finally, S. sonnei has 
found a protective niche in the ubiquitous Acanthamoeba castellanii amoebae which 
engulf Shigella species in the environment and as a result, the provide Shigella species 
with protection from sanitation processes, such as chlorination. While many Shigella 
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serotypes, such as S. flexneri, are lethal to A. castellanii, S. sonnei is not, allowing it to 





2.4. IMMUNOLOGICAL CORRELATES OF PROTECTION 
2.4.1. Immune Correlates and Their Use in Vaccine Development 
A correlate of protection (CoP) is defined as an immunological parameter that is 
statistically correlated with, and therefore predictive of, vaccine efficacy.78 CoPs are a 
vital aspect to understanding pathogen-specific protective immunity a parameter that 
can ultimately guide the rational design and assessments of candidate vaccines. 
Furthermore, a defined CoP can be used to accelerate vaccine licensure, especially in the 
case of multivalent vaccines where changes or additions to pathogen serotypes are 
required.79 CoPs are also useful post-licensure as well to determine an individual’s 
pathogen-specific immune status, or to assess a newly manufactured lot of an 
established vaccine to ensure comparability of the new lot with previously manufactured 
lots.79 
Before a CoP can be investigated however, the primary clinical endpoint must be 
clearly defined.80 The primary endpoint is the outcome targeted for prevention and can 
vary across different pathogens, trial settings and target populations. For example, a 
primary outcome of providing sterilizing immunity (i.e. preventing infection) in an infant 
population may require a different CoP as compared to a target outcome of only 
preventing clinical signs and symptoms (i.e. preventing disease) in an adult population. If 
the desired outcome is to prevent disease, the clinical signs and symptoms must be 
further defined to understand the level or severity of disease being targeted for 
prevention. Preventing disease could be stringently defined as the prevention of any 
visible clinical signs or, the perhaps the goal is prevention of hospitalization or, 
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prevention of death; each of which may have a different CoP and could vary by vaccine 
and pathogen type.80 The nuances of defining the primary outcome are exemplified by 
CoPs associated with the measles vaccine: serum IgG titers ≥200 milli-international units 
per ml (mIU/ml) provide sterilizing immunity and therefore prevent infection, whereas 
titers between 120-200 mIU/ml provide protection against clinical signs of disease but 
not infection and finally, titers <120 mIU/ml do not provide protection against infection 
or disease.80 
A CoP can be further divided into two categories: a mechanistic correlate of 
protection (mCoP) or a non-mechanistic correlate of protection (nCoP).78 The main 
difference between mechanistic and non-mechanistic CoPs is that mCoPs are a 
mechanistic and therefore causal protective immune parameter often functioning at the 
site of infection to provide protection, while nCoPs, although they are a predictor of 
protection, are not the causal means of the protective immune response. A CoP is either 
an mCoP or a nCoP but cannot be both;78 however, nCoPs can act as surrogate measures 
for mCoPs. Although it is preferable to define and implement the use of a mCoP rather 
than an nCoP, it is not always feasible or practical if the mCoP is difficult to obtain or 
measure, as in the case of the Zoster vaccine.78 Both serum antibody responses and 
cellular responses post-vaccination with Zoster are statistically correlated with protection 
and therefore both are defined as CoPs; however, when considering the biology of the 
pathogen inside the host, cellular responses are likely working at the site of infection to 
prevent disease. Furthermore, the statistical association of cellular responses and 
protection is more robust as compared to the association of serum antibody responses 
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and protection. Together, these data can be used to define cellular responses as the 
mCoP and serum antibody responses as the nCoP. In the case of Zoster, it is simpler and 
more efficient to measure antibody responses in serum as compared to cellular immune 
responses therefore, the nCoP is typically used in vaccine efficacy assessments.78  
While defining a CoP is an important goal in vaccine development, one must 
consider the possibility of multiple CoPs acting together as co-correlates to synergistically 
provide protection.78,80 This was exemplified in vaccine trial assessing the efficacy of a 
live-attenuated intranasal influenza vaccine. Subjects in this trial were administered the 
live-attenuated flu vaccine or placebo, and subsequently challenged with live influenza 
virus. The clinical endpoint for this study was defined as a reduction in viral shedding and 
hemagglutination-inhibiting (HAI) serum IgG and nasal wash IgA immune responses were 
determined. Subjects that did not have either HAI serum IgG or nasal IgA shed the virus 
63% of the time whereas subjects that had both immune parameters shed the virus 3% 
of the time. Interestingly, subjects with only HAI serum IgG shed the virus 15% of the 
time while subjects with only HAI nasal IgA shed the virus 19% of the time.80,81 Although 
viral shedding was significantly reduced with either HAI serum IgG or nasal IgA, an 
additional reduction in viral shedding to 3% clearly demonstrated the synergistic effects 
of having both serum IgG and nasal IgA.80,81 Therefore, when investigating CoPs 
associated with a clinical endpoint, it is essential to have a full understanding of organism 




Once the immune parameters are defined, levels of these parameters that are 
associated with protection should be investigated to determine if they can be used as 
absolute or relative CoPs. An absolute CoP is defined as a specific quantity or level of the 
CoP that provides protection in a binary manner close to 100% of the time (i.e. protected 
at a certain level or not protected below that level).80 The hepatitis B vaccine has a well-
defined absolute CoP of serum antibody levels ≥10 mIU/ml considered protective while 
anything below this level is considered not protective.82 On the other hand, a relative 
CoP usually provides protection at a certain level, however breakthroughs can occur 
below this threshold.80 A relative CoP is exemplified in an influenza vaccine trial where 
approximately 70% of subjects with a HAI serum IgG titer of ≥40 were protected, 
however, as the titer increased or decreased, the percent of protected subjects 
correlated with HAI titer.83 Although absolute CoPs are ideal, relative CoPs are more 
commonly observed as CoPs are often best described as a curve rather than as an 
absolute threshold.80 
Investigation of CoPs must take into account multiple factors such as the type of 
vaccine, disease pathogenesis, population genetics or epigenetics as well as the setting 
used for investigational studies versus the target population for the vaccine. Each of 
these factors can influence the interpretation of CoP investigations, especially in the 
context of determining absolute or relative levels required of a CoP.78 Vaccine types and 
route of administration can greatly affect the resulting immune response and associated 
CoP(s). For example, the live-attenuated oral polio vaccine (OPV) induces strong 
secretory IgA responses as well as cellular immunity dominated by CD8+ T cells. This is in 
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contrast to the intramuscularly delivered inactivated polio vaccine (IPV), which induces 
robust serum antibody responses and CD4+ T cell immunity.84,85 These two different 
vaccines and delivery routes provide different levels of protection and also have different 
CoPs: OPV protects against infection through secretory antibodies secreted at the site of 
infection while IPV prevents clinical disease through the generation of high levels of 
serum antibodies.84,85 Genetics and epigenetics, as well as nutritional status, play 
important roles in vaccine efficacy and CoPs. A CoP determined in a healthy American 
adult population may not translate to children in LMIC settings with varied immune or 
nutritional status.79,86 The same concept applies to immunosuppressed or 
immunocompromised individuals. All of these influencing and potentially confounding 
factors affecting CoPs must be taken into consideration when defining CoPs, especially in 
the context of vaccine licensure or vaccine lot comparability.79 
 
2.4.2. Methods of Investigating Immune Correlates of Protection 
Proposed CoPs must be thoroughly tested, ideally in the target host, in order to 
verify their ability to predict protection as well as to determine thresholds that may be 
associated with protection. While animal and in vitro models can be used, these types of 
data are not always easily extrapolated to human populations and may be misleading. 
Such was the case while using a mouse model to investigate rotavirus CoPs. The 
proposed mechanism of protection in this rotavirus mouse model was the discovery of 
active transport of serum IgA into bile.87 However, as this transport does not occur 
24 
 
efficiently in humans, this immune mechanism would likely not provide protection in the 
target population, requiring further investigations using an alternative model.87,88  
If the suspected mechanism of protection is antibody-based, the use of passive 
antibody administration studies or maternal-newborn observational studies can be 
useful tools to investigate protection provided by antigen-specific antibodies.89,90 
However, a caveat must be placed on passive administration and maternal antibody 
studies as the protective level of antibodies required for passive protection may not be 
representative of the levels required for protection after vaccination as passively 
administered antibodies receive additional support from the host immune system.88 
Studying the immune responses after natural infection can be a useful guide 
while investigating CoPs.91,92 Determining the specificity and magnitude of the immune 
response post-infection can help identify key immune parameters or antigenic targets 
that may significantly contribute to protection. However, unless the date of infection is 
known, this method of investigating CoPs is best applied in the context of pathogens that 
knowingly provide long-lasting immunity, such as measles. Otherwise, the protective 
immune parameters may no longer be measurable if infection occurred long ago.88 
Knowing the date of infection is also helpful in understanding which immune parameters 
are associated with acute infection versus convalescence. Likely, immune parameters 
determined in a convalescent state would be better candidates for CoPs. Observational 
studies, such as cohort or case-control studies, can be used to help ensure the date of 
infection is documented.82,93 In observational studies, subjects would be enrolled, their 
immune status investigated and then followed up for a period of time to monitor for the 
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occurrence of the clinical endpoint, thus providing pre- and post-exposure immune 
responses as well as the date of infection.88 Observational studies used for investigating 
CoPs must be well-designed to control for confounding factors, such as previous 
pathogen exposures, history of immune and nutritional status or genetic/regional 
differences in populations.  
If an established controlled human infection model (CHIM) exists for the 
pathogen of interest, one of the best ways to investigate CoPs is with the use of human 
challenge/re-challenge randomized controlled trials (RCT).88,94-97 A RCT allows for better 
control of potentially confounding factors and can help ensure as naïve a population as 
possible in order to accurately investigate protective immune parameters. Assessing the 
immune responses pre-challenge as well as post-primary and post-secondary challenge 
can provide key insights for establishing CoPs. In the case of pathogens with multiple 
strains, challenge/re-challenge studies can also be used to assess the potential of 
heterologous protection, leading to the understanding of broadly protective antigenic 
targets as well as determining the degree of multivalency required of a vaccine.96 The use 
of challenge/re-challenge studies in the Shigella field have been pivotal in the 
understanding that protection from Shigella infection is serotype specific and therefore, 
a multivalent vaccine will likely be required.98,99  
CHIMs are also commonly used to assess the efficacy of a vaccine candidate that 
has undergone appropriate safety and dose-determination studies.88 In this setting, 
subjects would be enrolled, vaccinated with either the candidate vaccine or a placebo 
control, and subsequently challenged with the pathogen of interest. Vaccine efficacy 
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RCTs are an excellent resource for the investigation of protective immune parameters 
induced by vaccination and their association with protection from the study defined 
clinical endpoint.100-102 One key point for consideration regarding vaccine efficacy CHIMs 
is the definition of the clinical endpoint and its use across different institutions 
investigating the same pathogen with different vaccine candidates. Consistent use of 
clinically meaningful and validated endpoints and disease outcomes is essential in 
accurately assessing CoPs and allows for better comparisons of different vaccine 
candidates. The use of a consensus clinical endpoint can assist in the comparability of 
studies performed at different sites which could lead to the acceleration of vaccine 
licensure or WHO pre-qualification.103-105 
 
2.4.3. Proposed Immune Correlates of Shigella Infection  
Although several of the aforementioned methodologies used to investigate CoPs 
have been employed in the context of Shigella infection, a consensus CoP has yet to be 
defined.92,99,106-108 This could be due, in part, to the complicated nature of the bacteria’s 
dynamic life cycle in the large intestine as it involves both an extracellular and 
intracellular phase.67 When considering the pathogenesis of Shigella species, one could 
propose that there are potentially several protective immune mechanisms, depending on 
the clinical endpoint of interest. If the desire is to provide sterilizing immunity and 
prevent transcytosis of the bacteria from the apical side of the mucosal epithelium to the 
basolateral side, it is likely that antibodies secreted into the lumen would be required, 
either by active secretion (IgA) or passive transudation (IgG). On the other hand, 
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protection from mild to moderate disease could be achieved within the intestinal lamina 
propria via antibody mediated mechanisms, including neutralization of the bacteria on 
the basolateral side of the epithelium to prevent epithelial cell invasion, direct killing of 
the bacteria by opsonization or complement activation and, antibody dependent cellular 
cytotoxicity mediated by natural killer cells or monocytes. Cell-mediated immunity may 
play a larger role in protection from more severe disease as it could work to prevent the 
intercellular spread of shigellae, thus preventing or reducing the bloody and mucoidal 
stools resulting from colonic ulceration induced by epithelial cell death.   
Studies of Shigella pathogenesis and CoPs have provided important insights into 
potentially protective antigenic targets and protective immune mechanisms. Since 
immunity to Shigella infection is serotype specific, and Shigella serotypes are determined 
by the antigenic structure of the OPS, a vaccine will likely require either the OPS or full 
LPS molecule in order to be protective.92,98,109 Serotype-specific Shigella immunity also 
reveals that a multivalent vaccine will be needed to protect against the most relevant 
circulating Shigella serotypes responsible for the majority of the global disease 
burden.24,26,110 In addition to the requirement of multivalency, the challenge of low to 
undetectable infant immune responses to polysaccharide vaccines must be taken into 
consideration when developing OPS or LPS based Shigella vaccines.79,80,84  
Additional antigenic targets have been identified, including the highly conserved 
virulence proteins IpaB, IpaC and IpaD, with research suggesting that vaccines containing 
these targets may provide pan-protection from all Shigella species.111,112 Although this 
concept of broadly protective antigens is interesting, heterologous challenge/re-
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challenge studies have demonstrated that protection from shigellosis is only achieved 
after homologous re-challenge, regardless of the fact that all pathogenic Shigella species 
contain the virulence plasmid encoding for the Ipa proteins.99 While immune responses 
directed against the Ipa proteins may not be protective in their own right, the inclusion 
of these highly conserved proteins in an OPS-containing vaccine may broaden protection 
to other serotypes within a particular serogroup.113 
As Shigella is a mucosal pathogen, immunological dogma predicts that a mCoP for 
Shigella infection would be a certain level of mucosal antibodies.114,115 A mucosal CoP 
was suggested after the completion of a vaccine trial assessing the efficacy of a live-
attenuated S. flexneri 2a vaccine. This vaccine efficacy trial demonstrated that vaccinated 
subjects with ≥75 LPS-specific IgA antibody secreting cells (ASC) per 106 total IgA PBMCs 
(N=4) were protected from the clinical endpoint of shigellosis.106 While the suggested 
CoP of ≥75 LPS-specific IgA ASCs fits dogmatic understanding, the study was 
unfortunately not appropriately powered to confirm this CoP with only 7 vaccinated 
subjects undergoing challenge.79 Furthermore, the assumption was made that all IgA 
ASCs would be contributing to the local mucosal antibody response, however, without 
knowing the homing pattern of these ASCs, it is difficult to confirm if the ASCs are 
homing to the intestine to secrete mucosal IgA, to the bone marrow to secrete serum IgA 
or potentially elsewhere in the body. Nonetheless, the importance of a mucosal IgA 




Alternative methodologies, aside from measuring LPS-specific IgA ASCs, can be 
employed to assess the Shigella-specific mucosal immune response. One such method 
includes measurement of the specialized secretory IgA response in mucosal secretions, 
such as stool, urine or oral fluids.106,116,117 As secretory IgA contains the secretory 
component allowing its active transport into mucosal compartments, measuring the 
antigen-specific secretory IgA responses can be a good representation of the mucosal 
immune response. Although fecal antibody responses are commonly used to measure 
the Shigella-specific mucosal immune response,118,119 the use of fecal samples in 
immunoassays is fraught with issues, including problems with sample quality, poor signal 
to noise ratios in immunoassays, and potentially low subject compliance.117 More 
recently, investigations of Shigella-specific mucosal responses have focused on the 
measurement the antigen-specific responses from B lymphocytes expressing the 
intestinal homing marker α4β7 integrin.120,121 Isolating B cells that are positive for the 
α4β7 integrin and using these cells in immunoassays to determine the Shigella-specific 
response can act as a better measure of the mucosal immune responses induced post-
vaccination or infection.  
Shigella LPS-specific serum IgG has also been identified as a potential CoP; 
however, it remains unclear if serum IgG is acting as a mCoP or a nCoP.122-124 The 
suggested mechanism of protection provided by serum IgG surrounds the concept of 
inducing high enough levels of Shigella-specific serum IgG such that these antibodies 
would transudate from systemic circulation into the intestinal lumen, thereby providing 
protection from mucosal epithelium invasion by Shigella species. Several clinical studies 
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investigating candidate polysaccharide-based conjugate vaccines have shown a 
correlation of LPS-specific serum IgG with protection from the clinical endpoint.125-127 
While LPS-specific serum IgG may be a CoP given the observed association with 
protection in these clinical studies, further investigations should be undertaken to fully 
elucidate if it is acting as a mCoP or a nCoP. Additionally, investigations into absolute or 
relative threshold levels required for protection from the clinical endpoint should be 
performed.  
Although T cell immunity has been extensively investigated in the context of 
Shigella pathogenesis and immune evasion, there has been little evidence so far to 
suggest their utility as a CoP for protection from Shigella infection115. In addition to T cell 
immune responses and IgA ASCs, memory B cell responses are another cellular immune 
parameter that could serve as a CoP for Shigella infection. Memory B cell responses have 
been associated with reduced disease severity as well as protective efficacy.115,128,129 
Although Shigella-specific memory B cells could provide the field with a mCoP, it would 
be useful in this circumstance to define a nCoP to substitute for measuring memory B cell 
responses since the opportunity to collect enough blood volume from subjects in order 
to isolate cells and perform these assays may not always be available, especially as the 
target population for a Shigella vaccine is infants.  
Statistical methods utilizing mathematical modeling or machine learning have 
also been employed to provide insight into Shigella-specific CoPs.114,128 These 
methodologies have suggested that a combination of a mucosal and systemic response 
working synergistically as co-correlates could provide protection from shigellosis. 
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Mathematical models using previously conducted vaccine efficacy trials suggested that a 
LPS-specific serum IgG ELISA endpoint titer of ≥300, in addition to any degree of a LPS-
specific IgA ASC response predicted nearly 100% protection in studies investigated.114 
However, as these models were derived using a low number of subjects (N = 78) after 
immunization with a live-attenuated Shigella vaccine, additional investigations should be 
conducted using additional subjects and different vaccine candidates.  
 
2.4.4. Immune Profiles of Protection 
 As outlined earlier, defining immune correlates of protection and developing 
efficacious vaccines can be complicated by variances in host and environmental factors 
such as population genetics, age, nutritional and immune status, as well as pre-existing 
immunity and/or concurrent infections.130-135 Host immune responses and the success of 
a vaccine is further complicated in the case of enteric pathogens since the intestinal 
microbiome and integrity of the gastrointestinal barrier must also be 
considered.133,134,136-138 Several enteric vaccines, including a rotavirus vaccine and a 
cholera vaccine, have demonstrated excellent success in one population followed by 
dramatically reduced efficacy in another population.139-141 
In addition to differences across host and environmental factors, defining 
protective immune mechanisms is further complicated by the pathogen itself. Many 
bacteria, viruses and parasites have the ability to quickly adapt in order to increase 
pathogen virulence or develop resistance to current treatments and/or 
prophylactics.137,142 Several other factors, including pathogen strain or serotype, route of 
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infection and dose can also influence pathogen virulence and host immune response.143-
145 The combination of host/population variances, environmental influences and 
differences in pathogen virulence gives rise to a dynamic interplay, not only between 
host and pathogen, but also within the host and the immune response mounted. 
Defining immune correlates of protection has long been deemed the holy grail of 
vaccine development and while there is no question regarding their value and 
importance, searching for a single immune correlate (or two co-correlates) may not take 
into consideration the complexities of the host immune response and host-pathogen 
interaction. Over the past decade, advancements in research technologies and a 
movement towards personalized medicine has led the fields of vaccinology and 
immunology towards considering a broader definition of a protective immune 
response.146-148 Rapid expansions in the areas of systems biology and omics research 
have provided essential insights into host responses to vaccination or pathogenic 
challenge,130,149,150 demonstrating that protective immunity likely requires an integrated 
and networked immune response profile.151  
Immune response profiles post-vaccination or post-challenge have been 
described or proposed for several pathogens including human immunodeficiency virus, 
Plasmodium falciparum and yellow fever.150,152-155 Immune response profiles have also 
been described for the enteric pathogen Salmonella Typhi after parenteral immunization 
with two different vaccine constructs (Vi capsular polysaccharide (Vi-PS) or Vi capsular 
polysaccharide conjugated to tetanus toxoid (Vi-TT)) followed by oral challenge with live 
S. Typhi.156 Interestingly, while both vaccine constructs provided similar levels of efficacy 
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post-challenge, they appear to have done so in different ways. Subjects immunized with 
Vi-PS and protected from challenge were found to have a serum IgA-dominated 
response, however, protected subjects immunized with Vi-TT demonstrated an increased 
serum IgA response in conjunction with an increased avidity of serum IgG1 antibodies.156  
The concept of achieving a protective immune response to the same pathogen 
through different immune mechanisms was also exemplified earlier by the OPV and IPV 
polio vaccines. While both polio vaccines are protective in their own right, each provide 
protection at different levels and in different ways.84,85 Being able to achieve protective 
immune responses via different immune mechanisms is an important consideration in 
vaccine development and further emphasizes the need for thorough immune response 
characterization post-vaccination or post-challenge in order to investigate immune 
response profiles.  
As Shigella species are enteric pathogens with over 40 different serotypes and a 
complex lifecycle, characterization of Shigella-specific immune response profiles is likely 
especially important. Additionally, multiple Shigella vaccine constructs using different 
routes of mucosal or parenteral delivery are currently in development157,158 and may 
provide protection from shigellosis in different ways. For example, an orally delivered 
whole cell vaccine may induce a predominantly mucosal profile with secretory IgA 
working to prevent or reduce bacterial invasion of the epithelium. In contrast, the profile 
after parenteral immunization with an LPS-conjugate may provide protection via 
transudation of systemic antibodies into the lumen or increased antibody effector 
functions within the lamina propria. Even within similar vaccine constructs, immune 
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responses could vary substantially depending variances such as the use of killed or live-
attenuated oral vaccines, delivery of conjugate vaccines intramuscularly versus 
intradermally, or even the use of adjuvants to alter the phenotype of the immune 
response. With no defined correlate of protection for shigellosis and multiple host 
immune mechanisms that could work to reduce the severity or duration of infection, 
protection from shigellosis is likely better described as an immune profile rather than a 
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3.1. ABSTRACT  
Shigella is a major cause of moderate to severe diarrhea largely affecting children 
<5 years old living in low- and middle-income countries. Several vaccine candidates are 
currently in development and controlled human infection models (CHIMs) can be useful 
tools to provide an early assessment of vaccine efficacy and potentially support licensure. 
A lyophilized strain of S. sonnei 53G was manufactured and evaluated to establish a dose 
that safely and reproducibly induced ≥60% attack rate. Samples were collected pre- and 
post-challenge to assess intestinal inflammatory responses, antigen-specific serum and 
mucosal antibody responses, functional antibody responses and memory B cell 
responses. Infection with S. sonnei 53G induced a robust intestinal inflammatory 
response as well as antigen-specific antibodies in serum and mucosal secretions, and 
antigen-specific IgA- and IgG-secreting B cells positive for the α4β7 mucosal-homing 
marker. There was no association between clinical disease outcomes and systemic or 
functional antibody responses post-challenge; however, higher LPS-specific serum IgA 
and IgA-secreting memory B cell responses were associated with a reduced risk of 
disease post-challenge. This study provides unique insights into the immune responses 
pre- and post-infection with S. sonnei 53G in a CHIM, which could help guide the rational 
design of future vaccines to induce protective immune responses more analogous to 




3.2. IMPORTANCE  
Correlate(s) of immunity have yet to be defined for shigellosis. As previous 
disease protects against subsequent infection in a serotype-specific manner, 
investigating immune response profiles pre-and post-infection provides an opportunity 
to identify immune markers potentially associated with the development of protective 
immunity and/or with a reduced risk of developing shigellosis post-challenge. This study 
is the first to report such an extensive characterization of the immune response post-
challenge with S. sonnei 53G. Results demonstrate an association of progression to 
shigellosis with robust intestinal inflammatory and mucosal gut-homing responses. An 
important finding in this study was the association of elevated Shigella LPS-specific serum 
IgA and memory B cell IgA responses at baseline with reduced risk of disease. The 
increased baseline IgA responses may contribute to the lack of dose response observed 
in the study and suggests that IgA responses should be further investigated as potential 




3.3. INTRODUCTION  
Shigella is a significant cause of bacillary dysentery resulting in moderate to 
severe diarrhea (MSD) in travelers, as well as children in low- and middle-income 
countries (LMIC).28,159-161 Using more sensitive molecular based methods, Shigella has 
also been shown to be a significant cause of watery diarrhea.27 In 2016, Shigella was 
identified as the second leading cause of diarrhea-associated mortality across all age 
groups with an increased disease burden among children under the age of 5 years.1,23 
Children are also at risk of impaired development after repeated enteric infections.6-8,10,14 
Infection with Shigella species can lead to reduced gut permeability, subsequently 
causing a reduction in intestinal absorption of nutrients, leading to childhood cognitive 
and physical stunting.7,15 Children stunted from the heavy burden of Shigella infection 
are also at higher risk of dying from other infectious diseases.17 Shigella remains a high 
priority vaccine target for the WHO because of its high global burden and increasing 
antibiotic resistance.55 
Although several vaccine candidates are in clinical development, there is currently 
no licensed Shigella vaccine. A useful tool for early assessment of vaccine efficacy and, at 
times utilized to support licensure, is the controlled human infection model 
(CHIM).104,105,162,163 In response to recent calls for model standardization,103,164-169 a 
lyophilized strain of S. sonnei 53G was produced using current good manufacturing 
processes (cGMP) and evaluated in a dose-escalation protocol to determine a dose that 
safely and reproducibly yielded a ≥60% attack rate for shigellosis (Appendix A). Disease 
39 
 
outcomes and attack rates with the lyophilized strain of S. sonnei 53G are described 
elsewhere (Appendix A). 
This study offered a unique opportunity to characterize systemic and mucosal 
immune responses given the repeated collection of multiple samples throughout the 
study. Since prior disease caused by Shigella infection can result in protection from 
subsequent infection in a serotype-specific manner,92,98,99,109,170 investigation of the 
immune responses associated with multiple disease outcomes post-infection could 
provide further insights into potential mechanistic or non-mechanistic immune correlates 
of protection. Investigating correlates, or surrogates, of protection can also help guide 
vaccine development and interpretation of results in future Shigella CHIMs aimed at 
assessing vaccine efficacy. 
As previously reported, LPS-specific serum and fecal IgG and IgA responses post-
challenge were not associated with challenge dose or clinical disease outcomes, including 
dysentery, diarrhea severity and disease severity score (Appendix A). These findings 
highlight potential gaps in understanding the contribution of other immunological or 
non-immunological protective mechanisms and may also confirm the importance of 
immune responses to non-polysaccharide antigens.120,171,172 
Finally, a subset of orally challenged subjects did not exhibit disease symptoms 
post-challenge, regardless of dose received (567 – 1760 colony forming units (cfu)) 
(Appendix A). Therefore, a more comprehensive evaluation of the Shigella-specific 
immune responses at baseline and at several time points post-challenge was undertaken. 
Investigating potential immunological mechanisms associated with observed resistance 
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to infection and subsequent lack of association between immune responses and disease 




3.4. MATERIALS AND METHODS  
Study Design and Inoculation. The study was an open-label dose-finding CHIM 
designed to determine a target dose of lyophilized cGMP S. sonnei 53G for use in future 
Shigella CHIMs that would induce shigellosis in ≥60% of subjects as described in Appendix 
A. Subject inclusion and exclusion criteria are detailed in Appendix A, along with subject 
screening and disposition. Five days post-challenge (or sooner if clinically warranted), all 
subjects initiated antibiotic treatment and were discharged from the inpatient facility 
after producing 2 culture-negative stool samples. Subjects returned 14, 28 and 56 days 
post-challenge for additional blood and stool sample collections. Demographic data and 
disease outcome data of enrolled subjects are described in detail in Appendix A. 
Blood Processing. Whole blood was collected on study days -1, 5, 7, 14, 28 and 
56. Serum samples were stored at -80 ± 10˚C. Peripheral blood mononuclear cells 
(PBMCs) were isolated on a Ficoll gradient with Leucosep tubes (Greiner Bio-One), frozen 
using Cool Cells (BioCision) and stored in liquid nitrogen.  
Stool Processing. Stool samples for immunoassays were collected on study days -
1, 0, 3, 7 and 14, and immediately frozen at -80 ± 10˚C. Archived stool samples were 
thawed and processed for immunoassays by suspending 2 grams of stool in a protease 
inhibitor buffer (Roche cOmpleteTM EDTA-free protease inhibitor tablets, 1X PBS, 0.05% 
Tween-20, 0.1% BSA), vortexed and centrifuged for 30 minutes at 4˚C at ~1900 x g. Fecal 
extract supernatants were collected and frozen at -80 ± 10˚C. Stool samples for 
inflammatory marker analyses were processed in myeloperoxidase or calprotectin-
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specific collection/processing kits according to manufacturer’s instructions (Epitope 
Diagnostics) and frozen at -80 ± 10˚C. 
Fecal Inflammatory Markers. Stool samples processed for inflammatory marker 
analyses were assayed by Enzyme-Linked Immunosorbent Assay (ELISA) to determine 
calprotectin and myeloperoxidase concentrations per manufacturer’s instructions 
(Epitope Diagnostics). Inflammatory marker concentrations were interpolated from a 
standard curve with values below the assay limit of detection (LOD) being assigned a 
value of half the lowest concentration in the standard curve (½ LOD). As this was a post-
hoc analysis, only stool from subjects consenting the use of their samples in future or 
additional investigations were used for this analysis. The investigation of fecal 
inflammatory marker concentrations in stool samples was the only post-hoc analyses 
conducted and therefore the only immune response analysis conducted on a smaller 
subset of subjects (N=45/56 subjects: 18 with shigellosis post-challenge and 26 without 
shigellosis post-challenge).  
Antibodies in Lymphocyte Supernatant (ALS) Generation. PBMCs used to 
generate ALS were suspended in complete RPMI medium (10% heat inactivated fetal calf 
serum, 1X penicillin-streptomycin, 1X glutamine) at 5x106 viable cells/ml, plated in a 
sterile 24-well tissue culture plate (1 ml/well) and cultured for 4 days at 37 ± 1°C with 5% 
CO2 (cell viability not monitored). Supernatants were collected and frozen at -80 ± 10°C 
until assayed by ELISA. 
α4β7 PBMC Separation. Frozen PBMCs from study days -1, 5 and 7 were thawed, 
washed and suspended at 1x107 cells/ml in complete RPMI medium prior to incubation 
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with an Alexa Fluor 647 (AF647) conjugated anti-α4β7 monoclonal antibody (Act-1; NIH 
AIDS Reagent Program) for 10 minutes at 4 ± 2°C, protected from light. After washing, 
the cells were incubated with anti-AF647 MicroBeads (Miltenyi) for 15 minutes at 4 ± 
2°C, protected from light. PBMCs were then washed and passed through a 30 µm cell 
strainer prior to separation of α4β7 positive and negative PBMC populations using a 
Miltenyi AutoMACS™. Both the α4β7+ and α4β7- populations were adjusted to 5x106 
cells/ml and cultured as described above to collect α4β7+ and α4β7- ALS. Immediately 
prior to ALS culture, 100 µl of both the α4β7+ and α4β7- populations was removed to 
assess population purity by flow cytometry. As α4β7+ cells were bound by the AF647 
conjugated anti-α4β7 monoclonal antibody, it is expected that only the positive 
population will fluoresce when analyzed by flow cytometry. The α4β7+ and α4β7- 
populations for a given subject/time point were analyzed using a FACSCanto II and 
determined to be ≥90% pure post-separation (data not shown).  
Memory B Cell Expansion and Quality Control. Frozen PBMCs from study days -1, 
28 and 56 were thawed, washed and expanded as previously described173 with minor 
modifications. Briefly, cells were suspended at 1x106 cells/ml in complete RPMI medium 
with 2-mercaptoethanol and polyclonal mitogens: Pokeweed Mitogen extract at a 
1:20,000 dilution (Sigma), CpG-ODN-2006 at 6 µg/ml (Invivogen) and fixed 
Staphylococcus aureus Cowan at a 1:10,000 dilution (Sigma). Cells were plated in a sterile 
6-well tissue culture plate (3-5 ml/well) and cultured for 6 days at 37 ± 1˚C with 5% CO2. 
After expansion, the cells were washed twice with mitogen-free complete RPMI medium, 
adjusted to 5x106 cells/ml and cultured as described above to collect memory B cell ALS.  
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A novel method was developed to characterize the memory B cell expansion and 
establish acceptability criteria in order to objectively determine successful expansion of 
memory B cell populations (manuscript in preparation). Briefly, samples were analyzed 
by flow cytometry before and after polyclonal mitogen stimulation using T and B cell-
specific markers (CD3-BV711, CD19-BV421, CD27-APC and CD20-PE-Cy7; BD Biosciences) 
and analyzed by flow cytometry using a FACSCanto II. Acceptance criteria for a successful 
expansion included assessing cell viability and cell concentrations pre- and post-
expansion as well as ensuring an overall increase post-expansion in the percent of cells 
positive for the CD19 B cell marker. Additionally, an expansion was considered successful 
if B cell populations post-expansion showed a ≥20% increase in B cells positive for the 
CD27 memory marker, as compared to pre-expansion B cell populations. 
Enzyme-Linked Immunosorbent Assay. Serum, stool extracts, and ALS samples 
were assayed by ELISA to determine Shigella antigen-specific antibody endpoint titers as 
previously described,174 with the exception of the use of Immulon 1-B ELISA plates 
(Thermo) and human-specific secondary antibodies (reserve AP-conjugated Goat-Anti-
Human IgG, IgA or IgM; Seracare; AP-conjugated Mouse-Anti-Human IgG1, IgG2, IgG3 or 
IgG4; Southern Biotech). ELISA titers were defined as the reciprocal of the last dilution of 
serum with an optical density (OD) above the assay cut-off value. Samples negative at the 
starting dilution were assigned a titer corresponding to half the starting dilution (½ LOD). 




Serum Bactericidal Activity (SBA). Antibody functionality was assessed by 
determining Shigella-specific SBA as previously described.175 Briefly, serum samples, 
bacterial suspensions and 20% baby rabbit complement (BRC) were added to duplicate 
wells of a 96-well round-bottom plate (Corning). Assay controls included wells with 
bacteria and BRC only, and wells with bacteria and heat-inactivated BRC only. Plates 
were incubated at 37°C for 2 hours and subsequently placed on ice for 10 minutes. 
Samples were spot plated (10 µl/sample) onto square LB agar plates (Greiner Bio-One) 
and plates were tilted to allow the suspension to run down the agar (~2 cm) in order to 
distribute the bacterial colonies. Plates were allowed to dry, and incubated overnight at 
37°C. The following day, a 2,3,5-triphenyltetrazolium chloride (TTC) agar overlay was 
added to the plates. As TTC is a cellular metabolism-indicating dye which stains bacterial 
colonies red, it allows bacterial colonies to be visualized and subsequently counted.  
Colonies were enumerated using NICE software, and SBA titers were interpolated 
from a standard curve generated from the dilution series used in the assay, as previously 
described.175,176 SBA titers were defined as the reciprocal serum dilution killing at least 
50% of bacteria as compared to control wells. Serum samples were assayed starting at a 
1:40 dilution and a titer of 20, corresponding to ½ LOD, was assigned to samples not 
exhibiting detectable serum bactericidal activity at the starting dilution. Immune 
responders were defined a priori as those with a ≥4-fold increase in SBA titer over 
baseline. Bactericidal activity directed to S. sonnei, Moseley, was determined, as well as 
to S. flexneri 2a, 2457T to investigate the cross reactivity of functional antibodies with 
other Shigella serotypes. 
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Disease Outcomes and Definitions. Immune responses pre- and post-challenge 
were compared across shigellosis outcome to determine the association of these 
immune parameters with progression to and severity of disease post-challenge. The 
outcome of shigellosis was chosen as at it is often the focus of Shigella vaccine 
development. However, immune responses demonstrating differences across additional 
disease outcomes are also presented. Diarrhea severity, dysentery (Appendix A) and 
disease severity score105 were defined as previously described. While the primary clinical 
shigellosis endpoint was defined a priori in the clinical protocol and is used to describe 
attack rates in Appendix A, all immunological analyses were conducted using an 
alternative definition of shigellosis developed through a convening of Shigella CHIM 
experts focused on the standardization of Shigella CHIM clinical endpoints.166 All disease 
outcomes used for immunological analyses are also described in Table 3.1. 
Statistical Analyses. Normally distributed continuous immune response data 
were analyzed using appropriate parametric tests (T-Test or ANOVA) with Bonferroni 
post-hoc analyses as applicable. Non-normally distributed data were log-transformed 
prior to analysis in parametric tests, or appropriate non-parametric tests were used 
(Mann-Whitney U). A multivariate logistic regression model was developed to assess the 
association between various immune parameters at baseline and the odds of progressing 
to either shigellosis MSD versus none or mild diarrhea. Continuous variables were 
analyzed for assumption of linearity by plotting the variable against the log odds of the 
outcome. As age did not demonstrate a linear relationship with either outcome, it was 
appropriately categorized (MSD: 18-25, 26-40 and 41-49; shigellosis: 18-25 and 26-49).  
47 
 
Covariates of interest (gender, age category, race and log-transformed dose) were 
investigated in univariate models (α=0.20) and included in the final model if they were 
significantly associated (p≤0.05) with the outcome of interest, or influenced the effect 
estimate of baseline immune responses by ≥10% (gender, age category and log-
transformed dose). Race did not meet either inclusion criteria and was excluded from the 
multivariate model. Cut-point analyses were performed by plotting receiver operating 
characteristics (ROC) and investigating sensitivity and specificity across different areas 
under the curve. Additional cut-point analyses were performed using Liu and Youden cut-
point methods. All statistical tests were interpreted in a two-tailed fashion (α=0.05) with 
p-values ≤0.05 considered statistically significant in either Stata (Version 14 for MAC) or 





3.5. RESULTS  
Fecal Inflammatory Marker Responses. Fecal calprotectin and myeloperoxidase 
concentrations were determined only in stool samples from subjects consenting the use 
of their stool samples in future investigations (45/56 subjects). Of these 45 subjects, 18 
progressed to shigellosis post-challenge while 26 did not. A substantial increase in 
calprotectin and myeloperoxidase (all p≤0.002, 2-way ANOVA) concentrations was 
observed 3 days post-challenge, regardless of shigellosis outcome, with concentrations 
returning to baseline levels by day 14 (Figures 3.1A and 3.1C). Subjects with shigellosis 
had significantly higher concentrations of both fecal inflammatory markers whether 
comparing day 3 concentrations (all p≤0.018, 2-way ANOVA; Figures 3.1A and 3.1C) or 
peak (observed on day 3 or 7) concentrations (p=0.0002 (calprotectin), p=0.008 
(myeloperoxidase), T-test; Figures 3.1B and 3.1D) demonstrating an association of 
increased intestinal inflammation with progression to shigellosis. In addition, fecal 
inflammatory marker peak concentrations were associated with multiple other disease 
outcomes, including diarrhea severity, disease severity score and dysentery (Figures 3.2 
and 3.3). 
Serum Antibody Responses. Shigella antigen-specific serum IgG, IgA, IgM and IgG 
subclass responses were determined for all subjects and compared across groups with or 
without shigellosis. While baseline antigen-specific serum antibody levels were 
consistent with observations from previous Shigella CHIMs, additional investigations into 
baseline serum antibody levels are described in more detail below. LPS-specific serum 
IgG, IgA and IgM peaked 14 days post-challenge and remained elevated over baseline 
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levels 14- and 28-days post-challenge (all p≤0.003, 2-way ANOVA; Figure 3.4). There were 
no significant differences in LPS-specific serum IgG or IgA titers post-challenge between 
subjects with or without shigellosis (Figures 3.4A and 3.4B). LPS-specific serum IgM levels 
on day 14 were higher (p=0.033, 2-way ANOVA) in subjects with shigellosis (Figure 3.4C).  
Serum IgG and IgA responses directed to additional antigens, including native 
invasion complex (Invaplex; IVP)174 and IpaB and IpaC were investigated; however, no 
differences in peak serum titers post-infection were observed across shigellosis outcome 
groups (Table 3.2). IVP-specific titers showed the highest magnitude of response 
followed by IpaB and IpaC. Although a moderate increase (p=0.0008, 1-way ANOVA) in 
LPS-specific serum IgG1 titers was observed by day 14 across all subjects, there was no 
difference in peak LPS-specific serum IgG1 responses across subjects with or without 
shigellosis (Table 3.2). There were minimal to undetectable increases in LPS-specific 
serum IgG2, IgG3 and IgG4 responses post-infection, and no differences in peak titer in 
these IgG subclass responses across shigellosis outcome (Table 3.2). 
α4β7 ALS Antibody Responses. PBMCs were collected prior to challenge (day -1) 
as well as 5 and 7 days post-challenge in an effort to capture the peak of lymphocyte 
circulation within in the blood. Robust LPS- and IVP-specific ALS IgA (all p≤0.0001, 2-way 
ANOVA; Figures 3.5A and 3.5C), and ALS IgG (all p≤0.0006, 2-way ANOVA; Figures 3.5B 
and 3.5D) responses from the α4β7+ B cells were observed 7 days post-infection, 
regardless of shigellosis outcome. Subjects with shigellosis had significant antigen-
specific α4β7+ ALS IgA and IgG increases over baseline by day 5 post-infection across all 
antigens and isotypes (all p≤0.048, 2-way ANOVA; Figure 3.5). Although lower in 
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magnitude, similar trends in the α4β7- ALS IgA and IgG responses were observed with 
peak responses 7 days post-infection. With the exception of the LPS-specific α4β7- ALS 
IgA responses, subjects with shigellosis had higher LPS-specific α4β7- ALS IgG and IVP-
specific α4β7- ALS IgG and IgA titers on day 7 as compared to baseline (all p≤0.006, 2-way 
ANOVA; Figures 3.5B, 3.5C and 3.5D).  
Across both shigellosis outcome groups, day 7 LPS- and IVP-specific α4β7+ ALS IgA 
and IgG responses were higher than α4β7- ALS responses (all p<0.0001, 2-way ANOVA; 
Figure 3.5). LPS-specific α4β7+ ALS IgG and IVP-specific α4β7+ ALS IgA responses were 
also increased as compared to α4β7- ALS responses 5 days post-challenge (p=0.037 and 
p=0.033, respectively, 2-way ANOVA; Figures 3.5B and 3.5C). 
Subjects progressing to shigellosis had substantially higher α4β7+ ALS responses 
on day 7 as compared to day 7 α4β7+ ALS responses in subjects without shigellosis (all 
p<0.0001, 2-way ANOVA; Figure 3.5). Interestingly, IVP-specific α4β7- ALS IgA and IgG 
responses on day 7 were significantly increased (p=0.011 and p<0.0001, respectively, 2-
way ANOVA; Figures 3.5C and 3.5D) in subjects with shigellosis yet this same difference 
was not observed in the LPS-specific α4β7- ALS responses (Figures 3.5A and 3.5B). In 
addition to the association with shigellosis, LPS- and IVP-specific α4β7+ ALS IgA 
responses were associated with diarrhea severity, disease severity score and dysentery 
(Figures 3.6 and 3.7). LPS- and IVP-specific α4β7+ ALS IgG responses showed similar 
trends and were also associated with all aforementioned disease outcomes at similar 
levels of significance (data not shown). 
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Fecal Antibody Responses. Fecal IgA and IgG responses were determined for all 
subjects and compared across shigellosis outcome groups. In subjects with shigellosis, 
peak LPS-specific fecal IgA and IgG titers were observed 7 days post-infection, and 
although lower by day 14, remained elevated over baseline (all p<0.0001, 2-way ANOVA; 
Figures 3.8A and 3.8B). In contrast, LPS-specific fecal IgA and IgG responses in subjects 
without shigellosis continued to increase through study day 14 (all p≤0.049, 2-way 
ANOVA; Figures 3.8A and 3.8B). LPS-specific fecal IgA and IgG titers on day 7 were higher 
in subjects with shigellosis as compared to subjects without (all p≤0.045, 2-way ANOVA; 
Figures 3.8A and 3.8B) with similar trends and levels of significance observed in the IVP-
specific fecal antibody responses (data not shown).  
Fecal antibody responses were compared with α4β7+ ALS antibody responses, 
revealing a moderate correlation when peak fold-rise in fecal IgA or IgG was compared 
with peak fold-rise in α4β7+ ALS IgA or IgG (r=0.51 (IgA), r=0.53 (IgG), p<0.0001 
Spearman correlation; Figures 3.8C and 3.8D). 
Memory B Cell Responses. LPS- and IVP-specific memory B cell IgG and IgA ALS 
titers on day 28 were elevated over baseline (all p≤0.013, 2-way ANOVA) and although 
responses decreased by day 56, ALS titers remained elevated over baseline levels (data 
not shown). The maximum fold-rise (day 28 or 56) over baseline was used to compare 
memory B cells responses across subjects with or without shigellosis post-challenge 
(Figure 3.9). With the exception of the LPS-specific memory B cell IgG responses, subjects 
with shigellosis had larger peak fold-rises in LPS-specific IgA and IVP-specific IgG and IgA 
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memory B cell ALS titers compared to subjects without shigellosis (all p≤0.027, Mann-
Whitney U; Figure 3.9). 
SBA Responses. Peak S. sonnei-specific SBA was observed 14 days post-challenge; 
however, levels were increased over baseline by day 7 (all p<0.0001, 2-way ANOVA; 
Figure 3.10A) and remained elevated through study day 56 (all p≤0.024, 2-way ANOVA; 
Figure 3.10A), regardless of shigellosis outcome. There were no differences in peak S. 
sonnei-specific bactericidal activity across subjects with or without shigellosis (Figure 
3.10B) and although not significant, it is interesting to note that subjects without 
shigellosis had higher S. sonnei-specific bactericidal titers 28- and 56-days post-infection 
(Figure 3.10A).  
Minimal increases in S. flexneri 2a-specific SBA over baseline were observed and 
there were no differences in peak titer (data not shown) or peak fold-rise over baseline 
(Figure 3.10C) across shigellosis outcome groups. A total of 8 subjects had a 4-fold or 
greater rise over baseline in S. flexneri 2a-specific bactericidal titers and interestingly, of 
these 8 subjects, 7 did not progress to shigellosis (Figure 3.10C).  
Baseline Immune Responses. A thorough evaluation of pre-existing immunity 
was conducted to better understand the lack of association between disease severity and 
certain immune parameters (Figure 3.11) in this study population. As described in 
Appendix A, 171 subjects were screened for study inclusion. After exclusions based on 
other criteria, 130 subjects were screened for S. sonnei LPS-specific serum IgG titers 
between study days -45 to -2. Of these 130, 4 subjects (~3%) had titers greater than the 
2500 cut-off used for study inclusion and were excluded from the study (Table 3.3). 
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Of the enrolled subjects, there were no differences in the LPS-specific serum IgG 
titers at baseline (study day -1) across shigellosis outcome group, and with the exception 
of one individual, all subjects had baseline LPS-specific serum IgG titers within 2-fold of 
the 2500 cut-off for inclusion (Figure 3.11A). In contrast, increased LPS-specific serum IgA 
baseline titers were associated with subjects not progressing to shigellosis (p=0.027, T-
test; Figure 3.11A). A similar association was observed with baseline S. sonnei-specific 
SBA (p=0.038, Mann-Whitney U; Figure 3.11B) as well as LPS-specific fecal IgA and IgG 
titers at baseline (p=0.027 and p=0.035 respectively, Mann-Whitney U; Figure 3.11C). 
There was also a significant association of increased LPS-specific memory B IgA baseline 
titers with subjects not progressing to shigellosis (p=0.034, T-test; Figure 3.11D); 
however, this same association was not observed in the LPS-specific memory B IgG 
baseline titers (p=0.082, T-test; data not shown). LPS-specific serum IgA baseline titers 
were also inversely associated with diarrhea severity, dysentery and disease severity 
score (Figure 3.12).  
Logistic regression analyses were used to investigate the association of increasing 
baseline LPS-specific serum IgG or IgA ELISA titers with progression to either mild to 
severe diarrhea (MSD), or to shigellosis (Table 3.4). Neither the unadjusted nor adjusted 
models showed an association of increasing baseline LPS-specific serum IgG with either 
outcome of interest. In contrast, both the unadjusted and adjusted models showed a 
significant association between progression to shigellosis or MSD and increasing baseline 
LPS-specific serum IgA titers. In the adjusted model, each fold-increase in baseline LPS-
specific serum IgA titer resulted in nearly a 40% reduction in odds of progression to 
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shigellosis (odds ratio (OR)=0.61, 95% confidence interval (CI)=0.40-0.94; Table 3.4) with 
an area under the ROC of 0.777. Similarly, increasing baseline LPS-specific serum IgA 
titers resulted in nearly a 50% reduction in odds of progression to MSD (OR=0.51, 
CI=0.32-0.80; Table 3.4) with an area under the ROC of 0.831. Additional cut-point 
analyses suggest an LPS-specific serum IgA titer of ≤300 or ≤150 as optimal cut-points for 





3.6. DISCUSSION  
The primary objective of the S. sonnei 53G CHIM was to determine a dose of a 
cGMP manufactured lyophilized strain that would safely and reproducibly induce a ≥60% 
shigellosis rate in challenged subjects (Appendix A). The study also provided a unique 
opportunity to extensively characterize the Shigella-specific systemic, mucosal and 
functional antibody immune responses pre- and post-infection with S. sonnei 53G in a 
more robust manner than previous studies. The more expansive immune response 
characterization further facilitates the understanding of host resistance to infection and 
could lead to determining immune markers that may be associated with recovery from 
shigellosis and/or protection against illness upon re-exposure. As expected, infection 
with S. sonnei induced robust intestinal inflammatory and mucosal responses as 
observed by sharp increases in fecal inflammatory markers and α4β7+ ALS antibody 
responses in diseased subjects, and both of these immune parameters were significantly 
associated with multiple disease outcomes. Interestingly, there was a lack of association 
with post-infection systemic immune responses (serum antibodies and bactericidal 
activity) and disease outcomes. The relationship between intestinal inflammatory 
markers and disease outcomes noted above is intriguing and deserves further 
investigation into its potential relationship to immune outcomes that are associated with 
recovery from acute illness or may be predictive of a reduced risk of illness when re-
exposed to Shigella.  
Fecal IgA responses are often used as a measure of the mucosal immune 
response post-infection with Shigella. In this study, fecal IgG responses were also 
56 
 
evaluated. Antibody responses from B cells positive for the gut homing marker α4β7 
were also determined and presented as a measure of the mucosal immune response. As 
α4β7+ cells home to the intestinal mucosa and secrete IgA and IgG antibodies that are 
actively transported or passively transudated into the lumen of the large intestine, the 
correlation of these two mucosal measurements was of particular interest. The observed 
correlation of α4β7+ ALS IgG and fecal IgG suggests that the IgG secreting α4β7+ cells 
may be partially responsible for the antigen-specific IgG detected in stool samples in 
addition to IgG transudate from systemic circulation.  
Antecedent shigellosis reduces the risk of subsequent infection in a serotype-
specific manner, indicating a role for LPS-specific adaptive immune responses in 
protection.98,99,170,177 LPS-specific serum IgG has been implicated as an immune correlate 
of protection responsible for this observed serotype-specific protection;114,122 however, 
several of these studies have investigated serum IgG levels after parenteral immunization 
with conjugate vaccines which would be expected to induce high amounts of LPS-specific 
serum IgG.116,122,178-180 Furthermore, immunological analyses in many previous studies 
have been limited with incomplete analysis of other immune parameters outside of 
serum IgG. In contrast, results from this report and other studies evaluating mucosal 
routes of immunization or infection106,114,181,182 suggest that LPS-specific IgA also 
contributes to protection. Together, these data provide insight that there exist alternate 




Interestingly, increased LPS-specific serum IgA, IgA-secreting memory B cells and 
SBA titers at baseline were inversely associated with risk of shigellosis. Increased baseline 
serum IgA titers have also been associated with reduced risk of disease in 
enterotoxigenic Escherichia coli (ETEC) CHIMs183 as well as reduced susceptibility to 
cholera infection in endemic settings.182 In an effort to recruit immunologically naïve 
subjects, exclusion criteria for this study included recent travel to Shigella endemic areas, 
known history of culture confirmed Shigella infection and a S. sonnei LPS-specific serum 
IgG ELISA titer of >2500, however, LPS-specific serum IgA responses were not assessed 
during study screening. The serum IgG exclusion criterion used in this study was 
developed using data from a prior Shigella CHIM demonstrating that subjects with 
disease post-oral challenge had a serum IgG ELISA titer of at least 2500.169 While this 
serological exclusion criterion has been applied to several Shigella vaccine studies and 
CHIMs,127,184,185 results described here suggest it may be insufficient, even when 
combined with exclusion based on previous Shigella exposure and travel.  
As outlined above, memory B cell IgA responses directed to LPS correlated with 
resistance to shigellosis. In addition, LPS-specific serum IgA responses and SBA also were 
associated with decreased risk of shigellosis, albeit at a lower magnitude. These results 
demonstrate that immune parameters other than serum IgG may contribute to 
resistance to shigellosis. Given these associations with resistance to shigellosis, it may be 
reasonable to expand the immunological parameters utilized for excluding subjects from 
Shigella vaccine studies or CHIMs when a naïve population is critical. While data 
presented here suggests that LPS-specific IgA-secreting memory B cell responses at 
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baseline may be the most suitable predictor of resistance to shigellosis, a balance needs 
to be maintained between subject exclusion criteria and the ability to successfully recruit 
subjects. Therefore, impractical, costly, or technically difficult screening assays must be 
weighed against study objectives. Functional immune responses at baseline, as 
determined by SBA, could also be considered; however, the association of baseline SBA 
with disease outcomes was less robust compared to LPS-specific serum IgA responses 
and the assay is also more technically challenging and time-consuming as compared to an 
ELISA. Collectively, these results suggest that LPS-specific serum IgA titers should be 
considered as a potentially useful and practical tool to more reliably exclude subjects 
with pre-existing immunity to Shigella, similar to ETEC CHIMs.101 Although setting 
additional or more stringent exclusion criteria may become problematic when 
developing CHIMs in LMICs, an alternative strategy may be to stratify and/or randomize 
subjects based on baseline immunity. 
Logistic regression analyses indicated an approximate 40% and 50% reduction in 
odds of progression to shigellosis and MSD, respectively; however, these same 
associations were not observed with baseline LPS-specific serum IgG titers. This lack of 
association with baseline LPS-specific serum IgG and progression to shigellosis or MSD 
may be due to the fact that subjects with high baseline serum IgG titers were excluded 
from the study, potentially providing a biased population after study enrollment. 
However, of the 130 subjects that underwent LPS-specific serum IgG screening, only 4 
subjects (3.1%) were excluded based on high S. sonnei LPS-specific serum IgG titers 
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(Table 3.3). Additionally, of the 56 enrolled subjects, 41 (73%) had a LPS-specific serum 
IgG screening titer of ≤625.  
ROC analyses revealed an optimal baseline LPS-specific serum IgA cut-point of 
≤300 for predicting progression to MSD. In an effort to investigate the lack of a dose 
response observed in this CHIM (Appendix A), systemic immune responses were re-
analyzed by approximate Shigella dose (500, 1000 or 1500 cfu) excluding subjects with a 
baseline LPS-specific serum IgA titer >400; however, removal of these subjects did not 
result in a dose-dependent LPS-specific serum IgG response or SBA response. This lack of 
association could be a function of the sample size (N=40) resulting in insufficient power 
to determine significant differences, or it could imply that there are other host factors, 
such as microbiome or genetics, that have not yet been measured or explored.  
There are multiple immune mechanisms that could be employed to protect 
against Shigella, which can be effective during the intracellular and extracellular phases 
of the bacterial infection. Protective immune responses could be driven, in part, by 
antibodies in the lumen preventing transcytosis of the bacteria across the epithelial cell 
layer (whether secretory IgA or IgG transudate), complement activation in the lamina 
propria or antibody dependent cellular cytotoxicity once Shigella has reached the 
intracellular phase of its life cycle. While assessing mechanistic correlates of protection is 
important, investigating immunological surrogates that represent the mechanistic 
correlates of protection is also informative. Additionally, rather than identifying one 
immune parameter responsible for protection, there may be multiple immune 
parameters working in concert, effectively defining a protective immune profile.168 
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Furthermore, depending on the initial route of antigenic exposure, there may be distinct 
protective immune profiles generated. Additional analyses, including Shigella-specific 
salivary antibody responses, determination of Fc glycosylation patterns, Shigella 
microarray analyses, transcriptomics and systems serology are currently planned to parse 
out more nuanced differences in immune responses across the disease spectrum. 
Similarly, ongoing analyses and determination of a protective immune profile in the 
context of parenterally administered Shigella vaccines could offer additional insights. 
Disease outcomes and immune responses post-infection may also be affected by 
the duration of antigenic exposure. In the S. sonnei 53G CHIM, the majority of subjects 
were administered antibiotics 5 days post-inoculation (or sooner if clinically indicated, 
N=9) which often does not occur during natural infection. Interrupting the infection with 
antibiotics may reduce the amount and exposure time to Shigella antigens potentially 
impacting the magnitude, specificity, duration, maturation and phenotype of the 
immune response induced in a CHIM,186 as compared to endemic settings. Depending on 
the duration of antigenic stimulation, more robust or perhaps different immune 
responses could occur, including generation of antibodies with higher affinity or avidity, 
antibodies with different Fc glycosylation patterns, or increased activation of cell-
mediated immune mechanisms.  
Additional immune response analyses by time and length of shedding S. sonnei in 
stool samples could also provide important insights into the relationship between 
Shigella infection and immune responses. Unfortunately, the current study was not 
powered to detect differences in immune responses across culture confirmed S. sonnei 
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shedding as the majority of subjects had culture negative stools within 3-5 days after 
their first culture-positive stool sample. Efforts are currently underway to quantify S. 
sonnei in stool samples using qPCR detection methods in order to further investigate the 
immune responses and S. sonnei shedding in stool samples post-infection.  
Other non-immunological factors may also contribute to the resistance to 
infection and lack of association of some immune parameters with disease outcomes 
observed in this study. While a CHIM attempts to control for many variables, such as 
challenge dose and age, there remain several uncontrolled factors in both CHIMs and 
natural infection settings that could contribute to differences in disease outcomes. 
Population genetics, prior exposure, contemporaneous host immune status or co-
infections, as well as microbiome and nutritional status may affect immune response 
profiles and disease outcomes post-infection.131-134 Finally, this study was conducted in 
healthy, North American adults who are a distinctly different population than the target 
population of children <2 years old living in LMICs. Infant immune systems do not fully 
mature until approximately 24 months of age and have been shown to have lower levels 
of circulating immunoglobulin and complement effectors leading to different immune 
responses being required to induce protection in this population.187 Furthermore, infant 
health and immune status can vary greatly in endemic settings, so caution is required 
when extrapolating immune responses post-infection in healthy North American adults. 
Nonetheless, as conducting a Shigella CHIM in the target population of LMIC 
children is not possible, data collected in this study are invaluable to understanding 
immune responses and their association with disease post-challenge with S. sonnei. In 
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addition to the immune response characterization post-infection, this study provides 
important information about immune status pre-infection. Increased levels of serum IgA 
may be a contributing factor to resistance after oral Shigella challenge, and while 
additional investigations with increased group numbers is important, this study has been 
able to provide some guidance on immunological screening assays for use in future 
Shigella CHIMs.  
Ideally, protective immunity against shigellosis would be assessed in the context 
of a challenge/re-challenge CHIM study design, however, the current study was designed 
and powered to only answer the primary clinical outcome. Nonetheless, as prior disease 
results in protective immunity against subsequent infection with the same Shigella 
serotype, subjects in this trial provide an important population for the investigation of 
potential immune correlates or surrogates of protection as those with moderate to 
severe disease would likely be protected against reinfection.98,109,177 With the dose of S. 
sonnei 53G now established, next steps should focus on the conduct of a challenge/re-
challenge study in order to fully elucidate the immunological mechanisms responsible for 
protection from shigellosis. Additionally, a heterologous challenge/re-challenge study is 
in the planning stages to investigate the potential of cross-protection provided across 
different Shigella species. The S. sonnei 53G CHIM has confirmed the relevance of robust 
mucosal immune responses post-infection and their potential role as a mechanistic 
correlate of protection in this model,120 while suggesting that systemic immune 
responses may play a lesser role as they were not as reflective of disease outcome and 
severity in this study. The observations that baseline levels of LPS-specific serum IgA and 
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IgA-secreting memory B cells are associated with reduced odds of disease point to these 
immune measures as being potentially more sensitive markers for underlaying protective 
immunity and therefore should be further studied. Together, these data may help guide 
the rational design of future Shigella vaccines while representing a framework for future 




Table 3.1. Disease Outcome Definitions and Source 
 
Outcome  Definition  Scale 




 Diarrhea severity is divided into the following 4 categories: 
1) None 
2) Mild: 2-3 grade 3-5 stools and <400g of grade 3-5 stools in 24hrs 
3) Moderate: 4-5 grade 3-5 stools or 400-800g of grade 3-5 stools in 24hrs 
4) Severe: ≥6 grade 3-5 stools or >800g of grade 3-5 stools in 24hrs 
 
Source: Defined per protocol (R.W. Frenck et al. 2020, Manuscript 
Submitted) 
 Binary Outcome:  
Subjects were combined 
into 1 of 2 categories:  
1) Those with no diarrhea 
or mild diarrhea  
2) Those with moderate or 
severe diarrhea 
     
Dysentery 
(Chapter 3) 
 A least 2 grade 3-5 stool with gross blood with reportable 
constitutional/enteric symptoms. 
 
Source: Defined per protocol (R.W. Frenck et al. 2020, Manuscript 
Submitted) 
 Binary Outcome:  
Subjects grouped by 
whether or not they 
received a dysentery 
diagnosis during the study 





 Subjects are assigned scores (as described by Porter et al.) across the 
following categories depending on severity and frequency: 
1) Objective Symptoms: gross blood, oral temperature, vomiting 
2) Subjective Symptoms: constitutional/enteric symptom 
3) Grade 3-5 stool output per 24hrs 
 
Source: Porter et al. 2018, DOI: 10.1371/ journal.pone.0194325 
 Ordinal Outcome:  
Subjects’ scores across 
three categories are added 
up to for a final score 
between 0 – 9 
     
Consensus 
Shigellosis 
(Chapter 3 & 
Chapter 4) 
 One of three definitions (as described by MacLennan et al.) must be met: 
1) Severe diarrhea 
2) Moderate diarrhea with one of the following: fever ≥38.0°C or ≥1 
moderate constitutional/enteric symptom or ≥2 episodes of vomiting in 
24hrs 
3) Dysentery with one of the following: fever ≥38.0°C or ≥1 moderate 
constitutional/enteric symptom or ≥2 episodes of vomiting in 24hrs 
 
Source: MacLennan et al. 2019, DOI: 10.1093/cid/ciz891 
 Binary Outcome:  
Subjects grouped by 
whether or not they 
received a shigellosis 
diagnosis during the study 
     




 One of three definitions (as described by Talaat et al.) must be met: 
1) Severe diarrhea (as defined above) 
2) Moderate diarrhea (as defined above) with one of the following: fever 
≥38.0°C or ≥1 moderate constitutional/enteric symptom  
3) Dysentery (as defined above) with ≥1 constitutional/enteric symptom  
 
Source: Defined per protocol (K.R. Talaat et al. 2020, Manuscript 
Submitted) 
 Binary Outcome:  
Subjects grouped by 
whether or not they 
received a shigellosis 
diagnosis during the study 
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Table 3.2. Shigella Antigen-Specific Serum Antibody Responses at Baseline (Day -1) and 
Peak Titer Post-Baseline (Day 14, 28 or 56) with Number and Percent Responders 
 
 Disease Outcome   
 No Shigellosis (N = 34)  Shigellosis (N = 22)   
Immune Parameter  GMTa Responders (%)b  GMT Responders (%)  P-Valuec 
         
IVP-Specific Serum IgG        
 Baseline 2,832 ---  1,704 ---   
 Peak Titer 10,654 14/34 (41%)  11,646 14/22 (64%)  0.793 
         
IVP-Specific Serum IgA        
 Baseline 347 ---  129 ---   
 Peak Titer 3,924 23/34 (68%)  6,400 22/22 (100%)  0.210 
         
IpaB-Specific Serum IgG        
 Baseline 521 ---  171 ---   
 Peak Titer 3,767 21/34 (62%)  1,651 15/22 (68%)  0.179 
         
IpaB-Specific Serum IgA        
 Baseline 78 ---  62 ---   
 Peak Titer 326 14/34 (41%)  234 8/22 (36%)  0.546 
         
IpaC-Specific Serum IgG        
 Baseline 326 ---  353 ---   
 Peak Titer 511 4/34 (12%)  683 4/22 (18%)  0.470 
         
IpaC-Specific Serum IgA        
 Baseline 87 ---  83 ---   
 Peak Titer 113 3/34 (9%)  107 2/22 (9%)  0.843 
         
LPS-Specific Serum IgG1        
 Baseline 55 ---  55 ---   
 Peak Titer 153 12/34 (35%)  100 5/22 (23%)  0.253 
         
LPS-Specific Serum IgG2        
 Baseline 80 ---  71 ---   
 Peak Titer 141 8/34 (24%)  113 5/22 (23%)  0.456 
         
LPS-Specific Serum IgG3        
 Baseline 50 ---  52 ---   
 Peak Titer 69 6/34 (17%)  73 3/22 (14%)  0.785 
         
LPS-Specific Serum IgG4        
 Baseline 50 ---  50 ---   
 Peak Titer 50 0/34 (0%)  50 0/22 (0%)  >0.999 
         
a GMT = Geometric Mean Titer 
b Responder defined as a subject with a ≥4-fold increase in titer over baseline. 





Table 3.3. S. sonnei LPS-Specific Serum IgG Screening ELISA Titers Across Screened 
Subjects, Enrolled Subjects and Subjects that Progressed to Shigellosis 
 
LPS-Specific 
Serum IgG ELISA 
Titer  
 Total Number of Subjects 
 
Screened 
(N = 130)a Percent
b  
Enrolled 
(N = 56) Percent
c  
Shigellosis 
(N = 22) Percent
d 
          
Category 1: <625  66 51%  27 48%  13 59% 
          
Category 2: 625  25 19%  14 25%  4 18% 
          
Category 3: 1250  25 19%  10 18%  4 18% 
          
Category 4: 2500  10 8%  5 9%  1 5% 
          
Category 5: ≥5000  4 3%  N/Ae ---  N/A --- 
          
a Of the 171 subjects screened for study inclusion, a total of 130 subjects underwent serological screening. 
b Calculated as (number of subjects within a given ELISA titer category / total number of subjects screened by ELISA) 
c Calculated as (number of enrolled subjects within a given ELISA titer category / total number of enrolled subjects) 
d Calculated as (number of subjects with shigellosis within a given ELISA titer category / total number of subjects with shigellosis) 





Table 3.4. Logistic Regression Models Investigating the Association of Progression to 
Shigellosis or Moderate-Severe Diarrhea with Baseline S. sonnei LPS-Specific Serum IgG 
and IgA ELISA Titers 
 
Outcome of Interest 
 Odds Ratio (Confidence Interval) 
 Unadjusted ORa P-Value  Adjusted ORb P-Value 
       
Shigellosis 
       
Gender:     Male (ref)  1.00   1.00  
                    Female  0.55 (0.18 – 1.63) 0.277  0.37 (0.09 – 1.47) 0.158 
       
Age:           18 – 25 (ref)  1.00   1.00  
                   26 – 49  0.69 (0.20 – 2.42) 0.564  0.54 (0.11 – 2.60) 0.439 
       
Dose (cfu)  7.65 (1.44 – 40.6) 0.017  15.3 (1.91 – 122.0) 0.010 
       
Baseline LPS-Specific Serum IgG  0.89 (0.61 – 1.29) 0.534  1.27 (0.72 – 2.24) 0.404 
       
Baseline LPS-Specific Serum IgA  0.70 (0.51 – 0.97) 0.033  0.61 (0.40 – 0.94) 0.026 
       
Moderate-Severe Diarrhea 
       
Gender:     Male (ref)  1.00   1.00  
                    Female  1.03 (0.35 – 2.98) 0.961  1.61 (0.40 – 6.53) 0.504 
       
Age:           18 – 25 (ref)  1.00   1.00  
                   26 – 40  1.39 (0.36 – 5.30) 0.633  1.40 (0.23 – 8.51) 0.712 
                   41 – 49   2.40 (0.52 – 11.0) 0.259  7.21 (0.87 – 59.6) 0.067 
       
Dose (cfu)  5.08 (1.10 – 23.5) 0.038  15.9 (1.95 – 129.5) 0.010 
       
Baseline LPS-Specific Serum IgG  0.79 (0.55 – 1.15) 0.216  1.18 (0.66 – 2.09) 0.582 
       
Baseline LPS-Specific Serum IgA  0.60 (0.43 – 0.85) 0.004  0.51 (0.32 – 0.80) 0.004 
       
a OR = Odds Ratio 






Figure 3.1. Fecal Calprotectin and Myeloperoxidase Concentrations after Oral Challenge 




Median (A) fecal calprotectin and (C) myeloperoxidase concentrations at baseline/B and 3, 7 and 14 days 
post-challenge, grouped by subjects with (N=18) or without (N=27) shigellosis. * = significant difference as 
compared to baseline concentrations within shigellosis outcome group; § = significant difference in 
concentrations between shigellosis groups at the same time point. Significance determined by 2-way 
ANOVA of log-transformed concentrations with Bonferroni post-hoc test. Individual peak (B) fecal 





Figure 3.2. Fecal Calprotectin Concentrations after Oral Challenge with S. sonnei 53G by 




Individual peak fecal calprotectin concentrations with group median, grouped by (A) subjects with none-
mild diarrhea (N=23) or moderate-severe diarrhea (N=22), and (B) subjects with (N=18) or without (N=27) 
dysentery. P-value determined by T-test of log-transformed concentrations. (C) Spearman correlation of 




Figure 3.3. Fecal Myeloperoxidase Concentrations after Oral Challenge with S. sonnei 




Individual peak fecal myeloperoxidase concentrations with group median, grouped by (A) subjects with 
none-mild diarrhea (N=23) or moderate-severe diarrhea (N=22), and (B) subjects with (N=18) or without 
(N=27) dysentery. P-value determined by T-test of log-transformed concentrations. (C) Spearman 








S. sonnei LPS-specific serum (A) IgG, (B) IgA and (C) IgM geometric mean ELISA endpoint titers prior to 
challenge (day -1) and 7, 14, 28 and 56 days post-challenge, grouped by subjects with (N=22) or without 
(N=34) shigellosis. * = significant difference as compared to baseline titers within shigellosis group; § = 
significant difference in titers between shigellosis groups at the same time point. Significance determined 









Individual ALS IgA and IgG ELISA endpoint titers with group geometric mean for α4β7+ (grey bars) and 
α4β7- (white bars) populations prior to challenge (day -1) and 5 & 7 days post-challenge, grouped by 
subjects with (N=22) or without (N=34) shigellosis. (A) S. sonnei LPS-specific ALS IgA; (B) S. sonnei LPS-
specific ALS IgG; (C) S. sonnei IVP-specific ALS IgA; (D) S. sonnei IVP-specific ALS IgG. § = significant as 
compared to matched α4β7+ or α4β7- baseline ALS titers within shigellosis group. P-values in red compare 
α4β7+ and α4β7- ALS titers on a given study day within shigellosis group. P-values in black compare 
matched α4β7+ or α4β7- ALS titers on a given study day across shigellosis group. Significance across all 











Individual day 7 S. sonnei LPS-specific α4β7+ ALS IgA ELISA endpoint titers with group geometric mean, 
grouped by (A) subjects with none-mild diarrhea (N=29) or moderate-severe diarrhea (N=27), and (B) 
subjects with (N=21) or without (N=35) dysentery. P-value determined by T-test of log-transformed titers. 
(C) Spearman correlation of day 7 S. sonnei LPS-specific α4β7+ ALS IgA ELISA endpoint titers and disease 











Individual day 7 S. sonnei IVP-specific α4β7+ ALS IgA ELISA endpoint titers with group geometric mean, 
grouped by (A) subjects with none-mild diarrhea (N=29) or moderate-severe diarrhea (N=27), and (B) 
subjects with (N=21) or without (N=35) dysentery. P-value determined by T-test of log-transformed titers. 
(C) Spearman correlation of day 7 S. sonnei IVP-specific α4β7+ ALS IgA ELISA endpoint titers and disease 




Figure 3.8. S. sonnei LPS-Specific Fecal IgA and IgG Responses and their Correlation with 




S. sonnei LPS-specific (A) fecal IgA and (B) IgG geometric mean ELISA endpoint titers at baseline/B and 3, 7 
and 14 days post-challenge, grouped by subjects with (N=22) or without (N=34) shigellosis. * = significant 
difference as compared to baseline titers within shigellosis group; § = significant difference in titers 
between shigellosis groups at the same time point. Significance determined by 2-way ANOVA of log-
transformed titers with Bonferroni post-hoc test. Spearman correlation of peak fold rise in (C) S. sonnei 










Tukey box and whisker plots of maximum fold-rise (day 28 or 56) over baseline memory B cell ALS ELISA 
endpoint titers, grouped by subjects with (N=22) or without (N=34) shigellosis. (A) S. sonnei LPS-specific 
memory B cell ALS IgA; (B) S. sonnei LPS-specific memory B cell ALS IgG; (C) S. sonnei IVP-specific memory B 










(A) Geometric mean S. sonnei-specific serum bactericidal titer (GMT) prior to challenge (day -1) and 7, 14, 
28 and 56 days post-challenge, grouped by subjects with (N=22) or without (N=34) shigellosis. * = 
significant difference as compared to baseline titers within shigellosis group. Significance determined by 2-
way ANOVA of log-transformed titers with Bonferroni post-hoc test. (B) Individual peak S. sonnei-specific 
SBA titers with group GMT grouped by subjects with (N=22) or without (N=34) shigellosis. P-value 
determined by T-test of log-transformed titers. (C) Individual fold-rise in S. flexneri 2a-specific SBA titers 
over baseline with group median grouped by subjects with (N=22) or without (N=34) shigellosis (line at 4 









Individual ELISA or SBA endpoint titers with group geometric mean prior to challenge (baseline), grouped 
by subjects with (N=22) or without (N=34) shigellosis. (A) S. sonnei LPS-specific serum IgG (dashed line = 
2500 cut-off titer used for study inclusion) and S. sonnei LPS-specific serum IgA, P-value determined by T-
test of log-transformed titers; (B) S. sonnei serum bactericidal activity, P-value determined by Mann-
Whitney U test; (C) S. sonnei LPS-specific fecal IgG and S. sonnei LPS-specific fecal IgA, P-value determined 










Individual S. sonnei LPS-specific serum IgG or IgA ELISA endpoint titers with group geometric mean prior to 
challenge (baseline), grouped by (A) subjects with none-mild diarrhea (N=29) or moderate-severe diarrhea 
(N=27), and (B) subjects with (N=21) or without (N=35) dysentery. P-value determined by T-test of log-
transformed titers. Spearman correlation of S. sonnei LPS-specific serum (C) IgG or (D) IgA baseline ELISA 





CHAPTER 4. IMMUNE RESPONSE CHARACTERIZATION IN A 
HUMAN CHALLENGE STUDY WITH A SHIGELLA FLEXNERI 






The data presented in Chapter 4 has been submitted for publication to the journal  
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4.1. SUMMARY  
Background. Diarrheal diseases are a leading cause of global morbidity and 
mortality affecting all ages, but especially children under the age of five in resource-
limited settings. Shigella is a top tier bacterial pathogen contributing to diarrheal 
diseases and is considered a significant antimicrobial resistance threat. While 
improvements in hygiene, and access to clean water help as control measures, 
vaccination remains one of the most viable options for significantly reducing morbidity 
and mortality. 
Methods. Flexyn2a is a bioconjugate vaccine manufactured using novel 
conjugation methodologies that enzymatically links the O-polysaccharide of S. flexneri 2a 
to exotoxin A of Pseudomonas aeruginosa. The protective capacity of Flexyn2a was 
assessed in a controlled human infection model after two intramuscular immunizations. 
Flexyn2a was well-tolerated and protected against severe illness post-oral challenge with 
S. flexneri 2a, 2457T. Immune responses post-immunization and post-oral challenge are 
described here. 
Findings. Flexyn2a induced lipopolysaccharide (LPS)-specific serum IgG responses 
post-immunization that were associated with protection against shigellosis. Additionally, 
several other immune parameters, including memory B cell responses, bactericidal 
antibodies and serum IgA, were also elevated in vaccinees protected against shigellosis 
after oral challenge. Immunization with Flexyn2a also induced mucosal-homing, LPS-
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specific IgG and IgA secreting B cells, indicating the vaccine induced immune effectors 
functioning at the site of intestinal infection. 
Interpretation. Collectively, the results of these immunological investigations 
provide insights into protective immune mechanisms post-immunization with Flexyn2a 
which can be used to further guide vaccine development and may have applicability to 
the larger Shigella vaccine field. 
Added Value of this Study. This is the first study to provide a thorough 
characterization of the systemic and mucosal immune responses induced after 
parenteral immunization with a Shigella conjugate vaccine, as well as to investigate the 
association of each immune parameter with protection from shigellosis. Additionally, this 
is the first study to report immune response data using the recently published consensus 
shigellosis endpoint, an outcome to be used in future Shigella challenge models and 
vaccine efficacy studies. 
Implications of all the Available Evidence. The current study provides essential 
insights into protective immune mechanisms associated with parenteral immunization 
with a Shigella bioconjugate. The precedent set in the current study of thorough 
characterization of the immune responses post-immunization may influence the design 
and immunological analyses of future Shigella clinical studies and can help move the field 




4.2. INTRODUCTION  
Shigella species are one of the leading causes of diarrhea-associated morbidity 
and mortality, accounting for millions of diarrhea-attributable deaths across all age 
groups annually.1,23 Diarrheal disease morbidity and mortality estimates are highest 
among children under the age of 5, with Shigella being the second leading cause of 
diarrhea-associated mortality in this age group.1,23 Furthermore, the impact of Shigella 
infection goes beyond the acute illness observed, as children with repeated enteric 
infections are also at risk of impaired cognitive performance and reduced height-for-age 
Z score.16 Children impacted by this physical and cognitive stunting have also been 
estimated to be at a higher risk of mortality due to other infectious diseases.17 Several 
additional post-infectious sequelae are also associated with Shigella infection, including 
post-infectious reactive arthritis and irritable bowel syndrome.20,40 
Antibiotics are generally effective in the treatment of shigellosis; however, 
increasing rates of antibiotic-resistance55,57 requires continual emphasis on primary 
prevention methods.61 Along with improved access to clean water, increased sanitation 
and improved hygiene, vaccine development efforts are considered an integral piece of 
reducing the Shigella disease burden.  
Epidemiological data and challenge/re-challenge studies have shown that prior 
Shigella infection protects from subsequent infection in a serotype-specific manner.92,98 
As Shigella serotypes are determined by the structure of their O-polysaccharide (OPS), 
lipopolysaccharide (LPS), or OPS alone, is considered to be a key protective antigen. 
Additionally, in order to protect against the most globally prevalent disease-causing 
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serotypes, an effective vaccine must be multi-valent. Although several Shigella vaccine 
approaches have been attempted in recent years, including live and killed whole cell 
vaccines, subcellular or subunit vaccines, as well as OPS conjugate vaccines,157,158 there is 
currently no widely available licensed vaccine. When considering candidate vaccines, OPS 
conjugates are of particular interest as the strategy has a well-demonstrated safety and 
efficacy history.123,125,188  
Flexyn2a is a bioconjugate vaccine manufactured using novel conjugation 
methodologies that enzymatically link the OPS of S. flexneri 2a to exotoxin A of 
Pseudomonas aeruginosa (EPA).126,127 The in vivo conjugation process leads to a highly 
reproducible product that is simple, reliable and inexpensive to manufacture. 
Additionally, the Shigella bioconjugate vaccines have demonstrated robust safety and 
immunogenicity profiles in prior Phase 1 clinical assessments.126,127 More recently, the 
Flexyn2a bioconjugate vaccine was assessed in a controlled human infection model 
(CHIM) to evaluate the preliminary efficacy following challenge with S. flexneri 2a strain 
2457T, as described in Appendix B.  
Promising efficacy results from the efficacy CHIM demonstrated the ability of 
Flexyn2a to protect against severe disease post-challenge with virulent S. flexneri 2a 
(Appendix B). Furthermore, robust S. flexneri 2a LPS-specific serum IgG and IgA responses 
were reported post-immunization, with serum IgG responses serving as a correlate of 
protection post-challenge (Appendix B). Efforts have since been underway to further 
characterize the immune responses induced post-parenteral immunization with the 
Flexyn2a bioconjugate, as well as post-oral challenge with S. flexneri 2a strain 2457T to 
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investigate potential correlates, or surrogates, of protection associated with Shigella 
infection. These analyses could further contribute to Shigella vaccine development 
efforts as well as enhance understanding of the mechanisms of protection associated 
with a parenterally administered Shigella bioconjugate vaccine. Moreover, data from the 
current challenge trial with the Flexyn2a bioconjugate were recently used to support the 
development of a consensus shigellosis endpoint and described herein is the first report 





4.3. MATERIALS AND METHODS  
Study Design and Efficacy. Trial design, conduct, randomization, masking and 
efficacy data are described in detail in Appendix B. Briefly, the trial was a randomized 
(1:1), double-blind, placebo-controlled study to assess preliminary efficacy post-
immunization with Flexyn2a. Subject inclusion and exclusion criteria are detailed in 
Appendix B, along with subject screening and disposition. In an effort to enroll 
immunologically naïve subjects, subjects with serologic evidence of prior exposure to S. 
flexneri 2a, described as a S. flexneri 2a LPS-specific serum IgG titer of ≥2500, were 
excluded from participation, in addition to other exclusion criteria (Appendix B). 
 Subjects were intramuscularly administered either unadjuvanted Flexyn2a (n=34) 
or placebo (saline, n=33) on study days 0 and 28 (see Appendix B Figure 1). Each dose of 
Flexyn2a contained 10μg of S. flexneri 2a OPS and 50μg of EPA. One month after the last 
immunization (day 56), subjects (30 vaccinees, 29 placebo recipients) were orally 
challenged with approximately 1500 colony forming units of S. flexneri 2a strain 2457T. 
Five days post-challenge (or sooner if clinically warranted), subjects received antibiotics 
(ciprofloxacin or trimethoprim/sulfamethoxazole) twice daily for 3 days. Subjects were 
discharged from the inpatient facility after producing two consecutive culture negative 
stool samples over a period of two days, and after having received at least 2 doses of 
antibiotics. Demographic data and disease outcome data of enrolled subjects are 
described in detail in Appendix B. 
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Blood Processing. Whole blood for serum and peripheral blood mononuclear cells 
(PBMCs) was collected at multiple time points during the vaccination phase (study days 
0, 7, 28, 35, and 56) as well as 3, 7 and 28 days post-challenge (study days 59, 63 and 84) 
(see Appendix B Figure 1). Serum samples were stored at -80±10˚C. PBMCs were isolated 
on a Ficoll gradient with Leucosep tubes (Grenier Bio-One), frozen and stored in liquid 
nitrogen until used in immunoassays.  
Antibodies in Lymphocyte Secretions (ALS). Frozen PBMCs were thawed, washed 
and suspended in complete RPMI medium (10% heat inactivated fetal calf serum, 100 
U/ml:100 µg/ml penicillin:streptomycin, 2 mM glutamine) at 5x106 cells/ml, plated in a 
sterile 24-well tissue culture plate (1 ml/well) and cultured for 4 days at 37 ± 1°C with 5% 
CO2 (cell viability not monitored). ALS supernatants were collected and frozen at -80 ± 
10°C until used in immunoassays. 
Enzyme-Linked Immunosorbent Assay (ELISA). Serum and ALS samples were 
assayed by ELISA to determine S. flexneri 2a LPS-specific antibody endpoint titers as 
previously described,174 with the exception of the use of Immulon 1-B ELISA plates 
(Thermo Scientific) and human-specific secondary antibodies (reserve alkaline 
phosphatase (AP)-conjugated Goat-Anti-Human IgG, IgA or IgM; Seracare; AP-conjugated 
Mouse-Anti-Human IgG1, IgG2, IgG3 or IgG4; Southern Biotech). ELISA titers were 
defined as the reciprocal of the last dilution of serum with an optical density (OD) above 
the assay cut-off value. Samples that were negative at the starting dilution (the assay 
limit of detection (LOD)) were assigned a titer corresponding to half of the starting 
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dilution (½ LOD). Immune responders were defined a priori as having a ≥4-fold increase 
over their baseline titer. 
α4β7 PBMC Separations. Frozen PBMCs from baseline (day 0), 7 days post-first 
immunization (day 7), as well as 3 and 7 days post-oral challenge (days 59 and 63) were 
thawed, washed and separated into α4β7 positive and negative PBMC populations as 
described in Chapter 3 using Miltenyi OctoMACS™ columns. The anti-α4β7 monoclonal 
antibody used for separation (Act-1; NIH AIDS Reagent Program) was conjugated to Alexa 
Fluor 647, allowing the purity of α4β7 populations to be assessed by flow cytometry. 
Post-separation, 100 µl from the α4β7+ and α4β7- populations for each subject/time 
point were analyzed using a FACSCanto II to ensure ≥90% purity in each of the α4β7+ or 
α4β7- populations (data not shown). 
Memory B Cell Expansion and Quality Control. Frozen PBMCs from baseline (day 
0), 28 days post-second immunization (day 56) and 28 days post-challenge (day 84) were 
thawed, washed and expanded as described in Chapter 3. After expansion, the cells were 
washed twice with mitogen-free complete RPMI medium, adjusted to 5x106 cells/ml and 
cultured as described above to collect ALS from memory B cells. Successful expansion of 
memory B cell populations was assessed using flow cytometry as described above in 
Chapter 3.  
Briefly, criteria for a successful expansion was defined as a post-expansion 
increase in cells positive for the CD19 B cell marker, as well as a ≥20% increase in B cells 
positive for the CD27 memory marker. Additionally, cell viability and cell concentrations 
were monitored pre- and post-expansion. Samples not meeting the criteria for successful 
89 
 
expansion of memory B cell populations were discarded and, using a new aliquot of 
frozen PBMCs, were expanded an additional time as outlined above. If the sample still 
did not meet the criteria for successful expansion, the sample was excluded from 
analyses. Additionally, memory B cell responses could only be determined for subjects 
with a sufficient amount of PBMCs available for the analysis: vaccinees (n=16/34), 
placebo recipients (n=27/33).  
Serum Bactericidal Assay (SBA). Antibody functionality was assessed by 
determining S. flexneri 2a-specific bactericidal activity as outlined in Chapter 3 and as 
previously described.175 Serum samples were titrated using serial 3-fold dilutions starting 
at 1:30 and titers were interpolated from a standard curve using NICE software.176 A titer 
of 10, corresponding to one-third of the lowest serum dilution tested, was assigned to 
samples not exhibiting detectable bactericidal activity at the starting dilution. Immune 
responders were defined a priori as those with a ≥4-fold increase in bactericidal titer over 
baseline.  
Disease Outcomes and Definitions. Immune responses pre- and post-challenge in 
subjects included in the challenge phase of the study (n=30 vaccinees and 29 placebo 
recipients) were compared across disease outcomes to evaluate the association of 
immune parameters with progression to, and severity of, disease. The majority of 
analyses were conducted using the recently developed consensus shigellosis CHIM 
endpoint.166 In addition, as this consensus definition did not exist prior to study-protocol 
development, a small subset of immune parameters are also presented using the per 
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protocol a priori shigellosis definition (Appendix B) to compare immune responses across 
both definitions. All disease outcome definitions are described in detail in Table 3.1. 
Statistical Analyses. Normally distributed continuous immune response data 
were analyzed using appropriate parametric tests (T-Test or repeated measures ANOVA) 
with Bonferroni post-hoc analyses as applicable. Non-normally distributed data were log-
transformed prior to analysis in parametric tests, or appropriate non-parametric tests 
were used (Mann-Whitney U). ELISA titer cut-point analyses were performed by plotting 
receiver operating characteristics (ROC) and investigating sensitivity and specificity across 
different areas under the curve using Liu cut-point methods. All statistical tests were 
interpreted in a two-tailed fashion with p-values ≤0.05 considered statistically significant 





4.4. RESULTS  
Serum IgG and IgA Responses. S. flexneri 2a LPS-specific serum IgG and IgA 
responses and percent seroconversions post-vaccination/challenge have been previously 
reported by treatment group (Appendix B, Table 5). Vaccinated subjects protected from 
shigellosis (regardless of the definition) had robust increases in serum IgG titers over 
baseline (all p<0.0001, 2-way ANOVA; Figure 4.1A and 4.2A); however, comparable 
significant increases over baseline were not observed in vaccinated subjects who 
developed shigellosis after challenge (all p>0.999, 2-way ANOVA; Figure 4.1A and 4.2A). 
In contrast, increases in LPS-specific serum IgA responses over baseline were observed in 
all vaccinated subjects, regardless of shigellosis outcome (all p≤0.05, 2-way ANOVA; 
Figure 4.1B and 4.2B). Furthermore, while serum IgG responses on, and after, day 28 
were higher in protected vaccinees compared to vaccinees with shigellosis, (all p≤0.01, 2-
way ANOVA; Figure 4.1A), only day 28 serum IgA titers were different across protected 
and unprotected vaccinees (p=0.02, 2-way ANOVA; Figure 4.1B). A second immunization 
with Flexyn2a did not increase the serum IgG or IgA responses for any of the vaccinated 
subjects, regardless of shigellosis outcome (Figure 4.1A-4.1B and 4.2A-B). In placebo 
recipients, no differences were observed over baseline in serum IgG or IgA titers across 
any of the shigellosis outcomes until after the day of challenge (day 56).  
Oral challenge with S. flexneri 2a, 2457T did not significantly increase the LPS-
specific serum IgG responses in vaccinated subjects, regardless of shigellosis outcome (all 
p>0.999, 2-way ANOVA; Figure 4.1A and 4.2A). Interestingly, while not statistically 
significant, serum IgA responses in unprotected vaccinees did increase by day 84 (all 
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p>0.999, 2-way ANOVA; Figure 4.1B and 4.2B), a trend not observed in protected 
vaccinees. Significant increases over baseline S. flexneri 2a LPS-specific serum IgG and IgA 
titers were observed post-challenge in placebo recipients progressing to shigellosis (all 
p≤0.05, 2-way ANOVA; Figure 4.1A and 4.1B). Similar magnitudes of increase in serum 
IgG or IgA responses were not observed in placebo recipients without shigellosis. 
Vaccinees protected from shigellosis had higher serum IgG responses on day 84 
compared to all placebo recipients, regardless of shigellosis outcome (all p<0.0001, 2-
way ANOVA; Figure 4.1A), whereas IgA responses in protected vaccinees were only 
higher compared to placebo recipients without shigellosis (p=0.008, 2-way ANOVA; 
Figure 4.1B).  
Serum IgG and IgA titers on day of challenge predicted efficacy post-challenge. 
Using Liu cut-point analyses (Table 4.1), a serum IgG titer of 25,600 provided 66% efficacy 
while a lower serum IgA titer of 800 provided 54% efficacy in vaccinated subjects (Figure 
4.1C and Table 4.1). Percent efficacy rose sharply thereafter with increasing serum IgG or 
IgA titers (Figure 4.1C and Table 4.2).  
Serum IgG Subclass and IgM Responses. Immunization with Flexyn2a induced 
higher LPS-specific serum IgG1 responses compared to placebo recipients (all p≤0.01, 2-
way ANOVA; Figure 4.3), an effect that appeared greatest among vaccinated subjects 
protected from shigellosis. Compared to vaccinees with shigellosis, protected vaccinees 
had higher serum IgG1 titers throughout the study (all p≤0.01, 2-way ANOVA; Figure 
4.4B). Furthermore, serum IgG1 titers in unprotected vaccinees and all placebo recipients 
were similar in magnitude throughout the observation period (Figure 4.4B). Identical 
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trends were observed with serum IgG1 across the per protocol shigellosis definition 
(Figure 4.2C). Serum IgG1 titers on day of challenge were also associated with vaccine 
efficacy with a titer as low as 100 providing 70% efficacy in vaccinated subjects (Figure 
4.4D and Table 4.1) which increases sharply to 85% when a titer of 200 is achieved 
(Figure 4.4D and Table 4.2).  
S. flexneri 2a LPS-specific serum IgG2 responses showed a different trend 
compared to serum IgG1 responses with all vaccinated subjects having detectable 
increases in serum IgG2 responses, regardless of shigellosis outcome (Figure 4.2D and 
4.4C). Although serum IgG2 titers were higher in protected vaccinees than in vaccinees 
with shigellosis, this difference was only significant on study day 28 (p=0.039, 2-way 
ANOVA; Figure 4.4C). Placebo recipients with shigellosis had increased LPS-specific serum 
IgG2 responses post-challenge (p=0.036, 2-way ANOVA; Figure 4.4C); however, a similar 
magnitude of response in placebo recipients without shigellosis was not observed (Figure 
4.4C). When comparing serum IgG2 responses across per protocol shigellosis, similar 
trends are observed with the exception of the difference between protected and 
unprotected vaccinees remaining significant different beyond day 28 (Figure 4.2D). 
Serum IgG2 titers at time of challenge (day 56) were associated with percent efficacy in 
vaccinated subjects however, at a higher magnitude of response as compared to serum 
IgG1. A serum IgG2 titer of 800 provided 56% efficacy (Figure 4.4D and Table 4.1) while a 




Immunization with Flexyn2a induced low but significant S. flexneri 2a LPS-specific 
serum IgM titers 28 days post-second immunization (p=0.23, 2-way ANOVA; Figure 4.3A). 
When vaccinated subjects are further grouped by shigellosis outcome, the significant 
increase in serum IgM on day 56 only remains for protected vaccinees (p=0.041, 2-way 
ANOVA; Figure 4.4A). A similar magnitude of increase was observed in the serum IgM 
responses of placebo recipients 28 days post-challenge (p=0.016, 2-way ANOVA; Figure 
4.3A). As IgM is an efficient complement activator, it is important to consider that serum 
IgM levels induced post-vaccination may play an important role in bactericidal activity 
and influence the observed responses. Minimal to undetectable increases in LPS-specific 
serum IgG3 and IgG4 responses were observed throughout the study with no significant 
differences across treatment groups at any time point (Figure 4.3D and 4.3E).  
Bactericidal Responses. Flexyn2a induced robust Shigella-specific bactericidal 
activity after one immunization, with responses in the vaccinated group remaining 
elevated over baseline through study day 84 (all p<0.0001, 2-way ANOVA; Figure 4.5A). 
While vaccinees protected from shigellosis had higher SBA titers compared to 
unprotected vaccinees, this difference was not statistically significant (Figure 4.5B). 
Across all vaccinated subjects, neither a second immunization with Flexyn2a, nor oral 
challenge with S. flexneri 2a, 2457T increased the overall magnitude of the bactericidal 
responses (Figure 4.5A and 4.5B); however, a second immunization with Flexyn2a did 
increase the frequency of responders from 70% to 83% (data not shown). Placebo 
recipients progressing to shigellosis showed a similar magnitude of increase in 
bactericidal responses by day 84 with responses in these individuals surpassing those 
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observed in unprotected vaccinees but not those observed in protected vaccinees (Figure 
4.5B). The relationship between percent efficacy and bactericidal titer increased steadily 
with an SBA titer of 3,415 providing 64% efficacy (Figure 4.5C and Table 4.1). When the 
bactericidal titer is increased to 13,933, the percent efficacy also increases 79% (Figure 
4.5C and Table 4.2).  
α4β7 ALS Responses. Flexyn2a induced significant increases in both α4β7+ and 
α4β7- ALS responses 7 days post-first immunization (all p≤0.01, 2-way ANOVA; Figure 
4.6). Protected vaccinees had higher α4β7+ ALS IgG responses on day 7 compared to 
unprotected vaccinees (p=0.0002, 2-way ANOVA; Figure 4.7A). Additionally, α4β7+ ALS 
IgG responses in protected vaccinees were higher 7 days post-first immunization 
compared to 7 days post-oral challenge with S. flexneri 2a, 2457T (p=0.004, 2-way 
ANOVA; Figure 4.7A). In unprotected vaccinees a minimal, non-significant boost in α4β7+ 
ALS IgG responses from day 7 to day 63 was observed (Figure 4.7A). Flexyn2a also 
increased the α4β7+ ALS IgA responses post-first vaccination; however, there were no 
differences between protected and unprotected vaccinated subjects (Figure 4.7B). The 
α4β7+ ALS IgA responses post-challenge showed similar trends to the α4β7+ ALS IgG 
responses, with protected vaccinees having higher α4β7+ ALS IgA responses on day 7 
compared to day 63 (p=0.044, 2-way ANOVA; Figure 4.7B) while oral challenge increased 
the α4β7+ ALS IgA responses in unprotected vaccinees (Figure 4.7B). 
Vaccinated subjects protected from shigellosis had robust α4β7- ALS IgG 
responses 7 days post-first immunization as compared to unprotected vaccinees 
(p=0.0002, 2-way ANOVA; Figure 4.8A); however, a similar magnitude of increase in 
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α4β7- ALS IgA responses was not observed (Figure 4.8B). Both α4β7+ and α4β7- antibody 
titers were associated with percent efficacy with any increase (≥2-fold rise over baseline) 
in α4β7+ or α4β7- antibody titer associated with 60-70% efficacy (Figures 4.7C and 4.8C 
and Tables 4.1 and 4.2). LPS-specific α4β7+ IgG responses quickly reached 86% efficacy at 
a low titer of 4 while the α4β7- IgG and α4β7 IgA responses did not reach this same level 
of efficacy until a titer of between 8-32 was reached (Figures 4.7C and 4.8C and Tables 
4.1 and 4.2). 
Memory B Cell Responses. Immunization with Flexyn2a induced robust S. flexneri 
2a LPS-specific memory B cell IgG responses by day 56 (p=0.02, 2-way ANOVA; Figure 
4.9A) which further increased post-challenge. Memory B cell IgG responses in vaccinated 
subjects on day of challenge (day 56) were comparable to the memory B cell IgG 
responses detected in placebo recipients post-challenge (day 84) (Figure 4.9A). Flexyn2a 
also increased the LPS-specific memory B cell IgA responses post-immunization; 
however, increases over baseline were not significant until after subjects were 
challenged with S. flexneri 2a, 2457T (p=0.004, 2-way ANOVA; Figure 4.9B).  
Correlation of Immune Parameters in Vaccinated Subjects. Not surprisingly, the 
strongest correlation in immune parameters among vaccinated subjects was between 
α4β7+ ALS IgG and IgA responses (Spearman r=0.87; Figure 4.10) while α4β7- ALS IgG 
and IgA were correlated at a lower level (Spearman r=0.51; Figure 4.10). With the 
exception of the α4β7- ALS IgG responses, which were most strongly correlated with 
serum IgG1 (Spearman r=0.61; Figure 4.10), all other α4β7+ and α4β7- ALS responses 
showed a moderate correlation with serum IgA (Spearman r=0.64-0.73; Figure 4.10). 
97 
 
Serum IgA also correlated with serum IgG1 (Spearman r=0.65; Figure 4.10) and IgG2 
(Spearman r=0.63; Figure 4.10); however, the immune parameters with the strongest 
serum IgA correlation was α4β7+ ALS IgG (Spearman r=0.73; Figure 4.10) and serum IgG 
(Spearman r=0.72; Figure 4.10).  
Of the serum IgG subclass responses, IgG2 was most strongly correlated with 
serum total IgG (Spearman r=0.82; Figure 4.10) whereas serum IgG1 was most highly 
correlated serum IgA followed by α4β7+ ALS IgG and α4β7- ALS IgG responses (both 
Spearman r=0.61; Figure 4.10). Bactericidal activity was most strongly correlated with 
α4β7+ ALS IgG responses (Spearman r=0.58; Figure 4.10) followed by serum IgG1 
responses (Spearman r=0.46; Figure 4.10). Memory B cell IgG and IgA responses 
correlated best with each other (Spearman r=0.66; Figure 4.10) however, memory B cell 
IgG also correlated with serum IgG and IgA responses (Spearman r=0.53-0.54; Figure 
4.10). Aside from the correlation with memory IgG responses, memory B cell IgA 
responses correlated best with serum IgA responses (Spearman r=0.62; Figure 4.10), as 





4.5. DISCUSSION  
Immunization with one dose of Flexyn2a elicited robust S. flexneri 2a LPS-specific 
serum IgG and IgA antibody responses, as well as functional bactericidal antibody 
responses. Interestingly, while Flexyn2a induced both LPS-specific serum IgG1 and IgG2 
responses, serum IgG1 responses were more closely correlated with protection from 
shigellosis as compared to serum IgG2, regardless of the higher magnitude of serum IgG2 
titers observed post-vaccination. There was an increase in serum IgG2 levels post-
challenge in placebo recipients but no increases in serum IgG1. When considering overall 
magnitude of the response, the IgG subclass titers observed in this study confirm 
previously documented differences across IgG1 and IgG2 responses based on Shigella 
serotype, with S. flexneri 2a and S. sonnei inducing either an IgG2 or IgG1 dominated 
response, respectively.124,189,190 However, in the current study, when the focus is placed 
on the association of each IgG subclass with protection from shigellosis rather than 
overall magnitude of response, a potentially important role for Shigella-specific serum 
IgG1 in protection from shigellosis post-parenteral immunization is suggested. As IgG1 
antibodies are highly efficient at activating complement as compared to IgG2, 191 they 
may be contributing to the killing of shigellae at a higher level compared to IgG2 while in 
the intestinal lamina propria during the process of transudation. The increased 
complement activation efficiency of IgG1 antibodies may therefore require a lower 
magnitude or threshold of response for them to be effective. Additionally, the role of 
IgG1 antibodies may be especially important in the context of the α4β7+ ALS IgG 
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responses observed in this study, which is further evidenced by the correlation between 
these two parameters.  
Indeed, another important finding in this study is the induction post-vaccination 
of Shigella LPS-specific α4β7+ ALS IgG and IgA secreting B cells which are likely homing to 
the gut. A traditionally accepted paradigm in regard to parenterally delivered vaccines in 
the context of mucosal pathogens is their inability to induce mucosal immune responses, 
making these vaccines reliant on robust systemic responses leading to transudation of 
systemic antibodies into mucosal effector sites.180,192,193 While this paradigm has been 
previously challenged in the context of other pathogen-specific parenterally delivered 
vaccines such as influenza, polio and tetanus,194-196 mucosal immune responses observed 
in these, and similar, studies may be a result of a secondary antigen exposure after an 
initial oral priming exposure.192,197 Furthermore, investigations of mucosal immune 
responses have largely focused on the importance of IgA secreting gut-homing B cells or 
secretory IgA in mucosal secretions.193,198,199 While there is no doubt that secretory IgA 
plays a vital role in protection against mucosal pathogens,200 investigations into the 
protective capacity of antigen-specific IgG secreting α4β7+ B cells against mucosal 
pathogens have been limited. 
Parenteral immunization with the Flexyn2a bioconjugate vaccine induced robust 
LPS-specific α4β7+ ALS IgG responses in vaccinated subjects protected from shigellosis. 
While lower in magnitude, vaccinees also had increased α4β7+ ALS IgA titers, 
demonstrating the ability of Flexyn2a to induce both an IgG and IgA α4β7+ immune 
response. To our knowledge, this is the first study to report antigen-specific B cells 
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positive for the gut-homing marker post-parenteral immunization with conjugate vaccine 
for an enteric pathogen. The induction of α4β7+ IgG and IgA secreting B cells post-
immunization may offer a mechanistic explanation of the protection afforded by the 
bioconjugate vaccine as LPS-specific B cells may home to the gut and produce antibodies 
at the site of infection, which can be actively secreted (IgA) or passively transudated (IgG) 
into the lumen. This finding could be especially important in the context of the α4β7+ 
LPS-specific IgG secreting B cells as these antibodies may contribute to the neutralization, 
or direct killing (either via complement activation or opsonization) of shigellae in the 
lamina propria that have transcytosed across the intestinal epithelial barrier.  
Additionally, the immune responses induced after natural infection or pre-existing 
immunity may offer different mechanisms of protection. 
Similar investigations into the LPS-specific α4β7+ IgG and IgA responses were 
conducted on samples from the Phase 1 clinical study of Flexyn2a administered with and 
without Alum.127 Results from the Phase 1 α4β7 analyses (data not reported) mirrored 
the responses achieved in the current study, further confirming the ability of Flexyn2a to 
induce an antigen-specific α4β7+ antibody response. Although the addition of Alum did 
not influence the magnitude of the LPS-specific α4β7+ ALS IgG and IgA response or the 
number of responders, it is important to consider the possibility that alternative 
adjuvants with enhanced capacity to augment mucosal immune responses or influence 
the phenotype of the immune response may provide different results, warranting further 
investigations.201 Therefore, as recently recommended,164 future studies should 
investigate the IgG subclass responses as well as the bactericidal activity in α4β7+ ALS 
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samples. Determining the dominant subclass of the α4β7+ IgG secreting B cells and the 
bactericidal ability of these antibodies could further inform mechanisms of protection 
during Shigella infection.  
A second immunization with Flexyn2a or oral challenge with S. flexneri 2a, 2457T 
did not substantially boost any of the tested immune responses in protected vaccinees. 
In contrast, challenge with S. flexneri 2a, 2457T increased multiple Shigella-specific 
immune responses in unprotected vaccinees as well as naïve subjects, specifically in 
serum IgA, serum IgG2 and α4β7+ IgA responses. The post-challenge immune response 
dampening in protected vaccinees may be due to a reduced duration of antigenic 
exposure during the challenge phase suggesting that, in some cases, Flexyn2a is capable 
of reducing the number of shigellae that are able to invade the mucosal epithelium. 
Additionally, antibodies in the lamina propria may also work to reduce the number of 
shigellae that are able to invade the basolateral surface of intestinal epithelial cells. 
Interestingly, this phenomenon of an immune response dampening has also been 
observed in other enteric human challenge studies.202,203 
As subjects were screened with multiple Shigella-specific exclusion criteria, 
including serological evidence of prior exposure to S. flexneri 2a, it was expected that the 
placebo subjects would progress to disease post-challenge. Nonetheless, only 59% and 
62% of the placebo recipients met the consensus and per protocol shigellosis endpoint, 
respectively, similar to previous reports.169,183,189 Prior S. sonnei and ETEC CHIMs have 
identified increased serum IgA titers to key antigens at baseline as predictive of post-
challenge disease risk.183,189 Similar investigations were performed in the current study 
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however no differences were observed in the pre-challenge serum IgA responses of 
placebo subjects across shigellosis outcome. Interestingly, when additional baseline 
immune parameters were investigated, naïve subjects not progressing to shigellosis were 
found to have significantly higher LPS-specific memory B cell IgA responses on the day of 
challenge as compared to placebo subjects with shigellosis (p=0.035, T-Test of log-
transformed titers; data not shown). This difference in LPS-specific memory B cell IgA 
response prior to challenge has also been recently reported in a S. sonnei CHIM.189 While 
no other differences in immune responses on day of challenge were observed, these 
data, as well as in other CHIMs, demonstrate the importance of additional investigations 
into reduced disease risk post-challenge as this may have a substantial effect in the 
assessment of vaccine efficacy. 
Consistent with results from the Phase 1 study of Flexyn2a,127 and other clinical 
assessments of Shigella conjugate vaccines,123,188 parenteral immunization with the 
bioconjugate induced robust systemic immune responses. Flexyn2a also induced 
functional antibody responses as well as LPS-specific memory and α4β7+ B cells. This 
study also confirmed the vaccine’s previously reported excellent safety profile and 
demonstrated the vaccine’s ability to induce a protective immune response in a S. 
flexneri 2a CHIM setting (Appendix B).126,127,204 The combination of a robust safety and 
immunogenicity profile, with efficacy against oral challenge and a simple, affordable and 
reproducible manufacturing process205,206 supported the cGMP production of a 
quadrivalent Shigella bioconjugate vaccine formulation. The quadrivalent formulation is 
currently undergoing safety and immunogenicity evaluations in an age-descending trial in 
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Kenya (ClinicalTrials.gov Identifier: NCT04056117). Promising results achieved in the age-




Table 4.1. Liu Analysis Cut-Points across Different LPS-Specific Immune Parameters 





Table 4.2. Cut-Points Providing ~70-80% Efficacy across Different LPS-Specific Immune 
Parameters Differentiating Vaccinated Subjects with Shigellosis from Vaccinated Subjects 









(A) S. flexneri 2a LPS-specific serum IgG responses grouped by vaccinated subjects with (N=11) or without 
(N=19) consensus shigellosis, and placebo subjects with (N=17) or without (N=12) consensus shigellosis. (B) 
S. flexneri 2a LPS-specific serum IgA responses grouped by vaccinated subjects with (N=11) or without 
(N=19) consensus shigellosis, and placebo subjects with (N=17) or without (N=12) consensus shigellosis. * = 
significant difference as compared to baseline titers within the same treatment group/shigellosis outcome. 
§ = significant difference in titers within treatment group across shigellosis outcome at the same time 
point. Significance determined by 2-way ANOVA of log-transformed titers with Bonferroni post-hoc test. 












S. flexneri 2a LPS-specific serum IgG (A), IgA (B), IgG1 (C) and IgG2 (D) geometric mean ELISA endpoint titers 
grouped by vaccinated subjects with (N=13) or without (N=17) per-protocol shigellosis, and placebo 
subjects with (N=17) or without (N=12) per-protocol shigellosis. * = significant difference as compared to 
baseline titers within the same treatment group/shigellosis outcome. § = significant difference in titers 
within treatment group across shigellosis outcome at the same time point. Significance determined by 2-





Figure 4.3. S. flexneri 2a LPS-Specific Serum IgM and IgG Subclass Responses by 






S. flexneri 2a LPS-specific serum IgM (A), IgG1 (B), IgG2 (C), IgG3 (D) and IgG4 (E) geometric mean ELISA 
endpoint titers grouped by vaccinated (N=30) or placebo (N=29) subjects. * = significant difference as 
compared to baseline titers within treatment group. § = significant difference in titers across treatment 
groups at the same time point. Significance determined by 2-way ANOVA of log-transformed titers with 
Bonferroni post-hoc test.  
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S. flexneri 2a LPS-specific serum IgM (A), IgG1 (B) and IgG2 (C) geometric mean ELISA endpoint titers 
grouped by vaccinated subjects with (N=11) or without (N=19) consensus shigellosis, and placebo subjects 
with (N=17) or without (N=12) consensus shigellosis. * = significant difference as compared to baseline 
titers within the same treatment group/shigellosis outcome. § = significant difference in titers within 
treatment group across shigellosis outcome at the same time point. Significance determined by 2-way 
ANOVA of log-transformed titers with Bonferroni post-hoc test. (D) Percent efficacy post-challenge in 










(A) S. flexneri 2a-specific geometric mean SBA endpoint titers grouped by vaccinated (N=30) or placebo 
(N=29) subjects. * = significant difference as compared to baseline titers within treatment group. § = 
significant difference in titers across treatment groups at the same time point. Significance determined by 
2-way ANOVA of log-transformed titers with Bonferroni post-hoc test. (B) S. flexneri 2a-specific geometric 
mean SBA endpoint titers grouped by vaccinated subjects with (N=11) or without (N=19) consensus 
shigellosis, and placebo subjects with (N=17) or without (N=12) consensus shigellosis. * = significant 
difference as compared to baseline titers within the same treatment group/shigellosis outcome. § = 
significant difference in titers within treatment group across shigellosis outcome at the same time point. 
Significance determined by 2-way ANOVA of log-transformed titers with Bonferroni post-hoc test. (C) 













S. flexneri 2a LPS-specific ALS IgG (A) and IgA (B) geometric mean ELISA endpoint titers for α4β7+ (solid 
lines) and α4β7- (dashed lines) populations grouped by vaccinated (N=30) or placebo (N=29) subjects at 
baseline (day 0), 7 days post-first immunization (day 7) and 7 days post-challenge (day 63). * = significant 
difference as compared to baseline titers within α4β7 +/- population and treatment group. § = significant 
difference in titers between α4β7+ and α4β7- populations within treatment groups at the same time point. 












Individual S. flexneri 2a LPS-specific α4β7+ ALS IgG (A) and IgA (B) ELISA endpoint titers with group 
geometric mean either 7 days post-first immunization (day 7) or 7 days post-challenge (day 63) grouped by 
vaccinated subjects with (N=11) or without (N=19) consensus shigellosis, and placebo subjects with (N=17) 
or without (N=12) consensus shigellosis. P-values determined by 2-way ANOVA of log-transformed ALS 
titers with Bonferroni post-hoc test. (C) Percent efficacy post-challenge in vaccinated subjects across 











Individual S. flexneri 2a LPS-specific α4β7- ALS IgG (A) and IgA (B) ELISA endpoint titers with group 
geometric mean either 7 days post-first immunization (day 7) or 7 days post-challenge (day 63) grouped by 
vaccinated subjects with (N=11) or without (N=19) consensus shigellosis, and placebo subjects with (N=17) 
or without (N=12) consensus shigellosis. P-values determined by 2-way ANOVA of log-transformed ALS 
titers with Bonferroni post-hoc test. (C) Percent efficacy post-challenge in vaccinated subjects across 











S. flexneri 2a LPS-specific memory B cell ALS IgG (A) and IgA (B) geometric mean ELISA endpoint titers at 
baseline (day 0), day of challenge (day 56) and 28 days post-challenge (day 84), grouped by vaccinated 
(N=16) or placebo (N=27) subjects. * = significant difference as compared to baseline titers within 
treatment group. Lines with p-values = significant difference in titers between groups at the same time 











Spearman correlation heat map of immune parameters in vaccinated subjects either 7 days post-first 












CHAPTER 5. SHIGELLA-SPECIFIC IMMUNE RESPONSE 









Shigella species are the second leading cause of diarrhea-associated global 
morbidity and mortality and, while Shigella infection affects all age groups, children 
under the age of 5 years old living in LMICs are an especially vulnerable population. 
Although advances in infrastructure and improved access to clean water sources have 
reduced the Shigella-specific disease burden, development and widespread 
implementation of an efficacious vaccine remains the best option to further reduce this 
burden. Unfortunately, the lack of a well-defined correlate(s) of protection for shigellosis 
has hindered vaccine efforts thus far.  
Prior Shigella challenge/re-challenge studies have demonstrated that infection 
provides protection against subsequent infection in a serotype-specific manner. These 
findings suggest that investigating immune responses associated with disease after 
Shigella infection may help to elucidate important mechanisms associated with 
protection from shigellosis. In the current analysis, two Shigella controlled human 
infection models were used investigate protective immune mechanisms and profiles 
associated with disease after challenge with two different Shigella serotypes.  
Shigella-specific immune profile investigations revealed the important finding 
that different protective profiles were induced post-infection with S. sonnei as compared 
to S. flexneri 2a. This is the first report of different protective immune profiles associated 
with different Shigella serotypes, a finding which should be further investigated as it 





Shigella species are a major cause of diarrheal disease associated morbidity and 
mortality with approximately 75 million annual episodes of shigellosis.1,23,27,159 Disease 
burden is further increased in vulnerable populations such as children less than 5 years of 
age living in under-developed nations.1,23,27,159 Shigella infection is also associated with 
multiple post-infectious sequalae including reactive arthritis and irritable bowel 
syndrome,20,40 as well as physical and cognitive stunting in children.8,15 Furthermore, 
children with repeated enteric infections are also at a higher risk of mortality due to 
other infectious diseases.17 Although antibiotics are generally effective in the treatment 
of shigellosis, increased rates of antibiotic-resistance require the development of 
alternate primary prevention methods, such as an efficacious vaccine.55,57 While several 
vaccine candidates are currently under clinical investigation,157,158 there is currently no 
widely available licensed vaccine to prevent shigellosis. A potential hindrance to the 
development of an efficacious vaccine is the lack of a defined immune correlate of 
protection (CoP) for Shigella infection.  
CoPs serve as immunological parameters that are predictive of vaccine efficacy, 
making them vital to understanding pathogen-specific protective immunity.78 CoPs can 
be mechanistic (mCoP) or non-mechanistic (nCoP), with mCoPs causally associated with 
protection often functioning at the site of infection. While nCoPs are not the causal 
means of protective immunity, they can predict protection and serve as surrogate 
measures for mCoPs.78 A defined CoP can not only guide the rational design and efficacy 
assessments of candidate vaccines but can also be used to accelerate vaccine licensure, 
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especially in the case of multivalent vaccines where alterations or additions to pathogen 
serotypes are required.79  
In order to investigate a CoP, the primary endpoint/outcome targeted for 
prevention should also be defined as it can affect the CoP.80 The primary outcome may 
vary depending on the pathogen and can be as stringently defined as sterilizing immunity 
(i.e. preventing infection), or more loosely defined, such as preventing clinical signs and 
symptoms (i.e. preventing disease). Two different polio vaccines for example have 
different targeted levels of protection and therefore different CoPs: the live-attenuated 
oral polio vaccine induces strong secretory IgA responses as well as CD8+ T cell 
responses, working to provide protection against infection. This is in contrast to the 
intramuscularly delivered inactivated polio vaccine which induces robust serum antibody 
responses and CD4+ T cell responses and works to prevent clinical disease through the 
generation of high levels of serum antibodies.84,85  
Shigella challenge/re-challenge studies have shown that prior infection protects 
from subsequent infection in a serotype-specific manner98,99 demonstrating the 
importance of O-polysaccharide (OPS) (or O antigen, a component of the bacteria’s 
lipopolysaccharide (LPS) molecule) as a key protective antigen. While there has yet to be 
a defined CoP for Shigella infection, LPS-specific serum IgG has been identified as a 
potential contender; however, discussions remain if serum IgG is acting as a mCoP via IgG 
transudate into the intestinal lumen or, as a nCoP or surrogate measure for a yet to be 
defined immunological protective mechanism.122,123 Additional CoPs have been 
suggested for Shigella infection including LPS-specific IgA secreting B cells (ASCs),106 
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memory B cells,129 and even a combination of a LPS-specific serum IgG and IgA 
ASCs.114,128 
Investigating CoPs and developing efficacious vaccines is complicated by multiple 
host and environmental factors, such as population genetics or epigenetics, the target 
population versus the investigational population, host nutritional or immune status as 
well as infection history, pre-existing immunity and/or concurrent infections.78,130-135 
Each of these confounding factors is further complicated in the case of enteric pathogens 
due to variances in the intestinal microbiome or integrity of the gastrointestinal 
barrier.133,134,136-138 Several enteric vaccines, including a rotavirus vaccine and a cholera 
vaccine, have demonstrated excellent success in one population followed by dramatically 
reduced efficacy in another population.139-141 Furthermore, pathogen strain or serotype, 
route of infection and dose can not only influence pathogen virulence but also host 
immune response.137,142-145 The combination of population level variances, 
environmental influences and differences in pathogen virulence gives rise to a dynamic 
interplay, not only between host and pathogen, but also within the host themselves and 
the immune response they mount. 
Defining a CoP is often the goal in the field of vaccine development and, while 
there is no question regarding the value and importance of a CoP, searching for a single 
immune correlate may not take into consideration the complexities of the host immune 
response or of host-pathogen interactions. Over the past decade, advancements in the 
areas of systems biology and omics research have provided essential insights into host 
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responses to vaccination or pathogenic challenge,130,146-150 demonstrating that protective 
immunity often requires an integrated and networked immune response profile.151  
Immune response profiles post-vaccination or post-challenge have been 
described or proposed for several pathogens including human immunodeficiency virus, 
Plasmodium falciparum and yellow fever virus.150,152-155 Salmonella Typhi-specific 
immune response profiles were recently investigated after parenteral immunization with 
two different vaccine constructs (capsular polysaccharide alone or conjugated to tetanus 
toxoid) followed by oral challenge with live S. Typhi.156 Interestingly, while both vaccine 
constructs provided similar levels of efficacy post-challenge, the polysaccharide alone 
protected from challenge through a serum IgA dominated response while the tetanus 
toxoid conjugate protected subjects through increased serum IgA responses in 
conjunction with an increased avidity of serum IgG1 antibodies.156  
As Shigella species are enteric pathogens with over 50 different serotypes (Table 
2.1) and have a complex lifecycle, thorough characterization of Shigella-specific immunity 
is essential. Additionally, multiple Shigella vaccine constructs using different routes of 
mucosal or parenteral delivery are currently in development157,158 and may provide 
protection from shigellosis in different ways. With no defined CoP for shigellosis and 
multiple host immune mechanisms that could work to reduce the severity or duration of 
disease, protection from shigellosis may be better described as an immune profile rather 
than a single immune correlate.  
The analysis presented in this Chapter uses two Shigella controlled human 
infection models (CHIMs) (Appendices A and B) in order to investigate immune profiles 
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associated with protection from the development of shigellosis in three different sub-
populations: 1) subjects parenterally immunized with a S. flexneri 2a bioconjugate 
vaccine followed by oral challenge with S. flexneri 2a 2457T, 2) subjects orally challenged 
with S. flexneri 2a 2457T with no prior intervention, and 3) subjects orally challenged 
with S. sonnei 53G with no prior intervention. The comparative analysis of immune 
profiles in these three populations holds the potential to elucidate the protective 
immune mechanisms associated with parenteral immunization with a Shigella conjugate 
vaccine. Additionally, this analysis could reveal immune mechanisms associated with 
protection after infection with two different Shigella serotypes, leading to discovery of 
similarities that could inform the prospect of heterologous protection, or differences that 





5.3. MATERIALS AND METHODS 
Source of Study Populations Used in Analyses. This analysis used immune 
response data from two Shigella CHIMs which are outlined in Appendices A and B. The 
first study is a S. flexneri 2a CHIM designed to assess the efficacy of a candidate 
bioconjugate vaccine (S. flexneri 2a O-polysaccharide conjugated to EPA). The study 
contained a vaccinated and orally challenged cohort (Figure 5.1 and Appendix B), as well 
as a cohort that underwent oral challenge with S. flexneri 2a 2457T without prior 
intervention (Figure 5.2 and Appendix B). Study population demographics, inclusion and 
exclusion criteria and disease outcomes are described in detail in Appendix B. Immune 
response characterization and immunoassay methodologies are described in detail in 
Chapter 4.  
The second study was a CHIM aimed at identifying the dose of a newly 
manufactured lot of S. sonnei 53G that would induce shigellosis in ≥60% of challenged 
subjects (Figure 5.3 and Appendix A). Subjects in this study underwent oral challenge 
with increasing doses of S. sonnei 53G without any prior interventions. Study 
populations, inclusions and exclusion criteria and disease outcomes are described in 
detail in Appendix A. Immune response characterization and immunoassay 
methodologies are described in detail in Chapter 3. 
Sub-Populations Used in Analyses. Three separate sample populations from the 
two studies outlined above were used to evaluate and compare immune response 
profiles after the following interventions: 1) parenteral immunization with a bioconjugate 
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followed by oral challenge with S. flexneri 2a 2457T, 2) oral challenge with S. flexneri 2a 
2457T and 3) oral challenge with S. sonnei 53G. 
The first sub-population (n=30) (Appendix B) was used to analyze a protective 
immune profile after parenteral immunization with a S. flexneri 2a bioconjugate vaccine 
(Figure 5.1).127,204 Subjects in this sample were immunized intramuscularly twice, 28 days 
apart, and orally challenged 28 days after their second immunization with either 1510cfu 
or 1707cfu of virulent S. flexneri 2a 2457T. After challenge, subjects not developing 
shigellosis (n=19) were used to characterize protective immune profiles after parenteral 
immunization by investigating pre-challenge immune responses induced after 
vaccination. 
Sample populations 2 and 3 investigate presumptively protective immune profiles 
post-challenge with S. flexneri 2a or S. sonnei, respectively. As prior Shigella infection 
protects from subsequent illness with the same serotype, the presumption was made 
that subjects progressing to shigellosis post-oral challenge would be protected from 
subsequent challenge with the same serotype.98,99,177  
Sample population 2 (n=29) investigates the immune profile after oral challenge 
with S. flexneri 2a 2457T (Figure 5.2). Subjects in this sample population were orally 
challenged with either 1510cfu or 1707cfu of virulent S. flexneri 2a 2457T and post-
challenge immune responses in subjects progressing to shigellosis (n=17) were used to 
characterize protective immune profiles associated with S. flexneri 2a infection.  
The S. sonnei CHIM (Appendix A and Chapter 3) used for sample population 3 had 
a total of 5 cohorts (n=56) (Figure 5.3) challenged with increasing doses of virulent S. 
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sonnei 53G. Cohort 1 (n=10) was excluded from the current analyses due to the low 
inoculum dose (567cfu) and absence of shigellosis cases, leaving a sample population of 
46 subjects used in subsequent immune profile investigations (Figure 5.3). Post-challenge 
immune responses in subjects progressing to shigellosis (n=22) were used to characterize 
presumptively protective immune profiles associated after S. sonnei infection. 
Principal Component Analysis (PCA). PCA were used to reduce immune response 
data dimensionality and redundancy in order to develop new uncorrelated variables 
(principal components) describing the greatest amount of variability in immune response 
data. Principal components were used to evaluate immune response profiles across the 
three sample populations outlined above. All immune response data were log-
transformed prior to analyses. Variable linearity and subsequent inclusion into PCA 
analyses was determined using a Pearson correlation matrix. Any immune response 
variable that did not have a Pearson r ≥0.3 with any other variable was excluded from 
PCA analyses. PCA sampling adequacy was assessed using Kaiser-Meyer-Olkin (KMO) 
measure (KMO value of ≥0.6 was required) as well as Bartlett’s test of sphericity (p-value 
of ≤0.5 was required). After PCAs were conducted, principle component scores were 
assigned to all subjects for any component with an eigen value ≥1. PCA score distribution 
was assessed for normality by looking at distribution plots and via Shapiro-Wilk normality 
test with any p-value ≤0.05 indicating component scores within a population did not 
follow a Gaussian distribution. PCA component scores were compared using a Welch’s T-
Test. Non-normally distributed data were compared using appropriate non-parametric 
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tests. All statistical tests were interpreted in a two-tailed fashion (α=0.05) with p-values 
≤0.05 considered statistically significant in Stata (Version 14 for MAC). 
Immune Response Heat Maps. The highest (peak) fold-rise over baseline (day 0) 
(Figures 5.1-5.3) across each immune response variable was represented using heat 
maps in order to investigate the magnitude of immune responses across each sample 
population. Peak fold-rise was calculated by dividing the max titer either post-vaccination 
(sample 1) or post-oral challenge (samples 2 and 3) by the day 0 titer. Fold-rise in 
memory B cell IgG and IgA responses could not be calculated for 10 vaccinees in sample 
population 1 (missing value represented by grey boxes) as baseline memory B cell 
responses were not determined in these subjects (Chapter 4). Heat maps were generated 
using log-transformed peak fold-rise responses with green representing the lower end of 
immune response values and red representing the high end. All heat maps were 






5.4.1. Immune Profiles after Parenteral Immunization or Oral Challenge 
Description of PCA and Statistical Results. Although Shigella is an 
enteric/mucosal pathogen, many Shigella vaccines currently in clinical development 
utilize the parenteral route of immunization with the goal of inducing potent systemic 
immune responses. Sample populations 1 (Figure 5.1) and 2 (Figure 5.2) were used to 
investigate immune profiles after parenteral immunization which were compared to the 
profiles induced after oral challenge with S. flexneri 2a 2457T. The following immune 
response variables had a Pearson r ≥0.3 with at least one other immune response 
variable and were therefore included in the PCA (data not shown): S. flexneri 2a LPS-
specific serum IgG, IgA, IgG1, IgG2, IgG3, IgG4, memory B cell derived IgG and IgA 
responses, IgG and IgA secreted from B cell populations that were α4β7+ or α4β7-, and 
serum bactericidal activity (SBA) directed to S. flexneri 2a 2457T.  
The peak titer post-exposure (post-vaccination or post-challenge in sample 
populations 1 and 2, respectively) was used for all immune response variables, with the 
exception of α4β7+ and α4β7- ALS responses, which were 7 days post-exposure. Immune 
response data from sample populations 1 and 2 were considered to have an adequate 
sample size for use in PCA with a KMO value of 0.761 and a significant result in the 
Bartlett test for sphericity (p<0.0001) (data not shown). Principal components 1-4 had 
eigen values ≥1 and explained 75.7% of the variability in immune response data across 
both populations. The first two components were used for comparisons across sample 
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populations with components (C1) and 2 (C2) accounting for 45.5% and 12.2% of the 
total variability, respectively (Figure 5.4A). 
PCA Loading Plot. All immune response variables were positively correlated with 
C1, with serum IgG and IgA having the strongest correlation with C1. As all immune 
response variables demonstrated a positive correlation with C1, the component appears 
to represent the presence, or magnitude, of an immune response. On the other hand, C2 
appears to differentiate the dominant phenotype of the observed immune response. 
Mucosal responses (as represented by α4β7+ ALS responses) are positively correlated 
with C2 and have the strongest correlation with this component. On the other hand, 
memory B cell responses, serum IgG, IgG2 and IgM are negatively correlated with C2 
(Figure 5.4A), while serum IgG1 and SBA responses show minimal associations with C2. 
When examining the variables that have the strongest positive and negative correlations 
with C2, the component can be generally divided into immune response variables that 
define a mucosal or systemic/memory B cell immune response phenotype.  
Principal Component Scores. When subject’s C1 and C2 scores are plotted by 
exposure route (Figure 5.4B), there is an apparent differentiation in the profiles. 
Parenterally immunized subjects are largely divided across C1 with 62% of subjects 
showing a positive correlation with C1 (Table 5.1). In contrast, orally challenged subjects 
are divided across C2 with 67% of subjects’ scores showing a positive correlation with C2 
(Table 5.1). The C1 scores in parenterally immunized subjects are higher (p=0.007, Figure 
5.4C) and show a strong positive correlation as compared to orally challenged subjects, 
demonstrating the robust immune response induced by parenteral immunization with 
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the bioconjugate vaccine as compared to the response induced after oral challenge with 
S. flexneri 2a. When examining C2 scores however, orally challenged subject scores show 
a stronger positive correlation with C2 as compared to parenterally immunized subjects 
(p=0.003, Figure 5.4C), indicating that oral challenge with S. flexneri 2a correlates with 
mucosal antibodies while responses in parenterally immunized subjects correlate better 
with serum antibodies and memory B cell responses (Figure 5.4). 
Principal Component Scores Grouped by Shigellosis Outcome. The majority of 
orally challenged subjects without shigellosis demonstrate a negative correlation with 
both C1 and C2 (Figure 5.5A). In contrast, immune response profiles in subjects 
developing shigellosis are mostly positively correlated with both components (Figure 
5.5A). Subjects with shigellosis show a higher magnitude of response compared to 
subjects without shigellosis, as represented by higher C1 scores (p=0.029, Figure 5.5B). 
Although not significant (p=0.071, Figure 5.5B), a similar trend is observed across C2 
values with subjects progressing to shigellosis having higher mucosal responses as 
compared to subjects without shigellosis (Figures 5.5A and 5.5B). 
Parenterally immunized subjects not protected from shigellosis demonstrate a 
similar profile as orally challenged subjects not progressing shigellosis, with negative C1 
and C2 values (Figures 5.5C and 5.5D). In contrast, parenterally immunized subjects 
protected from shigellosis had robust systemic immune responses (Figure 5.6) with 77% 
of protected vaccinees having positive C1 values (p=0.015, Figure 5.5D). As expected, 
there is a high degree of protected vaccinees clustering in the lower right quadrant of the 
score plot with a strong positive correlation with C1 and negative correlation with C2.  
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The clustering of protected vaccinees observed in the lower right quadrant 
demonstrates the robust systemic response associated with protection from shigellosis 
after parenterally immunization. Interestingly, there were some protected vaccinees 
(35%) with positive C2 values (Table 5.2), indicating that parenteral immunization with 
the bioconjugate vaccine is capable of inducing a protective immune response driven by 
mucosal antibodies (Figures 5.5C and 5.6 and Table 5.2). Overall, the trend in immune 
profiles comparing parenteral and oral exposure demonstrate strong correlations 
(p=0.015, Figures 5.5E and 5.5F) with C1 (systemic/memory responses) in protected 
vaccinees while orally challenged subjects progressing to shigellosis show a stronger 
correlation with C2 (mucosal immune responses) (p=0.008, Figures 5.5E and 5.5F). 
 
5.4.2. Immune Profiles after Oral Challenge with S. flexneri 2a or S. sonnei 
Description of PCA and Statistical Results. As previously described, subjects 
progressing to shigellosis post-oral challenge were used to characterize protective 
immune profiles associated with S. flexneri 2a 2457T (sample population 2, Figure 5.2) or 
S. sonnei 53G (sample population 3, Figure 5.3) infection. The following immune 
response variables had a Pearson r ≥0.3 with at least one other immune response 
variable (data not shown) and were therefore included in the PCA: S. flexneri 2a LPS-
specific serum IgG, IgA, IgG1, IgG2, IgG3, memory B cell IgG and IgA responses, IgG and 
IgA secreted from B cell populations that were α4β7+ or α4β7-, and serum bactericidal 
activity (SBA) directed to either S. flexneri 2a 2457T or S. sonnei Moseley. With the 
exception α4β7+ or α4β7- ALS, which use responses on day 7, all immune response data 
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is from 28 days post-challenge with either serotype. Immune response data from sample 
populations 2 and 3 were considered adequately sampled for use in PCA with a KMO 
value of 0.742 and a significant result in the Bartlett test for sphericity (p<0.0001) (data 
not shown). Principal components 1-3 had eigen values ≥1 and explained 68.3% of the 
variability in immune response data across both populations. The first two components 
were used for comparisons across sample populations 2 and 3 with C1 and C2 (C2) 
accounting for 43.1% and 15.9% of the total variability, respectively (Figure 5.7A). 
PCA Loading Plot. Similar to the loading plot comparing parenteral versus oral 
exposure, all immune response variables were positively correlated with C1, indicating 
this component describes the immune response magnitude, with serum IgG and IgA, as 
well as memory B cell IgG, having the strongest positive correlations with C1. There is a 
high degree of clustering across C2 which also appears to describe a mucosal versus 
memory/systemic immune response (Figure 5.7A). Serum IgG3 as well as α4β7+ ALS IgG 
and IgA responses have the strongest positive correlation with C2 while serum IgG2, SBA 
and memory B cell IgA responses, are negatively correlated with C2 (Figure 5.7A). Serum 
IgG1 is the only immune response variable which is minimally associated with C2. 
Principal Component Scores. Comparing subject’s C1 values across challenge 
strain shows a wide range of values (Figure 5.7B and Table 5.3) with no differences across 
strain (p=0.505, Figure 5.7C), indicating a large amount of variability in the magnitude of 
the individual immune responses induced by both Shigella serotypes. Interestingly, 
component scores appear to be divided across C2 with S. sonnei challenged subjects 
having more (59%) positively correlated C2 scores (p<0.0001, Figure 5.7C, Table 5.3) as 
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compared to S. flexneri 2a challenged subjects. The majority (78%) of C2 values after oral 
challenge with S. flexneri 2a demonstrate negative correlations (Figures 5.7B and 5.7C 
and Table 5.3), indicating that S. flexneri 2a infection may induce a predominantly 
memory/systemic immune response profile as compared to a mucosal response profile. 
Principal Component Scores by Shigellosis Outcome. Comparing S. sonnei 
challenged subject scores across shigellosis outcome shows no differences in C1 scores 
across subjects that did or did not progress to shigellosis (p=0.260, Figures 5.8A and 5.8B 
and Table 5.4). In contrast, subjects developing shigellosis following S. sonnei challenge 
had significantly higher C2 values (p<0.0001, Figures 5.8A and 5.8B) with the majority of 
subjects (77%) having positively correlated C2 values. The robust mucosal immune 
response profile is further evidenced when comparing the magnitude of α4β7+ ALS IgG 
and IgA responses in S. sonnei challenged subjects with and without shigellosis (Figure 
5.9). Furthermore, as previously reported (Appendix A and Chapter 3), there were no 
differences in serum antibody responses or SBA across subjects with and without 
shigellosis after challenge with S. sonnei. 
Interestingly, an opposite trend is observed in the correlation of subject scores 
with C1 and C2 after challenge with S. flexneri 2a (Figures 5.8C and 5.8D). Specifically, 
80% (Table 5.4) of subjects progressing to shigellosis after challenge with S. flexneri 2a 
have higher, positively correlated C1 values as compared to subjects without shigellosis 
(p=0.043, Figures 5.8C and 5.8D and Table 5.4). Furthermore, S. flexneri 2a challenged 
subject scores were negatively correlated with C2, regardless of shigellosis outcome, with 
no differences in C2 scores across shigellosis outcome (p=0.102, Figures 5.8C and 5.8D 
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and Table 5.4). This observation is further evidenced by the minimal to undetectable 
immune responses in S. flexneri 2a challenged subjects not progressing to shigellosis 
while, in contrast, subjects progressing to shigellosis have a range of immune response 






 An important finding in the current study is the difference in immune profiles 
post-infection with either S. sonnei or S. flexneri 2a. While infection with both serotypes 
induced a range of immune response magnitudes (Tables 5.3 and 5.4), there is a distinct 
difference across the serotypes with respect to the mucosal versus systemic profile of the 
immune response (Figures 5.8 and 5.9). Infection with S. sonnei induced similar systemic 
and functional immune responses, irrespective of shigellosis outcome (Chapter 3); 
however, the difference in the mucosal responses are substantial (Figures 5.8 and 5.9) 
(Chapter 3). While many S. sonnei-challenged subjects without shigellosis also develop a 
mucosal response, the magnitude of response post-challenge is significantly increased 
(p=0.0001, Mann-Whitney U, Figure 5.9 and Table 5.5) in subjects progressing to 
shigellosis. In contrast, subjects receiving S. flexneri 2a who do not develop shigellosis 
have minimal to undetectable immune responses across the majority of parameters 
while subjects developing shigellosis demonstrate increases across a range of immune 
parameters, with the most notable differences in serum IgG, IgA, SBA and α4β7+ ALS 
responses (Figure 5.9 and Table 5.5). This finding suggests that subjects with moderate to 
severe disease after oral challenge with S. sonnei present with a predominantly mucosal 
immune response whereas oral challenge with S. flexneri 2a may induce a more balanced 
systemic and mucosal response.  
 Another example of the difference in the immune response profile across Shigella 
strains is in the IgG subclass responses. While LPS-specific serum IgG3 responses are 
observed in subjects with shigellosis post-challenge, regardless of serotype, there is a 
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higher proportion of serum IgG3 responders post-challenge with S. sonnei (15%) as 
compared to S. flexneri 2a (3.7%). Additionally, S. flexneri 2a LPS-specific serum IgG3 
responses correlate with different immune parameters after infection across the two 
serotypes. Comparison of immune responses in subjects progressing to shigellosis after S. 
sonnei infection demonstrates that serum IgG3 correlates with few other parameters 
aside from α4β7+ ALS IgG responses (Spearman r=0.5, Figure 5.10). In contrast, serum 
IgG3 responses in subjects progressing to shigellosis after infection with S. flexneri 2a 
positively correlates with serotype-specific serum IgG, serum IgG1 and α4β7+ ALS IgG, 
(all Spearman r=0.5) (Figure 5.10). Serum IgG1 also shows a different pattern across 
serotypes with moderate correlations observed post-S. flexneri 2a infection with α4β7+ 
and α4β7- ALS IgG responses, serum IgG and memory B cell IgA responses (all Spearman 
r=0.4-0.5). On the other hand, serum IgG1 responses post-infection with S. sonnei show 
the strongest correlations with α4β7- ALS responses (Spearman r=0.5-0.6) and serum 
IgG2 (Spearman r=0.7) (Figure 5.10). Interestingly, while serum IgG1 is negatively 
correlated with serum IgG3 (Spearman r=-0.1) post-infection with S. sonnei, these two 
parameters are positively correlated post-infection with S. flexneri 2a (Spearman r=0.5) 
(Figure 5.10). 
S. sonnei is a unique serotype among Shigella species for many reasons, with one 
of the more recent discoveries revealing S. sonnei to harbor a type 6 secretion system 
(T6SS).75 T6SSs not only serve to directly kill other bacterial species, therefore playing a 
role in microbial competition, but T6SSs have also been associated with increased 
severity of host disease and prolonged survival during infection with other enteric 
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pathogens, including E. coli, Vibrio cholerae, and Salmonella.207-211 S. sonnei uses its T6SS 
during infection to kill nearby microbial host commensals, potentially having substantial 
effects on the immune response induced by S. sonnei. Intestinal microbiota play an 
integral role in host immune induction and regulation with especially important roles in 
the large intestine. Not only can commensals in this region contribute to fitness and 
tolerance of regulatory T cells,212 but they can also control the production of pro-IL-1β in 
order to condition resident macrophages to quickly respond to the mature active form of 
IL-1β.212 Furthermore, some resident bacteria have the ability to themselves induce 
inflammasome-mediated secretion of IL-1β and IL-18 during an active enteric 
infection.212 While the release of pro-inflammatory cytokines does increase intestinal 
inflammation, it also aids in recruitment of additional innate cells, such as neutrophils, to 
the site of infection to help clear the infection.213,214 Killing of commensal microbiota via 
the T6SS of S. sonnei may reduce the recruitment of innate cells as well as in the 
inflammatory environment within the intestine. 
Another unique feature of Shigella sonnei is the presence of an O-antigen group 4 
capsule (G4C)214,215 which, in other enteric pathogens, has been associated with 
increased virulence and environmental persistence.216,217 S. sonnei expresses O-antigen 
on both core-linked LPS as well as the G4C, creating a thick layer of O-polysaccharide 
(OPS) on its surface.213-215 This thick layer of OPS on the surface of S. sonnei reduces T3SS 
accessibility, thereby reducing the T3SS-dependent uptake into macrophages and 
subsequent vacuole escape of Shigella sonnei.213,214 While the T3SS and associated 
virulence proteins are essential during macrophage invasion and vacuole escape for S. 
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flexneri species, S. sonnei has recently shown T3SS-independent uptake into 
macrophages.213 The reduced T3SS-mediated cellular uptake ultimately works to further 
reduce the inflammatory response during S. sonnei infection as less cytosolic bacteria are 
present within host cells to contribute to the activation of caspase-1 inflammasome 
induced pyroptosis. Lowered caspase-1 activation would lead to reduced macrophage 
cell death, resulting in less release of pro-inflammatory cytokines and subsequent 
neutrophil recruitment.213,214 
Although neutrophils do work to eventually control Shigella infection, they 
unfortunately contribute to damaging the epithelial cell layer during the early stages of 
infection. Shigella species make use of this damaged epithelium and inflammatory 
environment by manipulating the epithelial cell layer and passing through without the 
use of M cells.67 Therefore, it would seem unusual for S. sonnei to use its unique 
virulence factors to reduce inflammation during infection; however, considering recent 
evidence suggesting that S. sonnei has adapted to an extracellular lifestyle,213 a reduction 
in the inflammatory environment and subsequent neutrophil recruitment would 
contribute to prolonged survival of extracellular S. sonnei. In an effort to investigate the 
differences in inflammatory responses induced across each serotype in the current study, 
calprotectin and myeloperoxidase concentrations in stool samples were compared post-
infection with S. flexneri 2a or S. sonnei. Both myeloperoxidase (p<0.0001, T-Test) and 
calprotectin (p=0.0001, T-Test) levels were significantly increased after infection with S. 
flexneri 2a as compared to S. sonnei (Figure 5.11) indicating that in a CHIM setting, at the 
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bacterial doses tested, S. flexneri 2a induces a higher degree of inflammation during 
infection. 
The thick OPS layer created by the G4C and LPS of S. sonnei has also been shown 
to increase resistance to killing by serum-mediated complement activity,214 thereby 
reducing the ability of the host immune system to directly kill S. sonnei. A reduction in 
complement-mediated killing would not only contribute to a further reduction in 
intestinal inflammation but may also contribute to an increased ability of S. sonnei to 
induce systemic shigellosis.214,218,219 Using the rabbit ileal loop model, encapsulated S. 
sonnei have been recovered in blood and distal organs at significantly higher levels as 
compared to unencapsulated S. sonnei.214 Furthermore, as intestinal commensal 
microbiota can also influence systemic immune responses,212 a reduction in commensal 
bacteria through T6SS-mediated killing could further enhance the ability of S. sonnei to 
cause systemic disease.  
 Non-pathogen specific factors, including study design and conduct, may also 
explain some of the observed differences in immune profiles across serotypes as the 
current analysis uses populations from two separate studies conducted at different times 
and geographical locations. Nonetheless, both studies used similar inclusion and 
exclusion criteria and, while the studies do not control for genetics, epigenetics or 
microbiome differences, all subjects were screened for both pre-existing health 
conditions as well as Shigella-specific pre-existing immunity, resulting in a similar 
baseline immune status observed across the two study populations. Antigenic dose can 
also impact immune responses post-challenge220,221 and it is important to consider that 
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subjects challenged with S. flexneri 2a were challenged with an approximate dose of 
1600cfu while subjects challenged with S. sonnei were challenged with a range of doses, 
averaging 1147cfu across cohorts. Although the broad range of doses used for S. sonnei 
challenge should be considered, no differences in immune responses across dose groups 
were identified (Chapter 3 and Appendix A). 
Antigenic content and route of delivery also impact the immune response post-
exposure156,220-222 as evidenced by comparisons of immune response profiles after 
parenteral immunization or after oral challenge with S. flexneri 2a. Parenteral 
immunization with the bioconjugate vaccine induced immune responses correlating with 
serum IgG, IgG2 and IgA, as well as memory B cell and functional antibody responses, 
while oral challenge induced a predominantly mucosal immune response. The 
comparison of parenteral versus oral exposure also confirmed previous findings that the 
bioconjugate is capable of inducing B cells secreting LPS-specific IgG and IgA which home 
to the intestine and are associated with protection from shigellosis (Chapter 4). While 
serum IgG1 responses had little correlation with the phenotype of the protective 
immune profile, it is interesting to note that the majority of subjects with strong serum 
IgG1 responses also typically had robust α4β7+ ALS IgG responses (Figure 5.6) and the 
two variables showed a moderate correlation with one another (Spearman r=0.5, Figure 
5.10). As a PCA generates principal components which are linear combinations of 
correlated data sets and variables load based off how they influence or correlate with 
each component, the robustness of the α4β7+ ALS IgG responses may have contributed 
to masking the influence serum IgG1 may have on defining a protective immune profile. 
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 Although both studies have characterized immune responses after parenteral 
immunization with a Shigella conjugate or post-oral challenge with Shigella species to a 
level not previously described, the number of immune parameters reported are relatively 
limited. The reporting of a limited selection of immune responses primarily focused on 
humoral immune responses, could have influenced or biased the conclusions drawn from 
current analyses. The addition of other immune parameters such a T cell responses or 
cytokine profiles may provide a more complete understanding of Shigella-specific 
protective immune profiles. Alternatively, a systems biology approach of investigating 
immune response profiles would likely provide a more refined picture of potential 
differences in Shigella-specific protective immune profiles. 
 Nonetheless, the evidence presented in the current study could have implications 
for vaccine development as the immune response required to protect from S. flexneri 2a 
infection may be different from than that required to protect from S. sonnei infection. 
While oral challenge with S. flexneri 2a induced a relatively balanced immune response 
with both systemic and mucosal antibodies associated with progression to shigellosis, 
this was not the case with S. sonnei, with the difference across shigellosis outcome being 
the induction and/or magnitude of the mucosal response. However, it is important to 
consider that post-infection protective immune profiles in the current analysis are 
presumptive as the subjects did not undergo a homologous re-challenge. It is also 
possible that the robust inflammatory responses post-infection with S. flexneri 2a 
impacted the kinetics of the immune response with the peak mucosal responses post-S. 
flexneri 2a infection missed due to the study sample collection schedule. However, while 
141 
 
the α4β7+ ALS responses 7 days post-infection were used in analyses, samples were also 
collected and analyzed 3 days post-infection with S. flexneri 2a with no significant 
increases in α4β7+ ALS IgG or IgA at the earlier timepoint. 
Many vaccines currently in clinical development are Shigella LPS-conjugate 
vaccines delivered parenterally125,127,223-225 and while the S. flexneri 2a bioconjugate 
vaccine provides an excellent example of a parenterally delivered Shigella vaccine being 
capable of inducing mucosal immune responses associated with protection, the response 
may not be at the magnitude required to protect from infection with S. sonnei. Reports 
of efficacy achieved after parenteral immunization with a S. sonnei conjugate vaccine are 
available,125,223 however efficacy in these studies was age related with only adults and 
children ≥3 years old protected from S. sonnei infection. It is also important to consider 
that the aforementioned S. sonnei conjugate vaccine efficacy studies were conducted in 
Shigella endemic populations and, as the majority of Shigella infections occur prior to the 
age of 4 in such settings,27,54 pre-existing immunity from prior infection may have 
contributed to the observed efficacy. While the trials did include cohorts immunized with 
a S. flexneri 2a conjugate vaccine, the S. flexneri 2a attack rate was too low to assess 
vaccine efficacy making it impossible to investigate potential differences in protective 
efficacy across Shigella serotypes using a similar vaccine construct, especially in the 
population of children ≤3 years old.125,223 
The current study provides important insights into potential immunological 
response differences associated with infection across different Shigella serotypes. The 
differences in immune responses post-infection may be understandable when 
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considering the number of molecular and pathogenic differences across the two 
investigated serotypes reported in recent years. Nonetheless, additional investigations 
should be conducted, not only from other studies of parenterally administered S. sonnei 
vaccines that have undergone efficacy testing, but also from studies of live-attenuated 
Shigella vaccines. Additionally, immune responses induced post-infection in subjects 
living in endemic settings may provide a different immune profile altogether and should 
be investigated as thoroughly as possible. Thorough characterization of immune 
responses and immune profiles may lead to discovery of Shigella serotype-specific 





Table 5.1. PCA Scores: Descriptive Statistics in Subjects Parenterally Immunized or Orally 
Challenged with S. flexneri 2a 
 
Exposure:   Oral (S. flexneri 2a) Parenteral 
Number of Subjects   27 26 
Component 1 
N with Positive C1 
Correlation (%)   8 (29.6%) 16 (61.5%) 
Mean ± Stdeva 
(Range)   
-0.9 ± 2.0 
(-4.1 – 3.8) 
0.9 ± 2.7 
(-4.2 – 7.7) 
95% CIb   -0.7 – -0.1 -0.2 – 2.0 
Median (IQRc)   -0.6 (-2.1 – 0.3) 
0.2 
(-0.6 – 2.9) 
Component 2 
N with Positive C2 
Correlation (%)   18 (66.7%) 9 (34.6%) 
Mean ± Stdeva 
(Range)  
0.5 ± 1.2 
(-1.3 – 3.1) 
-0.5 ± 1.2 
(-2.6 – 1.9) 
95% CIb  0.0 – 1.0 -1.0 – 0.0 
Median (IQRc)  0.3 (-0.6 – 1.3) 
-0.9 
(-1.4 – 0.8) 
a Stdev = Standard Deviation 
b CI = Confidence Interval of the Mean 









Table 5.2. PCA Scores: Descriptive Statistics in Subjects Parenterally Immunized or Orally 
Challenged with S. flexneri 2a Grouped by Shigellosis Outcome 
 
Exposure:   Oral (S. flexneri 2a)  Parenteral 
Shigellosis Outcome:   No Yes  No Yes 
Number of Subjects   12 15  17 9 
Component 1 
N with Positive C1 
Correlation (%)   3 (25.0%) 5 (33.3%) 
 13 (76.5%) 3 (33.3%) 
Mean ± Stdeva 
(Range)   
-1.8 ± 1.5 
(-3.8 – 0.4) 
-0.2 ± 2.0 
(-4.1 – 3.8) 
 1.9 ± 2.5 
(-1.7 – 7.7) 
-0.8 ± 2.4 
(-4.2 – 3.8) 
95% CIb   -2.7 – 0.8 -1.3 – 0.9  0.6 – 3.2 -2.6 – 1.0 
Median (IQRc)  -2.0 (-3.0 – -0.1) 
-0.5 
(-1.8 – 1.5)  
1.4 
(0.0 – 3.9) 
-0.3 
(-2.8 – 0.4) 
Component 2 
N with Positive C2 
Correlation (%)   7 (58.3%) 5 (66.7%) 
 6 (35.3%) 3 (33.3%) 
Mean ± Stdeva 
(Range)  
0.1 ± 0.8 
(-1.0 – 1.6) 
0.9 ± 1.4 
(-1.3 – 3.1)  
-0.5 ± 1.4 
(-2.6 – 1.9) 
-0.5 ± 1.1 
(-2.1 – 0.9) 
95% CIb  -0.4 – 0.6 0.1 – 1.6  -1.2 – 0.2 -1.4 – 0.3 
Median (IQRc)  0.1 (-0.6 – 0.6) 
1.2 
(-0.6 – 2.0)  
-0.9 
(-1.5 – 0.8) 
-1.0 
(-1.3 – 0.50 
a Stdev = Standard Deviation 
b CI = Confidence Interval of the Mean 





Table 5.3. PCA Scores: Descriptive Statistics in Subjects Orally Challenged with S. flexneri 
2a or S. sonnei 
 
Challenge Strain:   S. flexneri 2a S. sonnei 
Number of Subjects   27 46 
Component 1 
N with Positive C1 
Correlation (%)   15 (55.6%) 20 (43.5%) 
Mean ± Stdeva 
(Range)   
0.2 ± 2.1 
(-3.4 – 5.4) 
-0.1 ± 2.6 
(-4.7 – 6.2) 
95% CIb   -0.6 – 1.0 -0.9 – 0.6 
Median (IQRc)   0.4 (-1.2 – 1.3) 
-0.5 
(-1.8 – 1.1) 
Component 2 
N with Positive C2 
Correlation (%)   6 (22.2%) 27 (58.7%) 
Mean ± Stdeva 
(Range)  
-0.8 ± 1.0 
(-2.7 – 1.6) 
0.4 ± 1.5 
(-2.5 – 4.8) 
95% CIb  -1.2 – -0.4 0.0 – 0.9 
Median (IQRc)  -0.7 (-1.6 – -0.1) 
0.3 
(-0.5 – 1.1) 
a Stdev = Standard Deviation 
b CI = Confidence Interval of the Mean 









Table 5.4. PCA Scores: Descriptive Statistics in Subjects Orally Challenged with S. flexneri 
2a or S. sonnei Grouped by Shigellosis Outcome 
 
Challenge Strain:   S. flexneri 2a  S. sonnei 
Shigellosis Outcome:   No Yes  No Yes 
Number of Subjects   12 15  24 22 
Component 1 
N with Positive C1 
Correlation (%)   4 (33.3%) 12 (80.0%) 
 10 (41.7%) 10 (45.5%) 
Mean ± Stdeva 
(Range)   
-0.6 ± 1.6 
(-2.8 – 1.7) 
0.9 ± 2.2) 
(-3.4 – 5.4) 
 -0.5 ± 2.6 
(-4.7 – 4.5) 
0.3 ± 2.5 
(-3.0 – 6.2) 
95% CIb   -1.6 – 0.4 -0.3 – 2.1  -1.6 – 0.6 -0.8 – 1.4 
Median (IQRc)  -1.0 (-1.8 – 1.1) 
0.7 
(-0.6 – 2.6)  
-0.7 
(-2.7 – 1.3) 
-0.1 
(-1.4 – 1.2) 
Component 2 
N with Positive C1 
Correlation (%)   0 (0%) 6 (40.0%) 
 10 (41.7%) 17 (77.3%) 
Mean ± Stdeva 
(Range)  
-1.1 ± 0.6 
(-1.8 – 0.1) 
-0.5 ± 1.2 
(-2.7 – 1.6)  
-0.3 ± 1.0 
(-2.5 – 1.6) 
1.3 ± 1.4 
(-0.7 – 4.8) 
95% CIb  -1.5 –  -0.7 -1.2 – 0.2  -0.8 – 0.1 0.7 – 1.9 
Median (IQRc)  -1.2 (-1.5 – -0.5) 
-0.2 
(-1.8 – 0.2)  
-0.3 
(-1.2 – 0.6) 
1.1 
(10-5 – 2.3) 
a Stdev = Standard Deviation 
b CI = Confidence Interval of the Mean 
c IQR = Interquartile Range 
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Table 5.5. Comparisons of Percent Responders across Shigellosis Outcome after 
Parenteral Immunization or Oral Challenge with either S. flexneri 2a or S. sonnei  
 
 Percent Responders
a and Associated P-Value 
Shigellosis:  No Yes p-valueb  No Yes p-value  No Yes p-value 
            
 Parenteral Immunization Oral Challenge (S. flexneri 2a)       Oral Challenge (S. sonnei) 
Serum IgG 100.0% 66.7% 0.004  33.3% 66.7% 0.020  66.7% 100.0% 0.264 
Serum IgA 100.0% 66.7% 0.177  50.0% 86.7% 0.017  66.7% 100.0% 0.135 
Serum IgM 29.4% 11.1% 0.109  16.7% 40.0% 0.229  41.7% 77.3% 0.042 
Serum IgG1 58.8% 11.1% 0.022  0.0% 6.7% 0.220  37.5% 22.7% 0.332 
Serum IgG2 88.2% 55.6% 0.013  25.0% 53.3% 0.070  25.0% 22.7% 0.578 
Serum IgG3 5.9% 0.0% 0.844  0.0% 6.7% 0.107  16.7% 13.6% 0.721 
Serum IgG4 11.8% 0.0% 0.122  0.0% 0.0% ---  0.0% 0.0% --- 
Bactericidal Activity 88.2% 77.8% 0.056  16.7% 66.7% 0.026  83.3% 90.9% 0.629 
Memory B Cell IgG 66.7% 42.9% 0.120  16.7% 60.0% 0.221  54.2% 77.3% 0.347 
Memory B Cell IgA 55.6% 42.9% 0.706  25.0% 60.0% 0.055  54.2% 72.7% 0.121 
α4β7- IgG 82.4% 33.3% 0.014  16.7% 46.7% 0.045  12.5% 36.4% 0.030 
α4β7- IgA 35.3% 11.1% 0.165  0.0% 20.0% 0.107  4.2% 18.2% 0.093 
α4β7+ IgG 64.7% 11.1% 0.002  33.3% 86.7% 0.018  54.2% 90.9% 0.0001 
α4β7+ IgA 52.9% 33.3% 0.133  33.3% 66.7% 0.033  66.7% 95.5% 0.0001 
a Percent responder = peak fold-rise ≥4 
b Significance determined by Mann-Whitney test comparing peak-fold rise across subjects with or without shigellosis within a population.  
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Vaccine administration and sample collection schedule in subjects parenterally immunized with a S. flexneri 
2a bioconjugate vaccine and subsequently challenged with S. flexneri 2a 2457T. 
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Sample collection schedule in subjects orally challenged with S. flexneri 2a 2457T. 
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Sample collection schedule in subjects orally challenged with S. sonnei 53G. 
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PCA results comparing Components 1 and 2 in subjects parenterally immunized with the bioconjugate 
vaccine or orally challenged with S. flexneri 2a. (A) PCA loading plot for all systemic, memory and mucosal 
immune response variables included in analysis, (B) Component 1 and 2 scores for all subjects used in 
analysis and, (C) Tukey box and whisker plots of Component 1 and 2 scores across either parenterally 
immunized or orally challenged subjects. P-values determined by Welch’s T-test. 
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Figure 5.5. Immune Profiles after Parenteral Immunization or Oral Challenge with S. 




Comparisons of Component 1 and 2 scores in subjects orally challenged with S. flexneri 2a (A and C) or, 
parenterally immunized with the bioconjugate vaccine (B and D), grouped by shigellosis outcome. Tukey 
box and whisker plots of Component 1 and 2 scores grouped by shigellosis outcome. (E and F) Component 
scores and Tukey box and whisker plots in subjects either progressing to shigellosis after oral challenge or, 
in subjects protected from shigellosis after parenteral immunization. P-values determined by Welch’s T-
test. 
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Figure 5.6. Heat Map of Peak-Fold Rise in Immune Responses after Parenteral 




Immune response heat map comparing peak fold-rise in immune responses either post-vaccination with a 
bioconjugate vaccine or, post-challenge with S. flexneri 2a, grouped by shigellosis outcome.  
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PCA results comparing Components 1 and 2 in subjects orally challenged with either S. flexneri 2a or S. 
sonnei. (A) PCA loading plot for all systemic, memory and mucosal immune response variables included in 
analysis, (B) Component 1 and 2 scores for all subjects used in analysis and, (C) Tukey box and whisker 
plots of Component 1 and 2 scores across subjects orally challenged with either S. flexneri 2a or S. sonnei. 
P-values determined by Welch’s T-test. 
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Figure 5.8. Immune Profiles after Oral Challenge with S. flexneri 2a or S. sonnei Grouped 




Comparisons of Component 1 and 2 scores in subjects orally challenged with either S. sonnei (A and C) or, 
S. flexneri 2a (B and D), grouped by shigellosis outcome. Tukey box and whisker plots of Component 1 and 
2 scores grouped by shigellosis outcome. (E and F) Component scores and Tukey box and whisker plots in 
subjects progressing to shigellosis after oral challenge with either S. sonnei or S. flexneri 2a. P-values 
determined by Welch’s T-test.  
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Figure 5.9. Heat Map of Peak-Fold Rise in Immune Responses after Oral Challenge with S. 




Immune response heat map comparing peak fold-rise in immune responses post-challenge with either S. 
sonnei or S. flexneri 2a, grouped by shigellosis outcome. 
 157 
Figure 5.10. Immune Response Spearman Correlation Maps after Parenteral 








Spearman correlation heat maps of immune response peak fold-rise in subjects (A) parenterally immunized 
subjects that were protected from shigellosis after oral challenge with S. flexneri 2a, (B) subjects 
progressing to shigellosis after oral challenge with S. flexneri 2a, or (C) subjects progressing to shigellosis 
after oral challenge with S. sonnei.  
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Figure 5.11. Fecal Calprotectin and Myeloperoxidase Concentrations after Oral Challenge 




Peak inflammatory marker concentrations (mean with standard deviation) post-challenge with S. sonnei or 













6.1. RESEARCH CONCLUSIONS 
Major Accomplishments. The objective of the project was to characterize at a 
high level detail the immune responses generated in humans after parenteral 
immunization with a S. flexneri 2a bioconjugate vaccine, after oral challenge with S. 
flexneri 2a 2457T and after oral challenge with S. sonnei 53G. The immunological 
characterizations summarized within Chapters 3 and 4 have revealed important insights 
into immune responses associated with protection from Shigella infection. The insights 
gathered from these two chapters were then synthesized into protective immune 
profiles (Chapter 5) designed to inform the broader question pertaining to the 
development and assessment of Shigella vaccines. 
Protective immune profiles are different based on the route of antigenic 
exposure (parenteral versus oral exposure). Parenteral immunization with the 
bioconjugate vaccine induced protection from shigellosis through multiple LPS-specific 
immune parameters, including serum IgG, IgG1, IgG2 and IgA. While association with 
protection from shigellosis was most apparent with serum antibodies, a strong 
association was also observed between protection and LPS-specific IgG secreting B cells 
homing to mucosal surfaces; a novel finding which may offer a mechanistic explanation 
for the protection afforded by the parenterally administered S. flexneri 2a bioconjugate 
vaccine. Although fecal IgG responses were not investigated after immunization with the 
bioconjugate, oral challenge with S. sonnei (Chapter 3) revealed a correlation between 
α4β7+ IgG secreting B cells and fecal IgG levels, providing indirect evidence that α4β7+ 
cells are homing to the intestine and contributing to intestinal IgG. It is therefore 
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probable that LPS-specific α4β7+ derived IgG serves as a mCoP after parenteral 
immunization with a S. flexneri 2a bioconjugate vaccine while serum IgG responses may 
serve as a surrogate measure or a nCoP. 
Placebo subjects with moderate to severe disease after oral challenge with S. 
flexneri 2a 2457T were also used to investigate protective immune profiles. As expected, 
oral challenge induced a profile of robust mucosal responses accompanied by moderate 
systemic responses, a unique immune profile as compared to parenteral immunization 
characterized by robust systemic immune responses with moderate mucosal responses.  
An unexpected result when comparing the two profiles was the difference in 
serum IgG subclass responses across the routes of antigenic exposure (Chapter 4). 
Moderate to robust increases in LPS-specific serum IgG2 responses were observed across 
all populations, regardless of exposure route or shigellosis outcome; a finding which fits 
dogmatic understanding of S. flexneri 2a-based exposures, known to induce a 
predominant serum IgG2 response. In contrast, serum IgG1 was the predominant IgG 
subclass in protected vaccinees. Furthermore, although serum IgG1 responses in 
protected vaccinees were lower in magnitude as compared to serum IgG2, protection 
afforded by the bioconjugate vaccine showed a stronger correlation with IgG1 rather 
than IgG2. Given that serum IgG1 responses also correlated with α4β7+ ALS IgG 
responses, IgG1 antibodies appear to play an important role in protection from 
shigellosis after parenteral immunization, potentially contributing to immunity at the site 
of infection. If this is the case, serum IgG1 responses could serve as an alternative 
surrogate measure (or nCoP) post-parenteral immunization. 
163 
 
Protective immune profiles are different across Shigella serotypes (S. flexneri 2a 
versus S. sonnei). Protective immune profiles were also investigated in a S. sonnei CHIM, 
facilitating comparisons of the profiles induced after oral challenge with two divergent 
Shigella serotypes. Post-challenge immune profiles revealed an unexpected difference 
across Shigella serotypes. The profile after S. sonnei infection showed similar systemic 
immune responses, regardless of disease outcome; however, subjects progressing to 
shigellosis had significantly higher mucosal antibody responses. Interestingly, a dissimilar 
pattern was observed after S. flexneri 2a infection with subjects progressing to shigellosis 
having moderate to robust increases in both systemic and mucosal responses. In 
contrast, the profiles in subjects without shigellosis was characterized by low to 
undetectable increases across both responses. Furthermore, the difference in the 
magnitude of the mucosal response across Shigella serotypes was substantial. As 
outlined in Chapter 5, there are several molecular and pathogenic differences between S. 
sonnei and S. flexneri 2a which could contribute to the observed immunological 
differences associated with two Shigella serotypes. These observations should be further 
explored in future studies. 
In addition to comparing the immune responses post-challenge with either S. 
sonnei or S. flexneri 2a, the two CHIMs provided the opportunity to investigate immune 
responses prior to challenge and their association with a reduced risk of disease after 
challenge. Baseline LPS-specific serum IgA, memory B cell IgA, fecal IgA and IgG, as well 
as serum bactericidal activity were all associated with a reduced risk of progression to 
shigellosis caused by S. sonnei. While there were less S. flexneri 2a LPS-specific baseline 
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immune responses associated with a reduced risk of shigellosis post-challenge, a 
commonality was found across the two serotypes with increased baseline LPS-specific 
memory B cell IgA responses being associated with reduced risk of disease post-
challenge. Previous reports have also shown an association of S. flexneri 2a LPS-specific 
memory B cell IgA responses with reduced disease severity after a secondary oral 
exposure,129 further solidifying an essential role for LPS-specific memory IgA responses in 
protection against Shigella infection. Baseline immune responses associated with a 
resistance to infection have provided important information to the Shigella vaccine 
development field as potential mechanisms of protection that should be evaluated in 





6.2. PUBLIC HEALTH IMPLICATIONS  
6.2.1. Shigella Vaccine Development 
 Identification of key immunological mechanisms to guide the rational design of 
Shigella vaccines. Findings from the current research have important implications for 
future activities associated with Shigella vaccine development. Epidemiological data 
indicates that S. sonnei, in addition to S. flexneri 2a, 3a and 6, are responsible for 
approximately 80% of the global Shigella disease burden.24,26,110 Therefore, a 
quadrivalent vaccine may be required to significantly reduce global disease burden, and 
evidence from this project indicates that different protective immune mechanisms may 
be required across Shigella species. These findings could significantly impact vaccine 
design and clinical testing. 
 If different protective immune mechanisms are required across Shigella 
serotypes, investigations into different vaccine constructs or immunization strategies 
may also be required in order to provide protection against the globally predominant 
serotypes. An alternative immunization strategy that has shown promise across other 
mucosal pathogens with multiple serotypes is a heterologous prime-boost regimen.197,226-
228 Priming the immune system with a vaccine consisting of one pathogen serotype and 
boosting with a different vaccine serotype has demonstrated increased heterologous 
protection across influenza, rotavirus and HIV.229-231 For Shigella infection, priming the 
immune system with a S. sonnei vaccine and boosting with a multivalent S. flexneri 
vaccine (or vice versa) may induce increased protective immunity across the different 
Shigella species in order to provide the broad protection required. 
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 Alternatively, if protection from S. sonnei does require a stronger mucosal 
immune response as compared to S. flexneri 2a, a prime-boost strategy investigating 
different vaccine constructs delivered via different administration routes could be 
investigated. A parenteral (or oral) priming vaccination followed by an oral (or 
parenteral) booster immunization has demonstrated increased efficacy and enhanced 
mucosal and systemic immune responses with Heliobacter pylori, hepatitis B and herpes 
simplex virus.227,228,232 In fact, a parenteral prime/oral boost strategy has been previously 
investigated with S. flexneri in the rabbit ileal-loop model.226 This study demonstrated a 
proof-of-concept for this immunization strategy as it induced increased S. flexneri-
specific local IgA responses as well as increased systemic responses.226 Unfortunately, as 
only S. flexneri was included in the analysis, protection provided by this strategy across 
other Shigella species could not be investigated. Nonetheless, a parenteral priming of the 
immune system with a S. flexneri multivalent conjugate vaccine followed by an oral S. 
sonnei booster immunization may induce the required protective immune mechanisms 
across the different Shigella species. 
 Furthermore, depending on the construct of the orally delivered S. sonnei 
vaccine, it may contain some of the virulence plasmid proteins, providing the opportunity 
to mount immune responses to these highly conserved antigens and potentially broaden 
the protection provided by such vaccine strategies. Finally, as orally delivered enteric 
vaccines have demonstrated reduced efficacy in children living in endemic settings 
and,140,141 as the target population of a Shigella vaccine is children under the age of 4 
living in LMICs,27,54 priming an infant with a parenteral vaccine and boosting with an oral 
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vaccine when the child is slightly older may help increase oral vaccine efficacy in this 
population. The use of additional antigens or alternative immunization strategies 
certainly warrant further investigation. 
 Directly informing prioritization of future immunological evaluations. The field 
of Shigella vaccine development has placed a high priority on the standardization of 
clinical trial conduct and has not only recommended the use of consensus clinical 
outcome definitions but has also provided recommendations on standardized sample 
collection schedules and immunoassay prioritizations (Appendix C).164 Unfortunately, 
these recommendations were not designed with different antigenic exposure routes or 
Shigella serotype diversity in mind. As demonstrated here, key protective immune 
parameters may vary, not only depending on route of exposure (parenteral or oral) but 
potentially, also depending on the source of antigenic exposure (Shigella serotype). It is 
therefore critical to consider immunoassay prioritization across both of these factors as 
they may be crucial to the evaluation of vaccines currently in development and will 
contribute to critical decisions regarding down selections between candidate vaccines.  
Furthermore, extensive immune characterizations, such as those reported in this project, 
may be unfeasible in many future studies due to lack of funding and potential constraints 
on sample collection. Therefore, information from the two Shigella CHIMs used in the 
current research was compiled in order to create immunoassays prioritizations designed 
to supplement the currently published recommendations (Table 6.1). While this list is not 
comprehensive as it only includes LPS-specific humoral immune responses, the list does 
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inform decisions regarding which immune parameters should be focused upon based on 
routes of exposure and different Shigella serotypes being investigated. 
 Immune parameters evaluated in the current CHIMs were placed into three 
increasing priority levels based on their association with either protection from 
shigellosis after parenteral immunization or, progression to shigellosis after oral 
challenge (Table 6.1). In addition to suggesting immunoassay prioritizations for future 
studies, Table 6.1 also depicts the unique immune profiles discussed in Chapter 5. For 
example, the prioritization list highlights the importance of LPS-specific α4β7+ and α4β7- 
ALS IgG responses as these measures have been identified as a primary priority, 
regardless of antigenic exposure and route. However, the additional importance of 
serum IgG, IgG1 and IgG2 responses after parenteral immunization is clear as all have 
also been identified as a primary priority. When assessing protection after parenteral 
immunization, Table 6.1 suggests that these measures could be considered when 
comparing different parenterally administered LPS-based Shigella vaccines. 
 When evaluating immunoassay prioritization after either S. flexneri 2a or S. sonnei 
oral exposure, α4β7+ ALS IgA and memory B cell derived IgA responses are listed as a 
primary priority, indicating that these measures may be essential when evaluating an 
orally delivered Shigella vaccine. Serum IgG, IgA and SBA responses have increased 
prioritization levels across both oral and parenteral S. flexneri 2a exposures, indicating 
their potential importance in protection from S. flexneri 2a. Interestingly, while 
similarities do exist across oral exposure to both Shigella serotypes, serum IgG stands out 
as being ranked the lowest priority after S. sonnei oral exposure while serum IgA and SBA 
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are a higher priority after S. sonnei oral exposure compared to S. flexneri 2a. The 
immunoassay prioritization list created here further emphasizes the potential immune 
response differences across Shigella serotypes. 
 
6.2.2. Global Health 
A licensed and widely available Shigella vaccine is a high priority for the WHO 
which has translated into increased attention and availability of funding.55,56,61 The 
contributions provided within this research expands the current understanding of 
differences in protective immune mechanisms across Shigella species and can therefore 
make a positive impact on global health. If protective immunity is unique across multiple 
Shigella serotypes, different approaches to vaccine development may be required such 
as implementing prime/boost strategies, diversifying the antigens included in the 
vaccine, or utilizing adjuvants to modulate the immune response. While S. sonnei 
infections are historically associated with developed nations, there has been a shift in 
this paradigm with S. sonnei increasing in prevalence across LMICs.18,63-65 If current 
vaccine strategies cannot protect against S. sonnei infection, but can against S. flexneri 
infections, S. sonnei may continue to rise in global dominance. Given the ability of S. 
sonnei to utilize a T6SS to kill commensal bacteria, increased S. sonnei infections in LMIC 
populations may further contribute to reduced intestinal barrier function and increased 
malnutrition in children living in LMICs. Additionally, as outlined earlier, the killing of 
intestinal microbiota could increase the possibility of systemic Shigella bacteremia, 
leading to serious health complications or death in an already susceptible population. 
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As the CDC and WHO consider antimicrobial resistant Shigella species to be a 
significant public health threat and, given the adeptness of S. sonnei in acquiring 
antimicrobial resistance (AMR) genes,64 S. sonnei continuing to rise in dominance could 
pose a global health crisis. An increase in the prevalence of S. sonnei could not only 
provide the opportunity for lateral gene transfer of S. sonnei AMR genes to other 
bacterial species but could also allow the opportunity for S. sonnei to acquire additional 
AMR genes, further reducing available treatment options for S. sonnei infection. The 
seriousness of this threat could be further exacerbated in the context of infection with S. 
dysenteriae 1, the Shigella serotype typically associated with epidemics and known to 
harbor the deadly Shiga toxins. Should an outbreak of S. dysenteriae 1 occur in an area 
where S. sonnei has become endemic, it could potentially result in S. dysenteriae 1 
acquiring AMR genes from S. sonnei or, alternatively, S. sonnei acquiring the genes 
encoding for the Shiga toxins from S. dysenteriae 1, as previously reported with S. flexneri 
species.73,74 Either outcome could have significant impacts on global public health. 
With greater than 50 known Shigella serotypes,62 it is also possible that once the 
burden of the currently relevant serotypes is successfully reduced, other serotypes may 
fill the void in global dominance, a phenomenon termed serotype replacement.233 This 
process of serotype replacement has been well documented in the case of Streptococcus 
pneumoniae after the release of an efficacious 7-valent vaccine.233,234 Although this 
vaccine significantly reduced the disease burden caused by the globally relevant S. 
pneumoniae serotypes, within 5 years other serotypes not contained within the 7-valent 
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formulation had increased in global prevalence, bringing disease burden levels back to 
what was observed prior to vaccine implementation.233,234  
While extensive molecular characterizations have been performed on current 
globally relevant Shigella serotypes, it is important to consider that other Shigella 
serotypes have likely not undergone such extensive characterization testing. Additionally, 
given the potential for different protective immune mechanisms associated with 
different Shigella serotypes, it is essential to continue characterizing protective immunity 
across multiple Shigella serotypes. Understanding differences in molecular pathogenesis 
or protective immune mechanisms could help prepare the global health community for 





6.3. PROJECT LIMITATIONS  
While the molecular differences between the two Shigella serotypes could 
provide some explanation into the different immune response profiles induced post-
challenge, the two CHIMs used to define protective immune profiles in the current 
analyses were not originally designed or powered for this purpose. Although the studies 
used similar inclusion and exclusion criteria (Appendices A and B), the populations are 
nonetheless different with S. flexneri 2a challenged subjects recruited from the Baltimore 
MD area and S. sonnei challenged subjects recruited from the Cincinnati OH area. While 
both studies were conducted in North American adults, there are substantial genetic, 
epigenetic and microbiomic differences even within similar populations. Extrapolation of 
the current findings into populations from other geographical areas with potentially 
diverse genetic backgrounds becomes increasingly complex. Furthermore, while Shigella 
CHIMs are extremely useful tools for immunological investigations and for initial 
assessments of vaccine efficacy, North American adults are quite different compared to 
the target population of young children living in Shigella endemic settings. As previously 
mentioned, children in such settings add the additional complications of different 
immune system maturity as well as unknown or variable nutritional and immune status, 
each of which contribute to differences in immune and vaccine responses. 
The studies used in the current investigations were also designed and powered to 
answer a different primary outcome than defining immune response profiles. While the 
number of subjects and immune responses investigated met the statistical requirements 
for PCA, such investigations would be best conducted on a larger number of subjects 
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enrolled into a study better designed to answer the question of differences in immune 
profiles post-infection across serotypes. Additionally, it is important to understand that 
post-infection protective immune profiles described here are presumptive. While this 
presumption is based on a breadth of studies demonstrating that subjects progressing to 
disease post-infection with shigellae are protected from subsequent disease caused by 
the same serotype,98,99,109,177 the described immune profiles cannot be defined as 
protective without all subjects undergoing a secondary homologous challenge in order to 
fully assess immunological protection.  
Furthermore, although both studies have also characterized the immune 
responses post-challenge with S. sonnei and S. flexneri 2a to a level not previously 
reported, the selected immune parameters are nonetheless limited and are only a 
representation of humoral immune responses. The investigation of limited humoral 
immune responses could have introduced bias and influenced conclusions. The addition 
of cellular immune responses or cytokine profiles would be important, especially given 
the potential differences in extracellular and intracellular life-cycle stages across S. sonnei 
and S. flexneri 2a. Additionally, further characterization of humoral immune responses 
such as investigating Fc glycosylation patterns and antibody affinity and avidity, or next 
generation analyses such as systems serology could help refine the immune profiles 
described here and reduce the potential of biased conclusions. 
Immune responses to additional antigens, including the highly conserved Ipa 
proteins, should also be conducted to investigate the protective capacity of these 
antigens, or their ability to provide heterologous protection across Shigella serotypes or 
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species.111,113 Serum samples from the S. sonnei 53G CHIM have been analyzed in a 
recently developed Shigella protein and LPS microarray235 and results indicate a potential 
role for Shigella proteins in protection from shigellosis. One protein of particular interest 
is the highly immunogenic IpaB protein. Microarray analyses showed that increased IpaB-
specific serum antibody responses at baseline are associated with a reduced risk of 
disease post-challenge (Figure 6.2A); a result mirrored by ELISA titers generated from the 
study (Figure 6.2B). Furthermore, additional analyses of microarray results demonstrated 
that subjects with increased baseline serum responses to both S. sonnei LPS and IpaB 
have a reduced risk of progression to shigellosis post-challenge (Figure 6.3). The 
microarray data demonstrates the importance of additional Shigella antigens and their 





6.4. FUTURE RESEARCH AND NEXT STEPS  
 Fortunately, there are several upcoming or ongoing clinical investigations which 
may provide the opportunity to further elucidate or refine Shigella-specific protective 
immune profiles. In addition to the serum samples from the S. sonnei 53G CHIM, α4β7+ 
and α4β7- ALS samples have also been analyzed in Shigella-specific antigen microarrays 
which could provide important information regarding the antigen-specific mucosal 
responses. Initial results from these analyses indicate the potential of cross reactivity of 
LPS purified from S. sonnei and S. flexneri 6 (data not shown); however, results are 
preliminary and require further investigation into potential explanations for the observed 
cross-reactivity. There are also many other preserved samples from the S. sonnei CHIM 
which are planned for use in additional immunological analyses, including systems 
serology and microbiome analyses. While these samples are available from the S. sonnei 
CHIM, similar samples are not available from subjects in S. flexneri 2a CHIM. Additionally, 
in order to truly define protective profiles, a broader systems biology approach to 
investigating immune responses after a secondary homologous challenge could 
potentially be required. 
 Immune profile investigations using samples or data collected from additional 
retrospective CHIM studies could also help define Shigella-specific protective immunity. 
Several S. sonnei and S. flexneri 2a vaccine efficacy CHIMs have been conducted over the 
years which have investigated many vaccine types and administration routes, including 
oral live-attenuated or killed whole cell vaccines, intranasal subunit vaccines and, 
parenterally delivered conjugate or subunit vaccines. Immune response characterizations 
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using samples from these studies could provide information on the differences between 
S. sonnei and S. flexneri 2a protective immunity after different routes of exposure. One 
drawback of retrospective studies is that not all studies used similar sample collection 
schedules or disease outcome definitions, as recommended by the recent Shigella CHIM 
consensus papers.164-167 It is essential to incorporate the consensus information in future 
studies, as well as to focus on immunoassay standardization, in order to reduce the 
variability in CHIM results achieved across different institutions and therefore allow more 
accurate comparisons of immune responses and vaccine efficacy.  
 Several Shigella CHIMs have been recently funded and will also provide the 
opportunity to further characterize protective immune mechanisms. The Johns Hopkins 
University will conduct a heterologous re-challenge study with S. sonnei and S. flexneri 
2a. Subjects in this study will undergo a primary challenge with either S. sonnei 53G or S. 
flexneri 2a 2457T. After recovery, a subset of subjects challenged with each serotype will 
undergo a heterologous re-challenge in order to assess the potential cross-protection 
provided by the two Shigella serotypes. Sample collection schedules and disease 
outcome definitions to be used in this study have been aligned with the consensus 
reports in order to allow comparability across recently generated data. This study 
provides an excellent opportunity to not only further investigate the different S. sonnei 
and S. flexneri 2a immune profiles presented here but also to assess whether the profiles 
associated with each serotype could provide heterologous protection. 
 Finally, the exciting opportunity to establish the S. sonnei 53G CHIM in an 
endemic setting has also recently been funded. The same S. sonnei 53G lyophilized strain 
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will be used in a Kenyan adult population to determine the dose of S. sonnei that will 
induce a ≥60% shigellosis attack rate in a Shigella endemic population. As this study will 
follow an identical design to the S. sonnei CHIM conducted in North American adults 
(described in Chapter 3 and Appendix A), it will provide essential information regarding 
the bacterial dose required to achieve the desired attack rate, as well as immune 
responses pre- and post-infection in a population likely to have pre-existing Shigella-
specific immunity. This will also be the first time a Shigella CHIM would be conducted in 
an African LMIC, providing the opportunity to establish a model where Shigella-specific 
interventions can be tested in the adult subset of the target population. Data presented 
here contributes to both the Shigella-specific fields of vaccinology and immunology and 
can also help guide the design and conduct of upcoming Shigella CHIMs in order to 
ultimately better inform vaccine development investments as the field looks to reduce 




Table 6.1. Shigella CHIM Assay Prioritization List after Parenteral Immunization or Oral 








Memory and Functional 
Compartment 
S. flexneri 2a 
(Parenteral) 
IgG α4β7+ ALS IgG Memory B Cell ALS IgG 
IgG1 α4β7- ALS IgG Memory B Cell ALS IgA 
IgG2 α4β7+ ALS IgA Bactericidal Activity 
IgG3 α4β7- ALS IgA  
IgG4   
IgA   
IgM   
 
S. flexneri 2a 
(Oral) 
IgG α4β7+ ALS IgG Memory B Cell ALS IgG 
IgG1 α4β7- ALS gG Memory B Cell ALS IgA 
IgG2 α4β7+ ALS IgA Bactericidal Activity 
IgG3 α4β7- ALS IgA  
IgG4   
IgA   




IgG α4β7+ ALS IgG Memory B Cell ALS IgG 
IgG1 α4β7- ALS IgG Memory B Cell ALS IgA 
IgG2 α4β7+ ALS IgA Bactericidal Activity 
IgG3 α4β7- ALS IgA  
IgG4   
IgA   
IgM   
 
Pre-challenge (parenteral) or post-challenge (oral) immune response parameters were prioritized by 
examining significant differences (p≤0.05) across shigellosis outcome in the following measures:  
 
1) Peak titer (T-test of log-transformed titers) 
2) Peak fold-rise (Mann-Whitney U test) 
3) Percent responders (Mann-Whitney U test) 
4) Immune response kinetics (2-way ANOVA of log-transformed titers) 
 
Assay prioritization was assigned as follows: 
 
Primary = ≥3 measures significantly associated with shigellosis outcome 
Secondary = 1-2 measures significantly associated with shigellosis outcome 
Tertiary = 0 measures significantly associated with shigellosis outcome 
 
Additionally, any baseline immune response significantly associated with resistance to disease after oral 
challenge was categorized as a primary priority. 
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Figure 6.1. IpaB-Specific Baseline Immune Responses in Subjects Orally Challenged with 





IpaB-specific immune responses on study day -1 prior to oral challenge with S. sonnei 53G: A) Heatmap of 
microarray immune response signals generated as base 2 logarithm of the raw microarray signal for all 
samples. * = Significance determined by Wilcoxon rank sum test. Significant p-values (≤0.05) written in 
bold font. B) Individual IpaB-specific serum IgG ELISA endpoint titers with group geometric mean and 95% 




Figure 6.2. Shigellosis Attack Rates in Subjects Orally Challenged with S. sonnei 53G 





Shigellosis attack rates by quadrant: Serum IgG (A) and IgA (B) microarray immune response signals 
generated as base 2 logarithm of the raw microarray signal. Dashed lines represent the median value 
of LPS- and IpaB-specific signals. For the purpose of calculating attack rates in each quadrant without 
bias in the selection of the thresholds, signals above the median are categorized as positive (+) and 
below the median are categorized as negative (-). Boxes present attack rates among the subset of 
subjects in each corresponding quadrant.
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